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Hospital acquired pneumonia is a major problem in the nosocomial environment 
worldwide. The rise in the number and level of antibiotic resistant strains of bacteria 
means that conventional therapies are no longer as ffective as they once were. Many 
of the main causative organisms are Gram-negative rods, such as Escherichia coli, 
Klebsiella pneumoniae, Pseudomonas aeruginosa, Haemophilus influenzae and one 
that has become a greater problem in the last twenty years Acinetobacter genospecies 
13 TU. Lipopolysaccharide (LPS) is a molecule that is found on the cell surface of all 
Gram-negative organisms. LPS is a vital part of the out r membrane of Gram-
negative bacteria and is a major factor in these organisms’ ability to cause serious 
infection and disease. While many Gram-negative organisms, such as E. coli and 
Klebsiella pneumoniae, are well characterised, other species that have becom  
potential nosocomial pathogens more recently, such as Acinetobacter genospecies 13 
TU, are much less well characterised. It is unknown as to how widespread exposure to 
Acinetobacter genospecies 13 TU is in a healthy population. Also, little is also about 
pathogenesis of Acinetobacter genospecies 13 TU such as the capacity for induction 
of cytokines by the Acinetobacter genospecies 13 TU LPS 
LPS was extracted with the aqueous phenol method and re-purified by Voegel’s 
method from eight strains of Acinetobacter genospecies 13 TU, four strains of 
Haemophilus influenzae, two strains of Pseudomonas aeruginosa, two strains of 
Klebsiella pneumoniae and two strains of E. coli. These LPSs were used in enzyme 
linked immunosorbant assays (ELISAs) with serum taken from 475 blood donors 
from the Southeast Scotland Blood Transfusion Servic . The results from the ELISAs 
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were averaged for each individual blood donor across all the species tested. These 
averaged results were compared across the species. 
 LPS from two strains of each species, ten in all, were used to challenge the THP-1 
human monocytic cell line and the mRNA was extracted and used in quantitative 
polymerase chain reactions to measure cytokine induction. 
It was seen that exposure to Acinetobacter genospecies 13 TU LPS is about as 
widespread in a healthy population from Southeast Sco land as exposure to 
Pseudomonas aeruginosa LPS and somewhat similar to Klebsiella pneumoniae LPS. 
Antibodies to E. coli LPS and Haemophilus influenzae LPS were similarly 
widespread in a healthy population from Southeast Sco land. These last two were 
much more widely spread than the other organisms tested. Some individuals seem to 
produce antibodies at high levels to all of the LPSs tested. It may be possible to use 
serum from these individuals to make a hyper-immune immunoglobulin preparation 
to be used in the immunotherapy of hospital associated pneumonia. The LPS from one 
of the strains of Acinetobacter genospecies 13 TU was able to induce similar levels of 
cytokine production as Klebsiella pneumoniae and Pseudomonas aeruginosa. It was 
able to induce higher levels of cytokine production over a greater number of cytokines 
than both Haemophilus influenzae and E. coli LPS. LPS from the other strain of 
Acinetobacter genospecies 13 TU tested induced lower levels of cytokines compared 
to the other strain. These levels were lower than tose developed by Haemophilus 
influenzae and E. coli LPS as well as those induced by the LPSs from Klebsiella 
pneumoniae and Pseudomonas aeruginosa. It seems that there is a range of different 
levels of cytokine production induced by Acinetobacter genospecies 13 TU LPS with 
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A. g 13 TU - Acinetobacter genospecies 13 TU 
AME - Aminoglycoside modifying enzyme 
BIP – bactericidal/permeability increasing protein 
BHI - Brain heart infusion 
CAP - Community acquired pneumonia 
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cDNA - complimentary DNA 
Ct - cycle threshold 
DNA - deoxyribonucleic acid 
DnTP - deoxynucleoside  
E.c. - Escherichia coli 
E. coli - Escherichia coli 
ECD - Ecto domains 
ELISA - Enzyme linked immunosorbant assay 
ESBL - Extended spectrum β-lactamase 
FBS - Foetal Bovine serum 
GLcN - Glucosamine 
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HAP - Hospital acquired pneumonia 
HEPES - 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
H.i. - Haemophilus influenzae 
ICU - Intensive care unit 
Ig - Immunoglobulin 
IL - Interleukin 
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PCR - Polymerase chain reaction 
PF - Pyrogen free 
PRR - Pattern recognition receptors 
PS+ G - Penicillin and Streptomycin + L-Glutamine 
QPCR - Quantitative polymerase chain reaction 
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RIE - Royal Infirmary Edinburgh 
RNA - ribonucleic acid 
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RT - Reverse transcription 
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S-form - Smooth form 
sCD-14 – soluble CD-14 
TIR - Toll/IL-1 receptor homologue 
TLR - Toll like receptor 
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1.1  Lipopolysaccharide (LPS) 
1.1.1 Overview 
One of the main differences between Gram-positive and Gram-negative bacterial cell 
walls is that Gram-negative organisms have an outer and an inner membrane, whilst 
Gram-positive organisms have a large peptidoglycan cell wall. Lipopolysaccharide 
(LPS) is one of the essential components of the outr membrane of Gram-negative 
bacteria, as is shown in Figure 1.1 below. This LPS is composed of a carbohydrate 
and a lipid, hence the name lipopolysaccharide (Erridge et al, 2002). 
 
Figure 1.1: The outer membrane of a Gram-negative bacterium. The Lipid A moiety is bound to the 
outer membrane of the bacterial cell, whilst the O-antigen extrudes into the extra cellular space. (Raetz 
& Whitfield, 2002)  
In 1892 Richard Pfeiffer discovered endotoxin, as a bacterial structure and used it as a 
basis for paving the way to understanding how micro-organisms cause disease 
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(Beutler & Rietschel, 2003). Currently it is thought t at LPS is essential for the 
viability of all Gram negative outer membranes, as well as being an extremely potent 
antagonist of the innate immune system (Alexander & Rietschel, 2001; Dobrovolskaia 
& Vogel 2002). Thus far, two exceptions have been identified; some bacteria contain 
glycosphinolipids instead of LPS e.g. Sphingomonas (Kawahara et al, 1991) and there 
is an LPS-deficient mutant of Neisseria meningitidis, both these organisms have the 
ability to survive so both are viable (Gronow & Brade, 2001). 
The evolution of macrophages and monocytes alongside LPS has meant that the 
mammalian immune system is equipped with a rapid recognition of and reaction to 
infection by Gram-negative bacteria. The immune respon e is traditionally 
characterised by the production of a wide range of inflammatory mediators, such as 
TNF-α, INF-γ, Il-1β, IL-8 and Il-10. These, in moderate levels in a loca  site, are 
extremely beneficial to the host as they up-regulate inflammation and ready the 
immune system to fight the infection causing microbes (Erridge et al, 2002). 
However, in conditions where the host suffers an overexposure to LPS or the LPS is 
found systemically, it can be extremely dangerous as the immune system is over 
activated and starts to attack the host system. This can lead to severe sepsis and even 
to multiple organ failure (Prucha et al, 2003). LPS is found either as a causative effect 
or a modulator in a large number of other diseases. Many diseases caused by Gram-





1.1.2 General Structure of LPS 
It is known that each Gram-negative bacterial cell has approximately 3.5x106 
molecules of LPS in its outer membrane (Rietschel et al, 1994). Each molecule of 
LPS has a molecular weight of 2000-20000 (Caroff et al, 2002). About 75% of the 
outer bacterial cell surface is made up of LPS, which accounts for 10-15% of the total 
molecules of the outer membrane. Between 1-3% of the total mass of the cell is LPS.  
The structure of LPS is heat-stable and made up of carbohydrate and lipid (Dixon & 
Darveau, 2005). The linking of a carbohydrate to a lipid is a common method to 
attach a hydrophilic biopolymer firmly to the outer surface of a membrane 
(Wilkinson, 1996). LPS represents a family grouping. They all share these 
characteristics; they are a vital part of the outer m mbrane of Gram-negative bacteria; 
they have a phospholid anchor, the lipid A moiety; they are constructed in a similar 
fashion to each other and all have endotoxic properties. There is also O antigen 
recognition (Wilkinson, 1996). 
All LPS conforms to the same general structural archite ture, (Heumann and Roger, 
2002). The majority of LPS is composed of three parts; the highly conserved Lipid A 
moiety, which is embedded into the membrane; the cor oligosaccharide and the O-
specific polysaccharide chain (Wilkinson, 1996; Erridge et al, 2002; Dixon & 
Darveau, 2005). Whilst the general structure of the LPS is the same, there is a large 
amount of diversity in the exact composition of thedifferent parts, between species 
and also between strains of these species. This is mainly due to a high variety of 
different O-polysaccharide compositions. The core also varies between strains, but far 
more between species. The Lipid A moiety varies very little, if at all, between strains, 
but more so between species (Alexander & Rietschel, 2001; Erridge et al, 2002; 
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Dobrovolskaia & Vogel 2002). There are certain conserved domains within LPS, 
which are vital to the cells’ survival as they maint  the integrity or preserve the 
whole structure of the outer membrane. The variable domains are not vital to the 
survival of the organism and their lack could be advantageous for the bacteria. 
Mostly the changes in the length of the segment will result in small changes to the 
LPS structure, whereas a major change, such as something affecting the overall 
chemical construction or the attachment of charged groups can lead to the damaging 
of the overall structure (Dixon & Davreau, 2005). Typical LPS containing all three 
segments is found commonly in Escherichia coli and many other bacterial species. It 
is often called smooth or S-form chemotype (Poxton, 1995; Wilkinson, 1996 and 
Beutler & Rietschel, 2003). So far only one group of Gram negative wild type 
bacteria has been identified, which does not express LPS; these belong to the genus 
Sphingomonas and they express a glycosphinolipid on their outer m mbrane in place 
of LPS (Kawahara et al, 1991) 
  




1.1.2.1 O-Polysaccharide chain 
LPS which has an O-polysaccharide chain, also called n O-antigen, is referred to as 
smooth LPS. Smooth LPSs are found on members of the Enterobacteriaceae, 
Pseudomonadaceae, Pasturellaceae and Vibrionaceae along with many other Gram 
negative species. There is an incredible range of diversity in the O-antigen, with over 
60 different monosaccharides and 30 different non-carbohydrate components being 
recognised so far (Raetz & Whitfield, 2002). The O-antigen is made up of several 
repeating units, which can consist of between 1 and 8 of the monosaccharides 
mentioned above and can contain or not non-carbohydrate components, as well as 
having different positions and stereochemistry of the constituents (Erridge et al, 2002; 
Raetz & Whitfield 2002; Caroff et al, 2002). The way in which the O-antigen 
repeating units are arranged varies considerably. They can be linear or branched; there 
are even some with two different O-antigens attached to the Lipid A moiety i.e. 
Pseudomonas aeruginosa (Kintz & Goldberg 2008). There is also homopolymery 
(where only one type of monosaccharide is used) or the more common 
heteropolymery (where many different monosaccharides ar  used). It is also possible 
for non-stoichiometric modifications, such as glycosylation or O-acetylation, to 
change the O-antigen (Raetz & Whitfield, 2002).  
All this leads to there being almost limitless variability between the O-antigens inside 
species. There are more than 170 O serotypes within Escherichia coli for example 
(Raetz & Whitfield, 2002). Other species though exhibit a much smaller variation 
amongst their O-antigens e.g. Klebsiella pneumoniae, Pseudomonas aeruginosa and 
Burkholderia cepacia complex (Wilkinson, 1996). This massive variation between O-
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antigens and the fact that there can be highly specific antibody responses raised 
against them means that it is possible to categorise the strains by their O-antigen 
(Erridge et al, 2002). 
The O-polysaccharide chain is the outermost part of the LPS and also of the cell, thus 
it is the main part that the immune system acts against. The O-antigen’s main function 
is to protect the bacterial cell from host defences, like bile acids and cationic peptides 
(Alexander & Rietschel, 2001). It has also been linked to protection from the 
alternative complement cascade. The O-antigen protects he bacterium by interfering 
with the assembly of the membrane attack complex (Raetz & Whitfield, 2002). The 
complement appears to bind to the O-antigen and, owing to being further out from the 
cell membrane is unable to form the pores to destroy the cells. Short O-antigen on the 
rough LPS types does not offer the same protection that the smooth LPS types offer 
(Lerouge & Vanderleyden, 2002). Chain length has also been associated with ability 
of Escherichia coli to survive neutrophil bactericidal/permeability increasing protein 
(BIP) (Weiss et al, 1986). It has also been observed that the ability of Vibrio cholerae 
rough LPS mutants to colonise the intestinal epithelium is impaired. This is due to 
increased sensitivity to cationic peptides and comple ent (Nesper et al, 2001).  
It has been observed in some species that the O-antigen is very similar to host antigen. 
This is protective, as the host’s immune system is unable to identify the bacterial cell 
and thus it is able to survive e.g. this has been observed in Helicobacter pylori 
(Appelmelk et al, 2000). A large number of wild type pathogenic gram negative 
bacterial species have naturally rough LPS, for example Haemophilus influenzae, 
Neisseria meningitidis, Neisseria gonorrhoeae or Bordetella pertussis (Erridge et al, 
2002). These species easily colonise the mucosal surf ces of the respiratory and 
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urogenital tracts. It seems that these bacteria express different terminal 
oligosaccharide domains, which are very similar to human glycosphinolipids (Erridge 
et al, 2002). The immunogenicity of the O-antigen is dependent on the adjuvant effect 
of the Lipid-A component, as O-antigen on its own is ot very immunogenic (Reeves, 
1995). 
1.1.2.2 Core polysaccharide 
The oligosaccharide core of LPS is much more conserved compared with the O-
antigen. An example of this is that E. coli has only five distinct core regions (R1, R2, 
R3, R4, K12) as is shown in the figure 1.3 below, compared with over 170 O-antigens 
so far identified (Dobrovolskaia & Vogel, 2002; Erridge et al, 2002). 
 
Figure 1.3: The sugar makeup of the five core structures of E. coli. The figure shows the difference in 
the different E. coli core types. It can been seen that the inner core vari s less than the outer core (Raetz 
& Whitfield, 2002). 
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The core is madeup of two components the inner and outer cores. The outer normally 
consists of common hexose sugars, such as glucose, galactose and N-acetyl 
galactosamine. This is sometimes referred to as the hexose region. This region is 
mostly considered more variable in nature compared with the inner core (Wilkinson, 
1996; Erridge et al, 2002; Raetz & Whitfield 2002). 
The inner core consists of much rarer sugars, such as 3-deoxy-D-manno-oct-2-
ulosonic acid (Kdo) or heptose. Kdo has so far been fou d in all cores bound to the 
carbohydrate backbone of the Lipid A moiety. Only two exceptions have been found 
so far, those of the Burkholderia cepacia complex and Acinetobacter species, which 
both have a derivative of Kdo, 2-keto-D-glycerol-D-talo-octonic acid (Ko) instead 
(Wilkinson, 1996; Vinogradov et al, 2002; Erridge et al, 2002; Vinion-Dubiel & 
Goldberg, 2003). 
It is widely held that Kdo is vital for the viability of Gram-negative bacteria. This is 
supported by the fact that the shortest rough mutant, Haemophilus influenzae strain I-
69-/b+, consists only of a kdo residue attached to the Lipid A moiety (Helander et al, 
1988). Also Chlamydia species, which have the shortest naturally occurring core 
known, consists of only 3 Kdo residues (Brade & Brade, 1987). Both of these indicate 
that a Kdo residue bound to the Lipid A moiety is vital for cell structure stability 







Figure 1.4: The structure of the core region of various Gram-negative bacterial pathogens. This is a set 
of examples of different types of core polysaccharides. The E. coli is the rough mutant R1 and it can be 
seen to have both an inner and outer region with boheptose and Kdo in the inner core. The Neisseria 
meningitidis is the entire LOS region of the organism. All isolates of Chlamydia trachomatis so far 
investigated have been found with only these three Kdos. The Haemophilus influenzae deep rough 
mutant has the shortest core seen for a viable Gram negative bacteria (Erridge et al, 2002). 
The sugars of the inner and outer cores can be replac d with charged groups, such as 
phosphate, pyrophosphate, 2-aminoethylphosphate and others. These charged groups 
are suspected to have a close association with the Ca2+ and Mg2+ ions required for 
membrane structure and function (Rietschel et al, 1994). 
The inner core’s highly conserved nature is ideal for targeting with monoclonal 
antibodies, which would be able to bind to a wide sel ction of E. coli and Salmonella 
LPS (Di Padova et al, 1993). It is also possible to try to identify a common epitope or 
epitopes and produce a vaccine that will provoke a highly cross-reactive response in 
human sera (Bennett-Guerrero et al, 2000). It is hoped that these would aid in 




1.1.2.3 Lipid A Moiety 
Lipid A is a vital structural element of LPS, which also is the main site of interaction 
of LPS with the innate immune system (Cadenas & Caden s, 2002). It has been 
hypothesised since the 1950s that the Lipid A moiety is he cause of the endotoxic 
activity of the LPS. This was demonstrated by Galanos et al (1985), when they 
showed that synthetic lipid A had identical biological activity to E. coli lipid A. This 
proved that the Lipid A moiety is the part of the molecule responsible for endotoxic 
activity. 
The Lipid A moiety is composed of a β-D-GlcN(1-6)-α-D-GlcN disaccharide carrying 
two phosphoryl groups (at positions 1 and 4’). The two phosphates can be replaced 
with other groups, such as, ethanolamine, ethanolamine phosphate, ethanolamine 
diphosphate or 4-amino-4-deoxy-L-arabinopyranose for xample. There are up to four 
acyl chains attached to this structure by ester or amide linkage. The acyl chains can be 
substituted with further fatty acids, allowing LPS molecules to have up to seven acyl 
substituents. These can vary greatly between species in nature, number, length, order 
and saturation (Rosner t al, 1979; Galanos et al, 1984; Tanamoto et al. 1984 Erwin 
& Munford, 1990; Rietschel et al, 1994; Erridge et al, 2002; Dobrolskaia & Voegel, 
2002; Dixon & Darveau, 2005). The typical structure of an E. coli Lipid A can be 
seen in the figure below. 
   
Figure 1.5 E. coli Lipid A (Erridge et al, 2002). 
The chemical structure of E. coli Lipid A, 
is widely thought that this structure is close 
to that initially identified by human cellular 
receptors. Deviations from this six acyl 
chain form are typically less biologically 
active. (Erridge at al, 2002) 
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Evidence uncovered seems to indicate that the receptor-binding specificity of Lipid A 
is determined by its hydrophilic region i.e. the phosphorylated D-glucosamine 
disaccharide. On the other hand the main site of immune cell activation is thought to 
be mostly controlled by the hydrophobic region i.e. th  acyl groups (Rietschel t al, 
1994; Alexander & Rietschel, 2001) 
The highly conserved nature of Lipid A within all species, could lead to the 
conclusion that there might be a high degree of similarity between the levels of the 
endotoxic activities. This assumption though is most certainly not the common state 
of affairs according to the current evidence. It has been observed that differences in 
Lipid A function are normal and these differences closely affect the endotoxicity of 
the Lipid A. The dissimilarities are based on structural domains, such as, which 
hexosamine is found and the extent, type and architecture of the acyl groups attached 
(Rietschel et al, 1994; Netea et al, 2002). 
  
Figure 1.6 List of different Lipid A architectures and endotoxic activities (Erridge et al, 2002) 
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A list of structures of some Lipid A’s from common rganisms as well as some less common ones. The 
endotoxicity of the Lipid A’s is also shown with the most endotoxic at the top left and the least 
endotoxic at the bottom right. (Erridge et al, 2002) 
As can be seen in Figure 1.6, many of the organisms that have very high levels of 
endotoxicity are enterobacteria such as; E. coli, Salmonella spp and Klebsiella 
pneumoniae. However, there are also non-enterobacterial Lipid A’s that exhibit high 
levels of activity e.g. Haemophilus influenzae or Neisseria meningitidis. (Netea et al, 
2002; Erridge et al, 2002; Dehus et al, 2006; Bos et al, 2007). 
It has been observed that Lipid A, isolated from other species can also vary greatly. 
The D-glucosamine in some species is replaced by 2,3-diamino-2,3-dideoxy-D-
glucose; the number of acyl groups varies between 4,5,6 and 7 groups; the acyl groups 
chain lengths also vary; the symmetrical layout of the acyl groups (3+3, 4+2, 2+2) 
varies, as does the replacement of phosphate groups (Seydel et al, 2000; Brandenburg 
& Wiese, 2004; Fujimoto et al, 2005; Schromm et al, 2007). Low activity Lipid A 
moieties often have penta-acylated structures e.g. Porphyromonas gingivalis, 
Rhodobacter sphaeroides, Bordetella pertussis or the Lipid A precursor Ia (compound 
406) (Erridge et al, 2002). In fact precursor Ia (compound 406) and Rhodobacter 
sphaeroides both have antagonistic actions. Certain hexa-acylated Lipid A species 
also have a low endotoxicity e.g. Legionella pneumophila, which in this case is due to 
an extended acyl group that is 18 carbon atoms in length. Another example is Aquifex 
pyrophilus, which is a hyperthermophile. This organism’s LPS has a distinctive Lipid 
A type as it has no phosphate group. Instead it has a D-galacturonic acid linked to 
positions 1 and 4’ instead (Alexander & Rietschel, 2001; Netea et al, 2002). Ancuta et 
al, (1996) isolated an LPS from Francisella tularensis, which has an inert Lipid A i.e. 
 27 
it is neither an agonist stimulating immune response, or is it an antagonist inhibiting 
other normal LPS types. 
A lot of work has been done on the relationship betwe n the biochemical composition 
of the Lipid A moiety and its three-dimensional shape and its biological activity 
(Seydal et al, 2000). Those LPS molecules that have a conical structure e.g. E. coli, 
have a much higher endotoxicity level, than those with a cylindrical conformation, 
such as precursor Ia (compound 406), Rhodobacter capsulans or Chromobacter 
violaceum (Seydel et al, 2000; Netea et al, 2002). Numerous factors enter into play, 
such as the nature, chain length, number and asymmetry of the acyl chains. In 
addition there is the number and distribution of negative charges, which governs the 
three-dimensional structure of Lipid A (Rietschel et al, 1994; Schromm et al 1999; 
Netea et al, 2002). This has led to the hypothesis that endotoxic activity is not the sole 
property of endotoxin, but that any molecule with such characteristics would also 









1.2 The innate immune system and endotoxin 
 
1.2.1 General overview of the innate immune system 
The main functions of the innate immune system are the recognition of pathogens and 
providing a near instantaneous defence without the need for prior exposure, such as 
would be required with the acquired immune system (Vasselon & Detmers, 2002; 
Kaisho & Akira, 2006). Until reasonably recently the innate immune system was 
considered to be naive and simplistic, compared with the acquired immune system. 
This is known to be incorrect and a high level of cmplexity has now been shown 
(Triantafilou & Triantafilou, 2005). 
There are three main parts to the innate immune syst m, the mechanical, the chemical 
and the cellular. The mechanical part of the immune system is made up of both 
physical barriers, such as the epidermis or the mucosal linings and physiological 
functions, which includes cilia action, desquamation and mucous discharge. The 
chemical part of the innate immune system is easily sub divided into three more 
categories. These are soluble or cell-linked pattern r cognition receptors (PRRs), 
proteins or peptides with hydrolytic effects on micro-organisms and the cytokines and 
chemokines, which modulate and coordinate the innate immune response. The cellular 
part of the innate immune system contains a wide vari ty of host types, which include 
epithelial cells, mast cells, macrophages, neutrophils, natural killer cells and dendritic 
cells (Basset et al, 2003). 
The main difference between the acquired and innate immune systems lies in the 
differences of the receptors of the two systems. The acquired immune system’s T and 
B cell receptors are continually created throughout the development of the cells. The 
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receptors are created in such a way so as to have a unique receptor on each 
lymphocyte. The receptors are not kept encoded for eve nor are they passed on the 
next generation. There are believed to be between 1014 to 1018 different T and B cell 
receptors (Medzhitov & Janeway, 2000). The innate immune system receptors are 
found on a much wider variety of cells, such as macrophages, dendritic cells, certain 
specific T-cell types and also B-cells. They have also been isolated from non-immune 
cells like fibroblasts and epithelial cells (Medzhitov & Janeway, 2000; Medzhitov & 
Janeway, 2000a; Akira et al, 2006). The specificities of the receptors are not affected 
by which cell it is being expressed upon (Vivier & Malissen, 2005). The receptors 
also initiate an immediate effect. There is no wait for a proliferation process, as in the 
acquired immune system (Medzhitov and Janeway, 2000). 
Structurally PRRs are made up of a wide variety of different families of proteins. 
These include leucine-rich repeat domains, calcium-dependent lectin domans and 
scavenger-receptor protein domains. There are threemain methods for PRRs to act: 
secretion, endocytosis and signalling. An example of a secreted molecule is mannan-
binding lectin; it acts by binding to specific carbohydrate structures on the surfaces of 
the micro-organisms. Once bound it is able increase the binding potential of the 
micro-organism and thus make it more susceptible to phagocytosis and the 
complement system.  Endocytic PRRs are found on the surface of phagocytes are 
extremely important in distinguishing very specific highly conserved microbial 
structures, which then facilitates the uptake of the micro-organisms into lysosymes, 
where they are destroyed. The Toll-like receptor (TLR) family is an extremely 
important type of signalling receptor. It identifies specific highly conserved microbial 
structures and stimulates signal transduction cascades that lead to expression of a 
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wide variety of immune-response genes, such as inflammatory cytokines (Medzhitov 
and Janeway 2000).  
Rather than trying to identify all the possible antigens that might be presented by 
micro-organisms, PRRs recognise a small number of highly conserved structures 
which are held in common across numerous microbial species (Akira et al, 2006). The 
highly conserved microbial structures are often referr d to as pathogen-associated 
molecular patterns (PAMPs) (Janeway and Medzhitov, 1998). Examples of common 
PAMPs found in micro-organisms includes, lipopolysaccharide, petidoglycan, 
lipoteichoic acids, mannans, bacterial DNA and double stranded RNA (Medzhitov 
and Janeway 2000a). 
Whilst there are a wide variety of different chemical ompositions of PAMPs, there 
are three characteristics common to all of them. Firstly, PAMPs are microbial 
structures not found within host cells or molecules. Secondly, they are vital either for 
the viability or the pathogenicity of the micro-organism. Thirdly, PAMPs from a 
given microbial class are normally found throughout that entire microbial class 
(Beutler, 2004; Akira et al, 2006; Horner, 2006). Being vital for the survival or 
pathogenicity of the microbe is a way to make sure that the mutation of the PAMPs is 
kept to a minimum, as any mutation would be likely to the disadvantage of the 
organism with respect to the un-mutated strains (Beutler, 2004).  
1.2.2 The role of endotoxin 
The outer membrane of Gram-negative bacteria consists of a variety of amphiphilic 
molecules; of these molecules lipopolysaccharide is normally considered to be the 
most important immunologically and microbiologically as the principal surface 
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antigen (Dixon & Darveau, 2005). Endotoxin acts as the main indicator to the 
immune system of the presence of Gram-negative bacteri  (Medzhitov & Janeway, 
2002).  
Endotoxin has two main roles in the outer membrane, firstly it acts structurally as a 
supportive macromolecular domain of the cell envelop  and secondly it acts 
functionally as a selective permeability barrier to m lecules of either negatively 
charged or hydrophobic domains, due to its highly anionic nature (Horn et al, 1996; 
Lerouge & Vanderleyden 2002). It is also thought to be an adsorption receptor for 
certain bacteriophages. There is also the toxicity and immunongenicity to a wide 
variety of higher organisms (Leive et al, 1968; Morrison & Leive, 1975). 
It has been known for a long time that pure endotoxin is extremely toxic if injected 
systemically and has very similar physiological effects to Gram-negative bacteraemia 
(Rietschal et al, 1994; Horn et al, 1996). It is due to this that endotoxin is considered 
to act as the main molecule that informs the immune system of the presence of Gram-
negative bacteria in the body (Horn et al, 2000) 
It has been shown that endotoxic recognition is mediat  by specific host receptors 
(Schletter et al, 1995; Beutler & Poltorak, 2001). This allows even v ry low 
concentrations of endotoxin to stimulate a large immune response. Since the host 
receptors act as signal amplifiers, the immune respon e is boosted beyond what would 
be normal for the immune response to that concentration of another molecule (Beutler 
& Rietschel, 2003). Endotoxin acts almost solely through its Lipid A moiety, through 
the stimulation of a potent inflammatory response, which is entirely conferred by the 
host (Riestchel et al, 1994; Beutler & Rietschel, 2003). There are other bacterial 
structures that have endotoxic-like activity, such as lipopeptides, peptidoglycans, 
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lipoteichoic acids, double stranded RNA and some bacterial exotoxins. In the majority 
of cases the outcome is a successful resolution of the bacterial infestation, rather than 
the development of lethal toxicity (Beutler & Rietschel, 2003).     
Macrophages are the most important cell involved in the immune response to 
endotoxin (Michalek et al, 1980; Freudenberg et al, 1986). This is because they are 
the main source of tumour necrosis factor alpha (TNF-α), which is a potent pro-
inflammatory cytokine (Mannel et al, 1980). It is possible though for endotoxin to 
stimulate other cells, such as endothelial cells, smooth muscle cells and neutrophils to 
produce and release other mediators of an endogenous origin. These mediators 
include bioactive lipids (e.g. platelet activating factor or thromboxane A2), reactive 
oxygen species (e.g. nitric oxide) and most importantly cytokine proteins such as 
interleukin-1 (IL-1), IL-6 and TNF-α. The number of endotoxin molecules present is 
directly proportional to the amount of mediators released, up to a threshold, which in 
turn is proportional to the pathophysiological reaction to the endotoxin (Schletter t 
al, 1995; Beutler & Poltorak 2001). TNF-α is considered to be one the most important 
contributors to the lethal aspects of endotoxin exposure and thus its production is  an 
excellent measure of endotoxic activity with the immune system. It is for this reason 
that the macrophages are considered one of the best targe s for endotoxic research 
(Beutler et al, 1985; Poltorak et al, 2000). 
Endotoxin interaction with the immune system is a constantly changing dialogue. 
There are a variety of mechanisms deployed by the host to deal with endotoxin. Thus 
to understand endotoxic interactions all the different mechanisms have to be 
considered together, as there is a large amount of overlap between the different 
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mechanisms. So it is impossible to consider one mechanism without viewing the 
whole (Elsbach, 2000).  
The mechanisms of interaction between endotoxin are both intracellular and 
extracellular; these act in concert to stimulate the immune system. The extracellular 
mechanism consists mostly of recognition molecules that bind to the endotoxin and 
signal the intracellular mechanisms which stimulate the production of an immune 
response (Antal-Szalmás, 2000). 
1.2.3 Innate immune recognition of endotoxin 
This process is summarised in Figure 1.7 below. 
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Figure 1.7: Recognition of endotoxin by the innate immune receptors.LPS acts through a variety of 
receptors, but most importantly through TLR-4 with mediation from LBP, CD-14 and MD-2 (Raetz 
& Whitfield, 2002). 
1.2.3.1 Lipopolysaccharide binding protein (LBP) 
LBP is the thought to be the first host receptor to in eract with the LPS and to start the 
inflammatory response (Schumann et al, 1990). 
LBP is a 50 kDa polypeptide normally produced in hepatocytes, where it is released 
as a glycoprotein into the blood stream (Schumann et al, 1990). Other cells have also 
been shown to produce LBP including; epithelial cels of the skin, the lung, the 
intestine, as well as human gingival tissues, lung arteries, heart muscle cells and renal 
cells (Su et al, 1994; Dentener et al, 2000). 
LBP’s primary function is to act as an amplifying system that is capable of alerting 
immune cells to tiny quantaties of LPS present (Elsbach, 2000). 
LBP is normally found in the human serum at a concentration of between 5-15µg/ml 
(Zweigner et al, 2001). The concentration of LBP increases 50-100 fold in 
inflammation due to either increased production caused by the inflammatory response 
or caused by the presence of microbial stimuli (Tobias et al, 1999). 
At physiological concentrations, LBP greatly enhances the close contact between LPS 
and other recognition molecules. Either those in serum, like soluble cluster of 
differentiation (CD) -14 and high density lipoprotein or those attached to cells, such 
as membrane CD-14 (Freudenberg t al, 2001). These interactions can bring about the 
inhibition of LPS by high density lipoprotein or activation of cells by CD-14. This 
 35 
means that the host response is governed by which of the two processes is faster. 
Studies into the kinetics of the two reactions have shown that LPS/LBP complexes 
faster with CD-14. This suggests that an initial immune cell activation is beneficial, 
but the cell activation is neutralised by the action of high density lipoprotein to stop 
the overstimulation of the response (Heumann and Roger, 2002). 
LBP has been shown to increase the endotoxin-mediated stimulation of CD-14-
positive cells by 100-1000 fold in a serum free media. It has also been shown that 
LBP transfers LPS to soluble CD-14 (sCD-14) and this is able to activate membrane 
CD-14 (mCD-14) deficient cells, such as endothelial and epithelial cells (Zweigner t
al, 2006). LBP acts as an integral part of the stable trimolecular complexes, where it is 
able to interact with LPS and CD-14. This allows monocytes to respond to 
concentrations as low as 10pg/ml (Thomas et al, 2002). It has also been suggested that 
LBP is able to present hundreds of LPS molecules to CD-14 without itself being 
consumed (Tobias et al, 1995). 
The reduction or removal of LBP in laboratory animals brings about almost the 
complete removal on any LPS–induced toxicity, which indicates the importance of 
LBP for transfer of LPS to the receptor complex in vivo. Many studies have shown 
that LBP deficient mice are unable to generate a successful immune response to 
Gram-negative bacteria, such as Salmonella typhimurium, Klebsiella pneumonia and 
E. coli and suffered increased mortatily due to bacterial over growth (Opal et al, 1999; 





CD-14 is likely to be the important second step in the LPS-signalling pathway, as 
once the LBP-LPS complex is completed it is bound to either sCD-14 or mCD-14, 
which in turn leads to activation of the immune cells (Dixon & Darveau, 2005). 
CD-14 deficient cell lines are unresponsive to LPS, but regain their ability to sense 
LPS when transfected with CD-14 (Lee t al, 1992). Genetically CD-14-deficient 
human monocytes have very low affinity for LPS binding (Couturier, 1991). 
The formation of the CD-14 - LPS complex decreases th  concentration of LPS 
required to mediate signalling by 100-1000 fold (Landmann et al, 2000). CD-14 
doesn’t have identical binding affinity for all LPS types. It has been shown by 
Cunningham et al, (1999) that E. coli, Helicobacter pylori and Porphyromonas 
gingivalis LPSs bind in different ways to CD-14. The amount of LPS from 
Porphyromonas gingivalis required to gain a 50% bind to CD-14 was ten times that of 
E. coli LPS. 
CD-14 seems to be able to measure the concentration of LPS and in response to this to 
change the charge on its surface, which promotes LPS interactions in an electrostatic 
manner (Wright, 1995). This carrier role of CD-14 is unable to distinguish between 
different microbial ligands (Wright, 1995; Cunningham et al, 1999). It seems instead 
to be a step to collect sufficient LPS for recognitio  by a second receptor (Funda et al, 
2001).  
CD-14 is also able to bind to other microbial strucures, which suggests that CD-14 is 
a possible PRR (Freudenberg et al, 2001). These structures include peptidoglycan 
from Gram-positive cell wall and Porphyromonas gingivalis fimbrie (Pugin et al, 
 37 
1994; Hajishengallis et al, 2006). This ability to bind to a variety of PAMPs from 
different organisms might be the reason why sepsis is so similar whether caused by 
Gram-negative, Gram-positive or even fungi (Landmann et al, 2000). 
1.2.3.3 Myeloid differentiation protein 2 (MD2) 
MD2 is a small cysteine rich glycoprotein, which is secreted from B-cells (Janssens & 
Beyaert, 2003). It is known to join with the ectodomain of toll like receptor 4 (TLR4). 
It has also been shown that TLR4 is unable to transduce LPS signalling without the 
attachment of MD2 (Shimazu et al, 1999). If the MD2 gene expression is disrupted in 
mice then it halts LPS signalling, showing MD2’s importance in TLR4 function 
(Schromm et al, 2001; Nagai et al 2002). Some putative methods of MD2, TLR4 
interaction are suggested in Figure 1.8. 
 
Figure 1.8: Possible methods of CD-14/LPS binding to the TLR4 and MD2 complex. (a) CD-14 
delivers the LPS directly to the MD2/TLR4 complex inducing dimerisation. (b) CD-14 catalyses 
insertion of the LPS into the cell membrane, where the hydrophobic domain interacts with the 
transmembrane domain of TLR4 and the head region interacts with the MD2. (c) insertion of the LPS 
into the cell membrane causes changes in the membrane a chitecture sensed by TLR4/MD2 complex 
(Erridge et al, 2002) 
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1.2.3.4 Toll like receptors (TLR)  
TLRs are a family of PRR which is made up of type 1 integral transmembrane 
glycoproteins. These contain leucine rich repeat (LRR) units in the pathogen binding 
ectodomains (ECD). Signal transfer occurs due to intracellular structural components. 
This includes an almost identical structure in both TLR and IL-1 receptor family 
members, known as Toll/IL-1 receptor homologous (TIR) domain, which represents 
the cytoplasmic end (Akira et al, 2006; Kaisho & Akira 2006; Pandey & Agrawal, 
2006). This TIR domain has been found in a wide variety of transmembrane and 
cytoplasmic proteins in plants, worms, arthropods, and even some bacteria. All these 
molecules are involved in host defence, thus making TIR one of the earliest signalling 
domains found (Aravind et al, 1999). 
So far 13 mammalian TLRs have been recognised; 11 of these are expressed in 
humans, TLR 1-11. Each TLR is activated by a variety of different PAMPs, 
sometimes from a large number of different organisms. The different PAMPs each 
TLR is activated by are shown in Figure 1.9. 
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Figure 1.9 TLR ligand Specificities. A list of the different TLRs and the variety of ligands they can 
bind to. (Janssens & Beyaert 2003) 
Of these receptors, the ones of most interest in the investigation are TLR2 and TLR4 
due to their relation with endotoxin (Schaub et al, 2006) 
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TLR2 
TLR2 has the ability to recognise PAMPs from a wide range of micro-organisms, 
including Gram-positive bacteria, Gram-negative bacteria, mycobacteria, fungi, 
parasites and viruses (Raetz & Whitfield, 2002; Texer au et al, 2006). 
TLR2 has the ability to bind to LPS and activate an inflammatory immune response. 
It is still undecided as to how important a receptor for LPS it is (Hirschfield et al, 
2000). It has been shown that some of the expression to LPS was due to endotoxic 
proteins attached to the LPS, as when the LPS was re-ext acted to remove the protein, 
signalling through TLR2 stopped (Brightbill et al, 1999; Hirschfeld et al, 1999; 
Hirschfeld et al, 2000). The above results were carried out with Enterobacteriaceae. 
TLR2 is well documented to be able to bind and signal LPS structures from other 
bacterial species, such as Leptospira interrogans, Porphyromonas gingivalis, 
Helicobacter pylori, Rhizobium species Sin-1, Legionella pneumophilia, Bacteroides 
fragilis and Pseudomonas aeruginosa PAC-611 (Hirschfeld et al, 2001; Werts et al, 
2001; Smith et al, 2003; Girad et al, 2003; Erridge et al, 2004). These organisms tend 
to have different structural forms from those of classic LPS, such as that of E. coli, 
which activates TLR4. The variations including the different distribution and 
differentiation of acyl chains in the lipid A moiety seems to have a different 
recognition style (Netea et al, 2002). The conical and cylindrical types of LPS may 
bind to and signal through different receptor complexes. This was shown by the fact 
that Porphyromonas ginigivalis, which has a cylindrical LPS signals through TLR2, 
whilst the conical LPS of E. coli signals through TLR4 (Hirschfeld et al, 2001; Netea 




TLR4 is considered to be the main receptor for LPS signalling in the innate immune 
system. The main pieces of evidence to support this are: firstly the loss of the LPS 
response due to a specific mutation in lps locus in a mouse model, this lps locus is 
identical to the tlr4 locus and they both encode TLR4, secondly re-purified LPS was 
unable to elucidate a response from a non-responder mouse strain C3H/HeJ, thirdly 
no human or murine TLR2 transfected cells showed any response to either re-purified 
LPS or protein- free synthetic Lipid A and finally the unresponsiveness of these TLR4 
deficient mice when challenged with lethal dose of purified LPS (Poltorak et al, 1998; 
Hoshino et al, 1999; Hirschfeld et al, 2000; Heumann & Roger, 2002). 
The biophysical properties of LPS molecules have been suggested to have a role in 
TLR signalling. It is thought that the hexa-acyl conical structure of the 
Enterobacteriaceae LPS is more favourable to signall ng through TLR4, whilst the 
penta-acyl cylindrical structure LPS is more able to signal through TLR2 (Schromm 
et al, 2000; Netea et al, 2002). Tetra-acyl Lipid A alone is unable to stimulate human 
TLR4, whilst hexa-acyl Lipid A does (Poltorak et al, 2000). It has been suggested that 
human TLR4 is able to read the LPS structure, thus evaluating the nature of the acyl 
chains, allowing the differentiation between Lipid A and tetra-acyl Lipid A (Poltorak 
et al, 2000). The other suggestion is that the TLR4 is able to distinguish between the 
different conformations of the CD-14 molecules when they are bound to the different 
Lipid A structures (Lien et al, 2000; Poltorak et al, 2000). 
A reason that TLR4 is considered to be the main receptor for LPS could be that the 
vast majority of studies into TLR signalling used only classical LPS structures. These 
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were mostly E. coli and Salmonella spp.. More than 90% of all endotoxin publications 
were done with LPS from Enterobacteriaceae (Dehus t al, 2006).  
TLR4 also is able to signal PAMPs from other organisms, such as a specific viral 
protein from Hepatitis C, plant paclitaxel and the fusion protein from respiratory 
sysncytial virus (Kurt-Jones et al, 2000; Akira et al, 2006; Machida et al, 2006). 
TLR4 is able to induce a number of different immune responses through their 
cytoplasmic signalling domains. It has a very strong similarity to IL-1 receptor (IL-
1R). Myeloid differentiation factor 88 is recruited to the activated sites on TLR 
cystolic domains. From here it is able to catalase the activation of the serine/threonine 
kinases of the IL-1 receptor-associated kinases (IRAK) family. The IRAK family then 
acts through TNF-receptor associated factor 6 (TRAF-6) to promote myeloid-
activated protein (MAP) kinase cascades and the nuclear factor (NF)-κB-inducing 
cascade (Underhill & Ozinsky, 2002). This leads to the production of a variety of pro-
inflammatory cytokines, most notably TNF-α, INF-γ, IL-1β and IL-6, as well as 
chemokines IL-8. These chemicals lead to development of fever and also up-regulate 
the acute response through the production of compleent, C-reactive protein and 






1.3 Hospital Acquired Pneumonia (HAP) 
 
1.3.1 The disease 
HAP or nosocomial pneumonia is a case of pneumonia acquired whilst in a 
nosocomial environment. It is generally defined as an inflammation in the substance 
of the lungs, brought about by a microbial infection of the lower respiratory tract. The 
infection is most often caused by bacteria, but fungal pneumonia has also been 
isolated. Viral pneumonia is rarely seen in adults, although it is a slightly more 
common in children, where it is normally accompanied by a bacterial infection 
(Kumar & Clark, 2002; Langley & Bradley, 2005).  
Patients that develop pneumonia whilst in hospital are usually immunocompromised, 
mostly due to an underlying condition. This allows the micro-organisms to gain 
access to the lungs, as the immune system is too weak to remove the infections. Other 
risk factors for the development of HAP include being attached to a ventilator, which 
inhibits the cough reflex, the bacteria are also able to colonise the tubes with biofilms. 
This means that the patient is continuously breathing in bacteria.  There is also a 
greater prevalence of antibiotic resistant organisms in hospitals than in the 
community, which mean that it is harder to eradicate the infection with antibiotic 
therapies. Recovering from surgery is another major risk for patients as the immune 
system is already under pressure and can easily become over stretched, allowing the 
micro-organism to gain a foothold in the lung (Berba et al, 1999; Mehta & 
Niederman, 2003; Wolkewitz et al, 2008).  
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1.3.2 Incidence and Epidemiology 
HAP is a huge problem in the intensive care units (ICUs) of nearly all major hospitals. 
HAP is the second most common type of nosocomial infection and accounts for a 
quarter of all infections in the ICU. When combined with primary bacteraemia, HAP 
is the leading cause of death from infection (Bowton, 1999; Beardsley et al, 2006). 
The rate of HAP varies dramatically between different hospitals. This can be seen by 
the wide variations measured by the different percentages of incidences of HAP. 
These can vary between 9% and 68%, depending on the hospital (David & Bowton, 
2006). In a study of 98 hospitals around the world, Rosenthal et al (2008) recorded 
the incidence of ventilator associated pneumonia (VAP) in patients on mechanical 
ventilators across different ICU types. These varied from 40.74% of patients in 
medical ICUs (2408 patients), 19.82% in medical surgery ICUs (26155 patients), to 
7.85% in paediatric ICUs (1808 patients). So it canbe seen from this data that HAP is 
indeed a global problem. 
The main difference between community acquired pneumonia (CAP) and HAP is the 
causative organisms. In CAP the main organism is Streptococcus pneumoniae, with 
50% of cases caused by this organism. Mycoplasma pneumoniae, Chlamydia 
pneumoniae and Influenza virus account for 5% each of the cases (Kumar & Clark, 
2002). In HAP the microbiology is very different with a variety of less directly 
pathogenic species causing the infections due to antibiotic resistance. A study of the 
micro-organisms isolated from patients in post surgical ICU wards from hospitals 




Table 1.1 The Bacteriology of Postoperative Pneumonia EOLE study. 
Organism Number of Isolates Percentage of total 
E. coli 46 9% 
Klebsiella pneumoniae 12 2.4% 
Enterobacter spp. 12 2.4% 
Serratia spp. 15 3% 
Pseudomonas aeruginosa 56 11% 
Acineobacter baumannii 6 1.2% 
Haemophilus influenzae 63 12% 










Streptococcus pneumoniae 31 6.1% 
Other Streptococcus spp. 34 6.7% 
Yeasts 23 4.6% 
As can been seen in table1.1, the incidence of organisms is very different from that 
displayed by CAP infections. Streptococcus pneumoniae is also found on the list but 
there was only an incidence of 6.1% in the study compared to an incidence of 50% in 
CAP infections. The most common organisms in HAP are coagulase positive 
Staphylococcus, most often Staphylococcus aureus. This is due to their innate 
pathogenicity, as well as their being resistant to a wide variety of antibiotics. The 
most well known of these resistant staphylococci is methicillin resistant 
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Staphylococcus aureus (MRSA), which is likely to be the main organism in the 
coagulase positive Staphylococcus group (Wolkewitz et al, 2008).  
With regard to Gram-negative organisms, there is a much greater range of causative 
organisms, with the Enterobacteriaceae as a group being the most prevalent but the 
Haemophilus influenzae being the most common Gram-negative organism. 
Haemophilus influenzae is an organism that can cause CAP but it is much rarer than 
Streptococcus pneumoniae (Kumar & Clark, 2002; Dupont et al, 2003). It is an 
opportunistic pathogen that often causes lower respiratory tract infections. It is 
commonly found in the upper respiratory tract as a commensal but it is able to infect 
an immunocompromised patient, given the opportunity (Jorgensen et al, 1990; Gür et 
al, 2002).  
Pseudomonas aeruginosa, the second most commonly isolated Gram-negative 
bacterium, is an organism that only rarely causes CAP. It is a common environmental 
organism found throughout nature in soil and water samples. It is not in itself 
particularly pathogenic but it is a quintessentially opportunistic pathogen able to 
infect people, whose immune systems are rundown and no longer functioning fully. It 
is also resistant to a wide variety of antibiotics, which means that it is able to survive 
in a hospital environment without much difficulty (Kollef et al, 2005; McGowan, 
2006) 
Members of the Enterobacteriaceae are normally found in the gut but when a patient 
is immunocompromised they are able to translocate through the gut wall and thus 
spread throughout the body to cause a wide variety of diseases. Pneumonia is a 
common side effect of this and is a major problem. Again there is a wide level of 
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antibiotic resistance in these organisms, allowing them to colonise in a hospital 
environment (Kollef et al, 2005; Alekshun & Levy, 2006). 
1.3.3 Treatment regimes 
There are a number of different antibiotics available to physicians treating patients 
with HAP. Which one is to be used depends very much on the organism that is 
present and also the particular resistances the organism might show. This is why it is 
crucial to get samples sent to the laboratory for testing quickly. It is also important for 
accurate results to be returned swiftly so that the correct drug can be given (Kumar & 
Clark, 2002).  
There are a number of difficulties with correctly isolating and identifying the 
causative organism though, as the samples taken from the lung to be tested for 
bacterial presence are usually sputum. This can be extr mely difficult to isolate 
bacteria from, as the bacteria can often form biofilms in the sputum which makes 
them harder to isolate on agar. The sputum is normally isolated from the upper 
airways and thus is not representative of the lower respiratory tract and so could give 
incorrect results for the microbiological cause of the pneumonia. Sputum is also often 
contaminated with a variety of commensal bacteria, from the mouth and the upper 
respiratory tract, which may lead to incorrect identifications. Some organisms are 
more effective growers than others and so even thoug  they may not be the causative 
organism they may appear to be in the laboratory. P. aeruginosa is a good example of 
this, as it is a very effective grower much more so than something like Haemophilus 
influenzae and on normal agar will grow easily whilst Haemophilus influenzae will be 
unable to compete. The use of bronchial lavages is a possibility to improve the 
accuracy of the results as these get bacteria from the lower respiratory tract, but they 
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can be dangerous to perform with severely ill patients. Proper use of selective media 
will aid with the removal of false positive results (Berba et al, 1999; Kollef et al, 
2005; Wolkewitz et al, 2008) 
Initial treatment regimes, before the results from the lab are available, should be 
tailored to the make up of local microbiological flora. This will reduce the use of 
ineffective antibiotics and reduce resistance forming (Beardsley et al, 2006). 
The fact that the majority of people suffering from HAP have another underlying 
condition must be taken into consideration when designing an antibiotic regime. This 
condition may already require an aggressive regime of antibiotics and so any new 
ones will have to be added in carefully to avoid exacerbating the original condition 
(Kumar & Clark 2002). 
The rise of antibiotic resistance in the last 30 years is leading to a great deal of 
problems. The rise of MRSA has already meant that very few antibiotics can be used 
to treat this organism. There are now also pan-resistant strains of other bacteria 
species now found in a hospital environment, such as Klebsiella pneumoniae and 
Acinetobacter baumannii (Trouillet et al 1998; Giamarellou et al, 2008). This means 
that there are no possible treatments for people infected with these organisms. As a 
result, it is essential that alternative non antibio c treatments for people suffering 





1.4 Acinetobacter calcoaceticus- Acinetobacter baumannii 
1.4.1 Acinetobacter calcoaceticus- Acinetobacter baumanni i biology and 
taxonomy  
Acinetobacter calcoaceticus- Acinetobacter baumannii are Gram-negative 
coccobacilli, which are known to be non-fermentative, non-motile, non-pigmented, 
catalase-positive and oxidase-negative. They are usually found occurring in 
diplococcal formations, but can be found in chains of varying lengths (Giamarellou et
al, 2008). Traditionally the species was considered to have been a commensal with 
low pathogenicity and even used to be ignored when it was isolated from clinical 
specimens in the 1970s (Bérgogne-Bérèzin & Towner, 1996). However within the last 
20 years interest has grown dramatically in these organisms, especially in 
Acinetobacter baumannii, for two main reasons. Firstly the proliferation of ICUs has 
brought about a dramatic change in the type of infections caused by Acinetobacter 
baumannii and secondly the emergence of multidrug-resistant strains some of which 
are resistant to all known antibiotics, with the exc ption of colistin (Rello & Diaz, 
2003; Giamarellou, 2006; McGowan, 2006; Giamarellou et al, 2008). It has even been 
suggested that we are closer to the end of effective antibiotic therapy with 
Acinetobacter baumannii than with MRSA (Hanlon, 2005) 
The taxonomy of Acinetobacter spp. is confusing and the organism has had a variety 
of classifications, such as in the families Neisseriaceace or Moraxellaceace. It has also 
had a variety of names within these families, such as Moraxella, Herellea, 
Achromobacter or Alcaligenes (Hanlon, 2005; Giamarllou et al, 2008). The situation 
is still not fully resolved and Acinetobacter spp. are undergoing continuous changes 
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of nomenclature. So far 32 genomic species have been id ntified of which 17 have 
been given names (Van Looveren and Goosens, 2004). Traditional identification 
methods have been found to be generally ineffective, such as Acinetobacter 
baumannii, Acinetobacter calcoaceticus, along with the as yet unnamed genospecies 3 
and 13 sensu Tjernberg and Ursing (TU), are very had to distinguish phenotypically 
and thus are often referred to as the Acinetobacter calcoaceticus- Acinetobacter 
baumannii complex (Tjernberg & Ursing, 1989; Dolzani et al, 1995). These strains 
are the most commonly associated with hospital acquired infections and they account 
for about 75% of Acinetobacter spp. isolated from clinical specimens (Henwood et al, 
2002). 
1.4.2 Epidemiology of Acinetobacter calcoaceticus- Acinetobacter 
baumannii complex 
Acinetobacter calcoaceticus- Acinetobacter baumannii complex has been found in 
soil, water, animals and humans. The Acinetobacter spp. are normal inhabitants of 
human skin but have also often been isolated in the respiratory tract of hospitalised 
patients (Paterson, 2006; Fournier & Richet 2006). Acinetobacter calcoaceticus is a 
common environmental organism found ubiquitously throughout nature, but it has 
also been isolated from human clinical cases (Dijkshoorn et al, 2007).  Acinetobacter 
spp. have also been extracted from some unlikely sources, such as food and 
arthropods. It has further been shown that Acinetobacter spp. can be found in about 
17% of fresh fruit and vegetables. Of these Acinetobacter baumannii was isolated in 
56% of isolated strains. The strains were isolated from a variety of common fruits and 
vegetables, such as apples, melons, beans, cabbage, cauliflower, carrots, potatoes, 
radishes and peppers (Berlau et al, 1999). It has been suggested that hospital food 
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could be a potential source of Acinetobacter baumannii infections, but since the 
preponderance of cases are in the ICU, this would seem to invalidate such a 
hypothesis (Corbella et al, 1996).  
Acinetobacter spp. are common commensals of the human skin with up to 75% 
carriage in hospitalised patients and between 25% - 43% in the healthy population, 
although the majority of these were not the strains that are generally associated with 
nosocomial infections (Seifert e al, 1997; Sebeny et al, 2008). Even with this high 
commensal carriage of Acinetobacter spp., skin and soft-tissue infections are rare. In a
study in America it was found that only 4.1% of all soft tissue infections were caused 
by Acinetobacter baumannii (Sader et al, 2002). There is never the less a large 
increase in soft tissue infections in traumatic injury patients, especially in patients in 
military hospitals in Afghanistan and Iraq (CDC, 2004; Fournier & Richet 2006; 
Sebeny et al, 2008). This was also observed in the Vietnam War, where Acinetobacter 
baumannii was the most commonly isolated organism from traumtic injuries 
(Fournier & Richet 2006).  
Acinetobacter baumannii is most commonly associated with nosocomial pneumonia 
and bacteraemia, as are Acinetobacter genospecies 3 & 13 TU. Their ability to survive 
in hospital environments is mostly due to its resistance to antibiotics as well as its 
ability to survive in moist and dry environments (Giamarellou et al, 2008). This 
resistance to desiccation means that Acinetobacter baumannii can colonise many 
areas of hospitals, such as ventilators, mattresses, pillows, bed rails, bedsides, distilled 
water containers, intravenous nutrition equipment, drinking water, sinks, hygroscopic 
bandages, showers, stainless-steel trolleys, resuscitation equipment and tables, 
thermometers and soap dispensers (Paterson, 2006). So it can be seen that 
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Acinetobacter baumannii and Acinetobacter genospecies 3 & 13 TU are organisms 
that can be isolated from many areas in the hospital. It is due to these properties that 
Acinetobacter baumannii is such a huge problem in hospitals causing outbreaks. Most 
important though are their resistance to antibiotics. There are some strains that are 
pan-resistant to all known antibiotics, with the sole exception of colistin 
(Giamarellou, 2006; Petrosillo et al, 2008). This means that even though 
Acinetobacter baumannii is not as aggressive as other pathogenic species, in 
immunocompromised patients who are unable to fight off the infection themselves, it 
is unable to be treated effectively. This leads to outbreaks spreading through hospital 
wards especially the ICU and being unable to be contained with conventional 
treatments (Falagas et al, 2008).  
There are a number of epidemic clones isolated so far. The three European ones are 
called clone I, II, and III. Clones I and II have caused outbreaks in north western 
Europe, with clone I also being found in Spain, South Africa, the Czech Republic, 
Poland and Italy, whilst clone II has also been isolated in Spain, South Africa, France, 
Greece and Turkey. Clone III has been isolated in Fra ce, Italy, Spain and the 
Netherlands. This suggests that these clones are highly virulent and also multidrug 
resistant. These strains cause outbreaks that are extremely difficult to control and can 
lead to endemicity of these strains in hospitals (Van Dessel et al, 2004). 
1.4.3 Acinetobacter calcoaceticus - Acinetobacter baumann ii complex 
speciation 
The Acinetobacter calcoaceticus - Acinetobacter baumannii complex is a group of 4 
very closely related organisms of Acinetobacter calcoaceticus, Acinetobacter 
baumannii and genospecies 3 and 13 TU. These organisms are almost impossible to 
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differentiate from each other by traditional phenotypic methods and it requires 16S - 
23S DNA - hybridisation to differentiate between them (Tjernberg & Ursing, 1989, 
Dolzani et al, 1995). There is another method for the identification of Acinetobacter 
baumannii from the other organisms of the Acinetobacter calcoaceticus - 
Acinetobacter baumannii complex, because it has an OXA-51-like beta lactamase. 
This carbapenenmase is not found in the other organisms of the complex. 
Acinetobacter genospecies 13 TU on the other hand though can be differentiated from 
Acinetobacter baumannii through a PCR method that differentiates between 
differences in the gyrB gene sequences (Higgins et al, 2007). 
Acinetobacter calcoaceticus is a common environmental organism that has been 
isolated from a wide variety of different of environments, such as soil, water, fruit and 
also humans. Acinetobacter baumannii’s natural reservoir has never been properly 
isolated, but it is now commonly isolated in nosocomial infections and from the skin. 
Acinetobacter genospecies 3TU has been isolated from humans, includi g clinical 
isolates, soil and fruit samples. Acinetobacter genospecies 13T U has been most 
commonly isolated from humans, including clinical isolates (Dijkshoorn et al, 2007).  
This difficulty of being able to differentiate between the species of the complex has 
meant that there is high probability that there have been a number of mis-
characterisations of organisms. So many organisms that have been thought of as 
Acinetobacter baumannii were in fact Acinetobacter calcoaceticus. This is likely to be 
the reason that many papers state that Acinetobacter baumannii is an environmental 
organism, whilst is highly unlikely that they are in fact Acinetobacter baumannii. This 
also carries over to the genospecies 3 and 13 TU as these can be mis-characterised as 
 54 
Acinetobacter baumannii isolates, when they are not infact (Van Looveren et al, 
2004).  
1.4.4 Acinetobacter calcoaceticus - Acinetobacter baumann ii  complex 
virulence factors 
Whilst normally antibiotic resistance mechanisms are not considered virulence factors 
in the case of Acinetobacter calcoaceticus - Acinetobacter baumannii, but due to the 
very small number of virulence factors isolated from the organism so far and the fact 
that without these resistance mechanisms it would not be a hospital acquired 
infection. So it seems that in this case resistance mechanisms should be considered 
under the heading of virulence factors. 
1.4.4.1 Acinetobacter calcoaceticus - Acinetobacter baumannii complex 
lipopolysaccharide 
Acinetobacter baumannii - Acinetobacter calcoaceticus complex LPS is one of the 
virulence factors exhibited by the organism. It is normally found in a smooth 
formation with a long O-polysaccharide chain. It is generally considered to be similar 
in activity to E. coli (Haseley et al, 1998; Vinogadov et al, 2003). Acinetobacter 
baumannii - Acinetobacter calcoaceticus LPS has been shown to signal the innate 
immune system through the TLR4, which indicates that it is similar in structure of its 
Lipid A moiety to the classical E. coli model (Erridge et al, 2007). LPS stimulation of 
the immune system has been suggested as the main cause of Acinetobacter 
calcoaceticus - Acinetobacter baumannii complex disease (Leung et al, 2006). 
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1.4.4.2 Resistance mechanisms 
Acinetobacter baumannii - Acinetobacter calcoaceticus complex has a wide variety of 
different resistance mechanisms which protect the organism from a large number of 
different antibiotics.  
β-lactamases 
 These include β-lactamases, such as chromosomal cephalosporinases (AmpC), as 
well as a suggested novel family of β-lactamases, the Acinetobacter derived 
cephalosporinases (Corvec t al, 2003; Hujer et al 2005). Class A β-lactamases have 
been isolated such as TEM-1 and other extended spectrum β-lactamases (ESBLs), 
such as PER-1, SHV-12, TEM-92 and CTX-M-2 have alsobeen isolated from a 
number of strains across the world (Poirel et al, 1999; Yong et al, 2003; Nagano et al, 
2004; Perez et al, 2007). 
 Metallo-β-lactamases, such as IMP-1, IMP-2, IMP-4,IMP-5, IMP-6 and IMP-11, as 
well as VIM-2, have been isolated from a number of strains in Japan and Korea (Lee 
et al, 2004; Walsh et al, 2005; Perez et al, 2007). 
Class D OXA β-lactamases that are able to inactivate carbapenems have also been 
found in strains of the Acinetobacter baumannii - Acinetobacter calcoaceticus 
complex. These include OXA-23, OXA-40 and OXA-58 (Donald et al, 2000; Bou et 
al, 2000a; Poirel et al, 2005), whilst OXA-51is found only in Acinetobacter 
baumannii (Brown et al, 2005; Turton et al, 2006). 
Outer membrane protein (OMP) modifications 
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It has been observed in a number of Acinetobacter baumannii outbreaks that there is a 
reduction in the number of OMPs present on the surface of the organism, which limits 
the access of antibiotics into the organism (Bou et al, 2000; Quale et al 2003). It is 
unknown how much this mechanism affects the resistance of the organism, as it is 
very hard to measure. A couple of OMPs have been to shown to be involved with 
resistance to certain drugs, such as the 43-kDa homologue of OprD associated with 
imipenem resistance or the 29-kDa CarO, which confers r sistance to imipenem and 
meropenem (Limansky et al, 2002; Dupont et al, 2005) 
Efflux Pumps 
The efflux pumps are specialised molecular pumps that remove toxic compounds 
from the interior of bacterial cells. There are a variety of families of efflux pumps. 
The most common families are; the major facilitator family; the small multidrug 
resistance superfamily; the multidrug and toxic extrusion superfamily and the 
resistance-nodulation-cell division family (Poole, 2005). In Acinetobacter baumannii 
- Acinetobacter calcoaceticus complex, a member of the resistance-nodulation-cell 
division family, called the AdeABC efflux pump, has been well characterised. It 
removes aminoglycosides, cefotaxime, tetracyclines, erythromycin, chloramphenicol, 
trimethoprim and fluoroquinolones (Perez et al, 2007). Over-expression of the 
AdeABC efflux pump has been theorised to provide high level resistance to 






As well as the efflux pump mentioned above, Acinetobacter baumannii - 
Acinetobacter calcoaceticus complex also produces aminoglycoside modifying 
enzymes (AMEs). There are a variety of these including acetyltransferases, 
nucleotidyltransferases and phosphototransferases. Th e AMEs are widespread 
throughout the world and are expressed by a wide vari ty of Acinetobacter baumannii 
strains (Peleg et al, 2008).  
Quinolone resistance 
Quinolone resistance is primarily mediated by structural changes in DNA gyrase, 
caused by mutations in the gyrA and parC genes (Seward & Towner, 1998). These 
modifications mean that the quinolone has a lower affinity for the enzyme-DNA 
complex and as a result the quinolone cannot halt te DNA gyrase effectively. The 
efflux pump also acts a resistance mechanism for quinolones (Perez et al, 2007). 
Tetracycline resistance 
There are two separate mechanisms of resistance to tetracyclines described in 
Acinetobacter baumannii - Acinetobacter calcoaceticus complex. The first are 
specific transposon-mediated efflux pumps, known as TetA and TetB. TetA drives the 
removal of tetracycline, whilst TetB removes tetracycline and minocycline (Perez et 
al, 2007; Peleg et al, 2008). The second mechanism is a ribosomal protecti n protein, 





Polymyxin B and E are peptide antibiotics originally isolated in 1947 and are 
currently used as a last resort for cases of multidr g-resistant Acinetobacter 
baumannii. There have been recent reports of resistance developing to even these 
antimicrobials throughout the world (Urban et al, 2001; Gales et al, 2006). Currently 
the resistance mechanism remains unknown. However it has been shown that small 
changes to the LPS binding site have led to resistance in E. coli, Salmonella spp. and 
Pseudomonas aeruginosa (Conrad & Galanos 1989; Peterson et al, 1987). 
1.4.4 Control of the organism 
Pan-resistant strains have been isolated from a variety of hospitals world wide, which 
means that normal therapies and control strategies are no longer effective. Strategies 
such as proper observance of hand hygiene and also proper management of antibiotic 
programmes to slow the development of resistance need to be implemented fully 
(Giamarellou 2006). Also it is important to try to maintain the strength of currently 
available antibiotics. This can be achieved by the us  of antimicrobials that have more 
than one target of mechanism of action. Furthermore, β-lactams and fluoroquinolones 
should not be used together. It is also possible to maintain the effectiveness of 
antibiotics by making sure they are prescribed in shorter doses and that concentrations 
are at the correct levels (Peterson, 2005). There also needs to be much greater 
interaction between the labs and clinicians, so that when a susceptibility of the 




1.5 Aims of the Project 
1 The preparation and characterisation of LPS extracted from 
Acinetobacter genospecies 13 TU and Haemophilus influenzae 
(Escherichia coli, Klebsiella pneumoniae and Pseudomonas aeruginosa 
LPS was extracted as controls of common gram negative lung 
pathogens). 
2 To ascertain the levels of antibody to Acinetobacter genospecies 13 TU 
and Haemophilus influenzae LPS in the normal population, by ELISAs 
on serum from blood donors. 475 donors were tested to determine the 
range of levels and see if there are likely to be common epitopes in LPS 
of each species. This will be done initially by seeing whether people that 
are high responders to one LPS will also have high levels of response to 
other levels of  LPS and vice versa. 
3 Check through use of Inhibition ELISAs for cross-reactivity between the 
different LPS antigens. Thus seeing if there is a put tive target for a 
passive vaccine. 
4 The levels of the innate immune response to the diff rent LPSs will be 
investigated by measuring the induction of inflammatory cytokines from 
THP-1 cells using QPCR. This will demonstrate how potent the 
Acinetobacter and Haemophilus LPS are and also give us an idea of the 




2. Materials and Methods 
 
 
2.1 Growth and LPS extraction methods 
 
2.1.1 Strains used 
 
Samples were received from the diagnostic laboratories f om the Royal infirmary of 
Edinburgh (RIE), as follows 
 4 samples of Haemophilus influenzae.  
 2 samples of Pseudomonas aeruginosa.  
2 samples of Klebsiella pneumoniae.  
2 samples of Escherichia coli. 
8 samples from Acinetobacter genospecies 13 TU. 


























Species Strain Source 
Haemophilus influenzae MPRL 4790 Respiratory Tract 
Haemophilus influenzae MPRL 4838 Respiratory Tract 
Haemophilus influenzae MPRL 4839 Respiratory Tract 
Haemophilus influenzae MPRL 4840 Respiratory Tract 
Pseudomonas aeruginosa MPRL 4789 Respiratory Tract 
Pseudomonas aeruginosa MPRL 4845 Respiratory Tract 
Klebsiella pneumoniae MPRL 4841 Respiratory Tract 
Klebsiella pneumoniae MPRL 4844 Respiratory Tract 
Escherichia coli MPRL 4842 Respiratory Tract 
Escherichia coli MPRL 4843 Respiratory Tract 
Acinetobacter genospecies 
13 TU MPRL 4793 Blood 
Acinetobacter genospecies 
13 TU MPRL 4799 Blood 
Acinetobacter genospecies 
13 TU MPRL 4800 Blood 
Acinetobacter genospecies 
13 TU MPRL 4801 Blood 
Acinetobacter genospecies 
13 TU MPRL 4802 Respiratory Tract 
Acinetobacter genospecies 
13 TU MPRL 4803 Blood 
Acinetobacter genospecies 
13 TU MPRL 4808 Respiratory Tract 
Acinetobacter genospecies 
13 TU MPRL 4809 Respiratory Tract 
 
The strains received and where they were isolated from in the 
patient. 
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2.1.2 Growing the Strains 
 
The Pseudomonas aeruginosa, Klebsiella pneumoniae, Escherichia coli, and 
Acinetobacter genospecies 13 TU strains were grown in 100 ml of nutrient broth 
overnight at 37°C in an orbital incubator. The culture was gram stained to make sure 
that it was a pure growth of gram negative rods, the broth was also streaked out onto a 
nutrient agar plate, except for Acinetobacter genospecies 13 TU which was streaked 
onto blood agar. These were then incubated over night at 37°C to make sure that there 
was only one colony type. A 10 ml volume of the initial growth broth was added to 
each of 6 2L conical flasks containing 1L of nutrient broth. These were incubated 
overnight at 37°C in an orbital incubator. Again the cultures were gram stained and 
plated out as above to test for purity.  
Haemophilus influenzae was grown differently due to the additional growth 
requirements that it requires. It was grown as above except that the growth medium 
was brain heart infusion (BHI) with 5% fildes extract (Oxoid, Basingstoke, UK) as 
suggested by Bergeron et al (1987), with bacitracin to remove any Gram-positive 
contamination. The purity of the organism was tested by plating it on chocolate blood 
agar. Otherwise it was grown in the same manner as the other organisms. 
 
2.1.3 Harvesting the bacteria 
The broth containing the bacterial growth was centrifuged in a Sorval RC 26 at an rcf 
of 16911g for 15 minutes at 4ºC using an SLA 3000 rotor. This was repeated until all 
6L of bacteria had been pelleted. The pellets were re-suspended in phosphate buffered 
saline (PBS, 50nM, pH 7.4) and pooled together. This was then spun down in a Sorval 
RC 26 at an rcf of 15146g for 15 minutes at 4ºC using an SLA 1500. This was 
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repeated twice more, after which the pellets were frozen at -20ºC. They were then 
freeze dried overnight using a freeze drier. 
 
2.1.4 Extracting the LPS 
The LPS was extracted using the aqueous phenol method, as developed by Westphal 
& Jann (1965) and described by Hancock & Poxton (1988). The freeze-dried bacteria 
were weighed and were re-suspended in pyrogen-free wat r at a concentration of 5% 
w/v. The bacterial suspension was heated in a boiling bath to 65ºC, as was an equal 
volume of 90% (w/w) aqueous phenol. The two solutions were mixed together and 
kept at 65ºC for 15 minutes stirring every two to three minutes. The mixture was then 
placed on ice and allowed to cool to allow the layers to separate. This was then 
centrifuged in the Sorval RC 26 centrifuge at an rcf of 15146g for 15 minutes at 4ºC 
in a SLA 1500 rotor. The top layer of the phenol was removed and placed in a new 
tube and re-centrifuged in the Sorval RC 26 at an rcf of 14476g for 15 minutes at 4ºC 
in a SA – 600 rotor. Again the top layer was removed and placed into pre-prepared 
dialysis membrane (Viking 32/32) and left in a contai er with a running tap overnight 
to remove the phenol from the solution. The sample was centrifuged again in the 
Sorval Rc 26 at an rcf of 14476g to remove any impurities that may have remained. 
Now the sample was centrifuged in a Sorval ultracentrifuge at an rcf of 100 000g for 3 
hours at 4ºC. It was removed and the supernatant was discarded. The pellet was re-
suspended with pyrogen free water using a syringe fitted with a 26 guage needle and 
then re-centrifuged in the ultra centrifuge as above. The pellet was once again re-
suspended in about 4ml of pyrogen free water and transferred into a pre-weighed 
plastic bijou and frozen overnight at -20ºC. It was then freeze-dried overnight and 
weighed to determine the weight of LPS obtained from the extraction. 
 63 
 
2.1.5 Repurification of LPS. 
The Vogel’s method for the repurification of LPS after initial extraction, developed 
by Hirshfield et al (2000), was used to remove any remaining cell surface protein 
from the LPS. The freeze dried LPS was suspended in 0.2% triethylamine at a 
concentration of 5mg/ml. A 500µl volume of the suspension was transferred into a 
1.5ml microcentrifuge tube and 100µl of 3% sodium deoxycholate solution (creating a 
0.5% concentration of sodium deoxycholate). This wamixed briefly and then 600µl 
of water-saturated phenol was added. This new solution was vortexed intermittently 
for 5 minutes, the phase was then allowed to separate for 5 minutes at room 
temperature. The sample was then placed on ice for 5 minutes and then centrifuged at 
10000g for 2mins. 
The top aqueous layer (including any white material at the phase interface) was 
transferred to another 1.5ml microcentrifuge tube. The lower phenol layer was re-
extracted with 600µl of 0.2% triethylamine / 0.5% sodium deoxycholate, as described 
above. The top aqueous layer was pooled with the previously collected top aqueous 
layer. 
The pooled samples were divided into two 1.5ml microcentrifuge tubes and both 
extracted with 600µl of water-saturated phenol. The top aqueous layers w e 
transferred to another 1.5ml microcentrifuge and the volume was measured. 1 volume 
of 300mM sodium acetate was added to 9 volumes of the aqueous phase and mixed 
briefly. 
Volumes of 400µl of the above samples were transferred to separate microcentrifuge 
tubes and 1.2ml ethanol was added (making a concentratio  of 75% ethanol in each 
tube). This was allowed to precipitate at -20ºC for 1 hour. The samples were then 
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centrifuged at 10000g for 10 minutes. The supernatant w s discarded and the 
precipitate was resuspended and pooled in cold ethanol (-20ºC). This was wash 
precipitated by centrifugation at 10000g for 10 minutes. The supernatant was 
discarded and the precipitate allowed to dry at room temperature. The dried 
precipitate was dissolved, at a concentration of 5mg/ml, in 0.2% triethylamine and 
stored at -20ºC. 
 
2.2 Staining and gel methods 
 
2.2.1 Polyacrylamide gel electrophoresis (PAGE) 
A 10µl volume of the LPS dissolved in the 0.2% triethylamine was added to an equal 
volume of double strength sample buffer in a microcentrifuge tube. This was then 
heated to 100ºC for three minutes. A 15µl volume of the sample and buffer solution 
was added into a well in the NuPAGE 10% acrylamide mini-gel (Invitrogen). The gel 
was then run at 200 volts in the XCell SureLocktm Mini-Cell (Invitrogen) for 30-40 
minutes. The gel was then carefully removed from the casing and either placed in LPS 
fixative overnight for a silver stain the next day or used directly in a Western blotting 
experiment 
 
2.2.2 Western Blotting 
A rectangle of nitrocellulose membrane 2cm longer and 1 cm wider than the gel area 
was cut out marked on one side with a soft pencil mark. The nitrocellulose membrane 
was placed into Western blot electrode buffer and left for ten minutes. Four sheets of 
blotting paper larger than the nitrocellulose membrane were cut out and soaked in 
Western blot electrode buffer for 10 minutes. The gel was placed in the Western 
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electrode buffer for 10 minutes to remove salts. Two sheets of blotting paper were 
placed in the cathode side of the Western blot gel cassette and then the gel was placed 
on the blotting paper. The nitrocellulose membrane was carefully placed on the gel, 
making sure no air bubbles were trapped and the remaining two pieces of blotting 
paper were laid on top of the nitrocellulose membrane. The cassette was then sealed 
and placed into the Flowgen B4-0200 electro-blotting u it. The cassette was then 
covered in electrode buffer and the blotting tank was run at a constant voltage of 
about 5V, which gave a constant current of 40mA. The Western blot was run over 
night at a temperature of 4ºC. At the end of the transfer, the cassette was removed 
from the tank and the nitro cellulose membrane was transferred into a box and 
covered in 50ml of Tris buffered saline (TBS). 
 
2.2.3 Silver Stain for LPS 
The PAGE gel was placed in plastic box and covered in LPS fixative (25% propan-2-
ol, 7% acetic acid) overnight to fix the LPS into the gel. After this step, all other 
solutions were agitated on a rocker platform at a rate of 10-20 tilts per minute.  
The fixative was discarded and the gel was oxidised in 154ml of oxidiser solution 
(0.7% periodic acid in dilute fixative) for 15 minutes. The oxidiser was discarded and 
the gel was washed four times in 200ml of pyrogen-fr e water for one hour. The water 
was discarded between each wash. Ammoniacal silver nitrate solution (100ml 0.076% 
NaOH, 0.014% ammonia solution, 0.078% silver nitrate solution in pyrogen-free 
water) was freshly prepared and then added to the gel and left for 15 minutes and then 
discarded down a fume cupboard sink with lots of water. The gel was washed four 
times in 200ml of pyrogen-free water for 10 minutes. Developer (200ml 0.005% citric 
acid in .019% formaldehyde solution) was freshly prepared and poured onto the gel 
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until the correct staining intensity was achieved. The gel was then washed twice more 
for 5-10 minutes each time in 200ml of pyrogen free water. The gel was finally 
scanned and saved. 
 
2.2.4 Colloidal Gold Stain 
The nitrocellulose membrane from the Western blot was placed into 100ml of Tween-
20 Tris-Buffered Saline (TTBS) and washed for 20 minutes and repeated twice more. 
The nitrocellulose membrane was then rinsed with 100ml of pyrogen-free water for 2 
minutes, this was also repeated twice. Colloidal Gold T tal Protein Stain (50ml: 
Biorad) was poured onto the nitrocellulose membrane; this was left for 1-2 hours until 
all the bands had appeared. Once the bands had appeared, the Colloidal Gold Stain 
was poured off and the membrane was washed with 100 ml of pyrogen free water for 
1 minute; this was repeated twice and the membrane w s scanned and saved. 
 
2.2.5 Limulus Amoebocyte Lysate (LAL) assay 
The endotoxic activity of the different LPS extractions was ascertained through the 
use of an endpoint LAL assay. This was done using a Pyrochrome LAL kit 
(Associates of Cape Cod), which is based on the work d ne by Levin and Bang 
(1964). The kit was used following the instructions of the manufacturers. The 
Pyrochrome was re-suspended in 3.2 ml of Pyrochrome buff r and kept on ice. For 
the creation of a standard curve, firstly 4.0 ml of LAL reagent water (LRW) was 
added to 0.2 ng of E. coli endotoxin to create a concentration of 0.5 endotoxic units 
(EU)/ml. This was then used at a doubling dilution from 0.5 EU/ml with seven 
doubling dilutions, to make a seven point standard curve. All the LPS samples were 
diluted to 1 ng/ml, 100 pg/ml, 10 pg/ml, 1 pg/ml and 0.1 pg/ml in LRW. These 
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dilutions were then added at 50 µl per well of a 96 well plate. Pyrogen free water was 
used as a control. The Pyrochrome reagent (50 µl) was added to all samples and the 
control. The plate was then shaken gently and incubated at 37ºC for 30 minutes. 
Acetic acid (50%, 25 µl) in Pyrogen free water was added to each well to stop the 
reaction. The plate was then read at 405nm on an Anthos 2001 automated plate 
reader. 
 
2.3 Antibody work 
 
2.3.1 Serum samples 
After ethical approval was granted, the serum samples were obtained from 500 
healthy blood donors from the Southeast Scotland Blood Transfusion Service. These 
were collected and stored at -20ºC. The serum samples were diluted 1 in 200 in serum 
and conjugate dilulent (0.05M sodium phosphate buffer pH 7.4, 0.85% w/v sodium 
chloride, 0.05% Tween-20, 0.02% w/v sodium azide) and lso stored at -20ºC for four 
months before more was made. 
 
 
2.3.2 Pooled serum 
Pooled serum was made by mixing together 100µl of serum from 250 blood donors to 
make 25ml. This was stored at -20ºC and was diluted 1 in 50 in serum and conjugate 




2.3.3 LPS and Polymyxin B complex formation. 
The repurified LPS was diluted to a concentration of 1mg/ml (w/v) and 1 ml was 
mixed with an equal volume of polymyxin B also at a concentration of 1mg/ml (w/v). 
The solution was sonicated at 10µm for 30 seconds. The solution was then gently 
rotated for 1.5 hours at room temperature after which it was re-sonicated as above. 
The solution was dialysed overnight (Spectra pore membrane MWCO 2000) against 
pyrogen free water to remove any non complexed LPS or polymyxin B. The 
complexed LPS and polymyxin B was stored at -20ºC. 
 
2.3.4 Enzyme Linked Immunosorbant Assay (ELISA) protocol. 
The procedure was taken from Allan et al. (1995). 
The LPS and polymyxin B complex was diluted 1 in 50 in antigen diluent (0.05M 
carbonate/bicarbonate, pH 9.6, containing 0.02% sodium azide) and 100µl was 
pipetted into each well in a 96 well Medisorp plate (Nunc) and incubated at room 
temperature overnight. The plates were washed threeim s in ELISA wash buffer 
(PBS, pH 7.4 containing Tween-20, 0.05% w/v) and then blocked with 100µl of 3% 
fish gelatine (Sigma) in PBS with 0.02% sodium azide and incubated at room 
temperature overnight. The plates were washed threeim s with ELISA wash buffer 
and twice with pyrogen-free water. They were then stored at -20ºC until required.  
A volume of 100µl of the 1 in 200 diluted serum samples collected from the Blood 
Transfusion Service were placed into the wells and incubated at 37ºC for 1.5 hours 
and then washed three times in ELISA wash buffer. Anti-human IgG alkaline 
phosphatase conjugate goat antibody (Sigma) was dilute  1 in 1000 in serum and 
conjugate dilulent and 100µl per well was pipetted onto the plate. The plate was 
incubated for 1.5 hours at 37ºC and then washed thre times in ELISA wash buffer. 
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Alkaline phosphatase substrate was prepared at a concentration of 1mg/ml (w/v) in 
0.05M carbonate bicarbonate buffer pH 9.8 containing 1mM MgCl2. This was added 
to the plate and incubated for 30-40 minutes at room temperature. The plates were 
then read in an Anthos 2001 plate reader at an optical density of 405nm. The 96th well 
of each plate was a control serum sample from a known healthy donor. 
 
2.3.5 ELISA inhibition assay 
This protocol was developed from Allan et al (1995). 
The LPS was diluted 1 in 8 in antigen diluent (0.05M carbonate/bicarbonate, pH 9.6, 
containing 0.02% sodium azide) and 100µl per well was pipetted into a 96 well 
Medisorp plate (Nunc) and incubated at room temperature overnight. The plates were 
washed 3 times with ELISA wash buffer (PBS, pH 7.4 containing tween 20, 0.05% 
w/v) and then the plates were blocked with 200µl of 3% fish gelatine (Sigma) in tris 
buffered saline with 0.02% sodium azide. The plates w re incubated overnight at 
room temperature and then washed three times in ELISA wash buffer and twice with 
pyrogen free water. LPS extracted from the strains of bacteria was mixed at 
concentrations of; 1mg/ml, 200mg/ml, 40mg/ml, 8mg/ml, 1.6mg/ml, 0.32mg/ml, 
0.06mg/ml and 0.01mg/ml with the 1 in 50 dilution of the pooled serum samples. 
They were incubated for 30 minutes at 37ºC. The dilutions of LPS (100 µl) and 
pooled serum were plated onto the plate and incubated for 1.5 hours at 37ºC. The 
plate was then washed three times in ELISA wash buffer. Anti-human IgG alkaline 
phosphatase conjugate goat antibody (Sigma) was dilute  1 in 20000 in serum and 
conjugate dilulent and 100µl per well was pipetted onto the plate. The plate was 
incubated for 1.5 hours at 37ºC and then washed thre times in ELISA wash buffer. 
Alkaline phosphatase substrate was prepared at a concentration of 1mg/ml (w/v) in 
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0.05M carbonate bicarbonate buffer pH 9.8 containing 1mM MgCl2. This was added 
to the plate and incubated for 30-40 minutes at room temperature. The plates were 
then read in an Anthos 2001 plate reader at an optical density of 405nm. Dilutions of 
control LPS from E. coli O18 were used as a positive control. 
 
2.4 Cell Culture 
 
2.4.1 Cell line 
The cell line used for this study was the human acute monocytic leukaemia cell line 
(THP-1). This cell line was derived from a 1 year old human male, (Tsuchiya et al, 
1980). 
2.4.2 Media used 
The cells were grown initially in a start up culture of RPMI-1640 medium (Sigma), 
20% foetal bovine serum, 10 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
(HEPES) (Sigma), 6mM L- glutamine (Sigma) and 1% pen-strep (Sigma) 
(RPMI/20%FBS/HEPES/L-Glu/PS+G). For routine growth once the cells were 
established a medium containing RPMI-1640 with 10% FBS, 6mM L-glutamine and 
1% pen-strep (RPMI/10%FBS/L-Glu/PS+G) was used. To differentiate the cells a 
solution of 20µM vitamin D3 (sigma) was added to the medium to make  final 
concentration of 20nM. This was added every day for three days. The cells were 
incubated at 37ºC with 5% CO2 in a CO2 incubator. The cells were placed into liquid 
nitrogen storage in a freezing medium containing 30% sterile glycerol (Sigma) and 




2.4.3 Cell preparation for cytokine production 
The cells were counted using an improved Neubauer counter and re-suspended at a 
concentration of 1x106 cells/ml. 1ml of the cells was plated in 14 wells of a 24 well 
cell culture plate (Costar). This was incubated at 37ºC in a CO2 incubator for 1 hour to 
allow the cells to re-attach to the plastic. The cells were then stimulated with LPS 
from the following species and strains. 
Table 2.2: Strains used for TNF-α production. 
Haemophilus influenzae MPRL 4839 
Haemophilus influenzae MPRL 4840 
Pseudomonas aeruginosa MPRL 4789 
Pseudomonas aeruginosa MPRL 4845 
Klebsiella pneumoniae MPRL 4841 
Klebsiella pneumoniae MPRL 4844 
Escherichia coli MPRL 4842 
Escherichia coli MPRL 4843 
Acinetobacter genospecies 
13 TU MPRL 4802 
Acinetobacter genospecies 
13 TU MPRL 4809 
 
The LPS was added at 100ng/ml to the first well and then underwent ten-fold 
dilutions in the other wells until it reached a cone tration of 0.1pg/ml. This was 











2.5 RNA analysis 
 
2.5.1 Primers 
The Primers were designed using the primer 3 websit 
(http://fokker.wi.mit.edu/primer3/input.htm) and ordered from VhBio. The genes of 
interest were; 18S Ribosomal RNA, Tumour Necrosis Factor α (TNF-α), Interferon-γ 
(IFN-γ), Interleukin-1β (IL-1β), Interleukin-8 (IL-8) and Interleukin-10 (IL-10). 
Table 2.3: Primers of the genes of interest. 
Gene of Interest Primers Size 
18S Ribosomal RNA 
Forward 
CTCAACACGGGAAACCTCAC 





TNF-α Forward AGCTGTTGAATGCCTGGAAG 
TNF-α Reverse TGTTGGGGAGAAGGAGAATG 
 
151 bp 
IFN-γ Forward CGGGGAGTACTGAGAAGCAG 
IFN-γ Reverse CAGTTCCTTGGTGGCTGAGT 
 
155 bp 
Il-1β Forward TGCACTGCTGTGTCCCTAAC 
Il-1β Reverse TCTTTCAACACGCAGGACAG 
 
151 bp 
Il-8 Forward CAGGAATTGAATGGGTTTGC 
Il-8 Reverse TGGATCCTGGCTAGCAGACTA 
 
151 bp 
Il-10 Forward CCAAGACCTGGGTTGTCATC 








2.5.2 DNA extraction 
The DNA was extracted from the THP-1 cells using NucleoSpin® Tissue (Machery-
Nagel)  
The THP-1 cells were used at a concentration of 2x106 cells/ml. The cells were 
centrifuged at 1500g for 5 minutes at room temperature and the medium discarded. 
The cells were re-suspended in a 200µl of buffer T1. 25µl of proteinase K solution 
and 200µl of buffer B3 was added to the solution. The soluti n was incubated at 70ºC 
for 10-15 minutes. 
Ethanol (210µl,100%) was added to the sample and vortexed vigorously to adjust the 
binding conditions of the DNA. Each sample was added to a NucleoSpin® Tissue 
column, loaded into a collection tube, and centrifuged at 11000g for 1 minute to bind 
the DNA to the filter. The flow-through was discarded and the column replaced into 
the collection tube.  
Buffer BW (500µl) was added to the column and centrifuged at 11000g for 1 minute. 
The flow-through was discarded and the column was replaced into the tube. Buffer B5 
(600µl) was added to the column and centrifuged at 11000g for 1 minute. The flow-
through was discarded and the column replaced into the collection tube. The column 
was centrifuged at 11000g for 1 minute to dry the membrane and remove any residual 
ethanol. 
The column was then placed in a 1.5ml microcentrifuge tube and 100µl of pre-
warmed (70ºC) elution buffer BE was added. This wasincubated at room temperature 
for 1 minute and then centrifuged at 11000g for 1 minute.  




 2.5.3 RNA extraction 
The RNA was extracted using the Purelink™ Micro-to-Midi total RNA purification 
system (Invitrogen). Fresh RNA lysis buffer was prepared by adding 1% (v/v) to the 
lysis buffer. The lysis buffer was pipetted onto the THP-1 cell monolayer at 0.3ml in 
each well, once the supernatant had been removed. This was then pipetted up and 
down until the cells appeared lysed. The lysis buffer was then passed through a 19 
gauge needle attached to an RNase free syringe. This was then transferred into an 
RNase free 1.5ml Eppendorf tube. An equal volume of 70% ethanol was added to the 
lysis buffer. This mixture was vortexed thoroughly to disperse any precipitate.  
Then 700µl was transferred to an RNA Spin Cartridge inserted into a collection tube. 
The tube was centrifuged at 12000g for 30 seconds at room temperature and the flow-
through was discarded. The spin cartridge was replac d in the collection tube. Wash 
buffer 1 (700µl) was added to the spin cartridge and centrifuged at 12000g for 30 
seconds at room temperature. The flow-through and collection tube were discarded 
and the spin cartridge was replaced with an RNA wash tube. Wash Buffer 2 (500µl) 
was placed in the spin cartridge and centrifuged at 12000g for 30 seconds at room 
temperature. The flow-through was discarded and the spin cartridge was replaced in 
the tube. This step was repeated once. 
The spin cartridge was centrifuged at 12000g for 1 minute at room temperature to dry 
the membrane. The collection tube was discarded and the spin cartridge was placed in 
an RNA recovery tube. RNase free water (50ul) was added to the spin cartridge and 
left for 1 minute at room temperature to incubate. This was then centrifuged at 
12000g for 2 minutes at room temperature to elute the RNA. The eluted RNA was 
stored at -70ºC. 
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2.5.4 Reverse transcription of the RNA 
This was carried out using the Ambion RETROscript Reverse Transcription for RT-
PCR. Total RNA (1-2µg) and 2µl Oligo(dT) were mixed in a 1.5 ml Eppendorf tube 
and made up to 12µl with nuclease-free water. This mixture was briefly mixed and 
heated for 3 minutes at 70-85ºC. The tubes were then removed to ice before being 
centrifuged briefly and returned to ice. 10X RT Buffer (2µl), 4 µl dNTP mix, 1 µl 
RNase inhibitor and 1 µl reverse transcriptase were added to give a final volume of 20 
µl. The mixture was mixed gently and centrifuged briefly before being incubated for 1 
hour at 42-44ºC. The tubes were then incubated at 92ºC for 10 minutes to inactivate 
the reverse transcriptase. The RNA had now been converted into complementary 
(c)DNA. The samples were stored at -20ºC for future us . 
 
2.5.5 Polymerase Chain Reaction (PCR) 
In a 200µl PCR tube 5µl of PCR buffer (VhBio), 2µl of DnTPs (Amersham 
Pharmacia Biotech), 1µl of PCR Enhancer (VhBio), 1.5µl Forwards Primer, 1.5µl 
Reverse Primer, 4µl DNA and 0.5µl Moltaq (VhBio) were mixed. Nuclease free water 
34.5 µl was added to make the final volume 50µl. This was all carried out on ice.  
The tubes were placed in a TC 412 Techne PCR machine and heated to 95ºC for 5 
minutes for initial denaturisation. The samples were then denatured at 95ºC for 30 
seconds, then annealed at 56ºC for 30 seconds and the  extended at 72ºC for 30 
seconds. This was repeated for another 39 cycles. Then there was a final extension at 
72ºC for 10 minutes.  
The samples were mixed with loading buffer at a concentration of 90%(v/v) then run 
on a 2% agarose gel for 3 hours with a 100bp ladder (promega). The gel was imaged 
using a Gel Imager. 
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2.5.6 Quantitative PCR (QPCR) 
2.5.6.1 Primer concentration testing 
Firstly, it was necessary to calculate the ideal concentration of primers to be used for 
each gene. To this end, four dilutions of the primes were prepared. These dilutions 
were 50nM, 100nM, 200nM and 400nM and they were tested with DNA extracted 
from THP-1 cells. The 50nM concentration contained 1µl of forward primer (from the 
1µM stock solution), 1µl of reverse primer (the 1µM stock solution), 2µl of DNA, 6µl 
of nuclease free water and 10µl of SYBR green (Sigma-Aldrich). The 100nM 
concentration contained 2µl of forward primer (from the 1µM stock solution), 2µl of 
reverse primer (the 1µM stock solution), 2µl of DNA, 4µl of nuclease free water and 
10µl of SYBR green. The 200nM concentration contained 4µl of forward primer 
(from the 1µM stock solution), 4µl of reverse primer (the 1µM stock solution), 2µl of 
DNA and 10µl of SYBR green. The 400nM concentration contained 0.8µl of forward 
primer (from the 10µM stock solution), 0.8µl of reverse primer (the 10µM stock 
solution), 2µl of DNA, 6.4µl of nuclease free water and 10µl of SYBR green. A 
negative control was used for all primers. This wasthe same as for the 100nM primer 
concentration, but without any DNA. The make up of the negative control was thus as 
follows: 2µl of forward primer (from the 1µM stock solution), 2µl of reverse primer 
(the 1µM stock solution), 6µl of nuclease free water and 10µl of SYBR green. Each 
primer dilution and negative control was carried out in triplicate. 
The plate was then placed into a Stratagene Mx3000P QPCR machine and heated to 
95ºC for 5 minutes for initial denaturisation. The samples were then denatured at 95ºC 
for 20 seconds, annealed at 56ºC for 20 seconds and the  extended at 72ºC for 20 
seconds. This was repeated for another 39 cycles. There was a final cycle of heating 
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to 95ºC for 1 minute, annealed at 50ºC for 30 seconds a d then a final heating at 95ºC 
for 30 seconds. 
 
2.5.6.2 Dilution of antigen testing for complimentary DNA (cDNA). 
After the best concentrations of primer were calculated, it was also necessary to work 
out which two concentrations of the cDNA to use. The THP-1 cells had been 
challenged with 7 different concentrations of LPS, ranging from 100ng/ml to 
0.1pg/ml. It was decided that only two of these concentrations for each gene would 
need to be tested. To test which of the cDNAs would be best to use, all the different 
cDNAs were used in a QPCR experiment. All 7 concentrations of LPS used to 
challenge the THP-1 cells were tested, using the cDNA from the THP-1 cells 
challenged with Acinetobacter genospecies 13 TU 4809 LPS. 
This was carried out as above with all the primers being used at the 200nM 
concentration, except for TNF-α, which used the 400nM primer concentration. So the 
make up of the solution for all the genes, except TNF-α, in each tube was 4µl of 
forward primer (from the 1µM stock solution), 4µl of reverse primer (the 1µM stock 
solution), 2µl of cDNA (from the cells challenged with LPS from A.b. 4809), 0µl of 
nuclease free water and 10µl of SYBR green. The solution for TNF-α was as follows: 
0.8µl of forward primer (from the 10µM stock solution), 0.8µl of reverse primer (the 
10µM stock solution), 2µl of cDNA, 6.4µl of nuclease free water and 10µl of SYBR 
green. 
The positive control was the 18S ribosomal RNA primers at a concentration 200nM, 
using the DNA extracted from the THP-1 cells directly. The negative controls were 
the same as in experiment 2.5.6.1. All the samples were done in triplicate. The plate 
was run in the Stratagene Mx3000P, as in experiment 2.5.6.1.  
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2.5.6.3 QPCR of the cDNAs against all the genes. 
The final stage measured the cDNA, at the concentrations that were decided to be the 
most effective in experiment 2.5.6.2, against all the genes of interest. This was carried 
out as in the previous experiments. The genes of interest were used at the primer 
concentration of 200nM except TNF-α, which was used at the primer concentration of 
400nM. The cDNA used was from the cells challenged by the LPS dilutions of 
10ng/ml and 1ng/ml for 18S ribosomal RNA, TNF-α, IL-1β and IL-10. The cDNA 
used for IFN-γ and IL-8 was from the cells challenged by the LPS dilutions of 
100ng/ml and 10ng/ml. The positive control and the negative controls were the same 
as before. All the samples were run in triplicate.  
The samples were run under the same heating conditis as in the previous 
experiments.  
 
2.6 Statistical analysis 
All statistical analysis for the ELISA data was carried out using Microsoft Office 
Excel and Minitab 15 statistical software. All the QPCR data were analysed using 
MxPro QPCR software version 3.0 and Minitab 15 stati tical software. All the data 
sets from the ELISA results were tested against one another using 2 sample t-tests. 






3. Results  
3.1 Extraction and purification of Lipopolysaccharide 
3.1.1 Amount of LPS extracted from the bacterial strains 
The LPS was extracted from between 0.87g and 2.5g of lyophilised bacteria. The 
extraction was carried out using the aqueous phenol method developed by Westphal 
& Jann (1965), modified by Hancock & Poxton (1981), as described in chapter 2.1.4.  
The bijou bottles were weighed, before the re-suspended LPS in pf water was added. 
They were then weighed again, after the LPS had been lyophilised, and the extra mass 
was taken to be the mass of the LPS extracted from the bacteria. These results are 
detailed in table 3.1. 
Table 3.1: Mass of LPS extracted from the bacterial strains. 
Bacterial Strain 
Weight of dried 
bacteria Weight of extracted LPS  
Percentage of total bacterial 
weight 
A. g 13 TU 4793 1.00g 0.025g 2.50% 
A. g 13 TU 4799 1.36g 0.026g 1.91% 
A. g 13 TU 4800 2.40g 0.05g 2.08% 
A. g 13 TU 4801 1.20g 0.016g 1.33% 
A. g 13 TU 4802 2.00g 0.037g 1.85% 
A. g 13 TU 4803 1.32g 0.041g 3.10% 
A. g 13 TU 4808 2.10g 0.045g 2.14% 
A. g 13 TU 4809 2.00g 0.096g 4.80% 
H.i. 4790 0.87g 0.018g 2.06% 
H.i. 4838 2.00g 0.049g 2.45% 
H.i. 4839 1.92g 0.01g 0.52% 
H.i. 4840 1.00g 0.028g 2.80% 
E.c. 4841 2.00g 0.042g 2.10% 
E.c. 4844 1.60g 0.037g 2.31% 
K.p. 4842 1.30g 0.031g 2.38% 
K.p. 4843 1.20g 0.028g 2.33% 
P.a. 4789 2.50g 0.035g 1.40% 
P.a. 4845 1.70g 0.027g 1.59% 
 80 
As can be seen in table 3.1, the amounts extracted vary between 96 mg, from 
Acinetobacter genospecies 13 TU 4809, and 10mg from Haemophilus influenzae 
4839 being the largest and smallest amounts extracted respectively. The weights of 
the majority of the LPS extracted from the organisms were very similar. This is as 
was expected, as it has been observed that LPS makes up between 1 and 3% of the 
total weight of dried bacteria. 
3.1.2 Silver stain gels of the LPS extractions. 
The silver stain was carried out to see the purity of the LPS extractions. Both the 
original aqueous phenol extractions and the re-extracted LPS samples were used. 
Figures 3.1, 3.2 and 3.3 show all the bacterial species and strains used throughout this 
project in both their original and re-extracted forms they all show the purity of the 
LPS extracted and also what type of LPS had been extracted from the bacteria. If it is 
a smooth LPS, it will have a pattern of bands.  Each band is made up of the Lipid A 
moiety and the core polysaccharide, with a number of the polysaccharide repeating 
units that make up the O-polysaccharide chain attached. This is why there are often a 
large number of bands, as each band is a different number of the repeating units 
attached to the core i.e. Lipid A + core + 1 repeating unit, Lipid A + core + 2 
repeating unit … Lipid A + core + n repeating units. Rough LPS is just made up of 
the Lipid A + core polysaccharide. An example of a smooth LPS is the E. coli O18 on 
the left side of the figure. The bands can easily be seen. K12 is the positive control for 
the rough LPS and as can be seen in the figures below, there is only the core present 
without a banding pattern. A semi rough pattern is one with a small number of 




Figure 3.1: Silver stain of A. genospecies 13 TU strains A. g 13 TU 4800, A. g 13 TU 4801, A. g 13 
TU 4802, A. g 13 TU 4803, A. g 13 TU 4808, A. g 13 TU 4809 
O = original extraction, R = re-extracted LPS, B = blank the negative control,  
1-A. g 13 TU 4800, 2-A. g 13 TU 4801, 3-A. g 13 TU 4802, 4-A. g 13 TU 4803, 5-A. g 13 TU 4808, 6-
A. g 13 TU 4809, O18- E. coli positive control for a smooth LPS, K12- E. coli positive control for a 
rough LPS. 
The original extractions of Acinetobacter genospecies 13 TU 4803 and Acinetobacter 
genospecies 13 TU 4808 both still had some bacterial surface proteins attached, but 
these had been removed by the re-extraction process, as the re-extracted LPS had no 
bands remaining. The LPS of most Acinetobacter genospecies 13 TU strains appears 
to be rough on gels. This is due to the make up of the Acinetobacter genospecies 13 
TU LPS, which does not bind to the silver stain properly. It has been shown by 
Haseley et al, 1998 and Pantophelet t al, 2001 that the Acinetobacter genospecies 13 
TU LPS is normally smooth. 
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Figure 3.2: Silver stains of strains P.a. 4789, P.a. 4845, H.i. 4790, H.i. 4838, H.i. 4839, H.i. 4840 
O = original extraction, R = re-extracted LPS, B = blank the negative control,  
1-P.a. 4789, 2-P.a. 4845, 3-H.i. 4790, 4-H.i. 4838, 5-H.i. 4839, 6-H.i. 4839, O18- E. coli positive 
control for a smooth LPS, K12- E. coli positive control for a rough LPS. 
Figure 3.2 is laid out in the same manner as Figure 3.1, but the gel was run with LPS 
from different strains. In this case the strains were two Pseudomonas aeruginosa 
strains and four Haemophilus influenzae strains. The Haemophilus influenzae strains 
are rough forms and most of them are very pure samples, as there are no banding 
patterns in either the original or the re-extracted LPS. The original extraction of 
Haemophilus influenzae 4839 still had bacterial proteins attached to the LPS but these 
were removed by the re-extraction. The original extraction of Pseudomonas 
aeruginosa 4789 also had bacterial proteins attached, but these were removed by the 
re-extraction. Both Pseudomonas aeruginosa 4879 and Pseudomonas aeruginosa 
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4845 seemed to have rough LPS, but Pseudomonas aeruginosa like Acinetobacter 
genospecies 13 TU also does not always appear to be smooth when it often is.  
 
Figure 3.3: Silver stains of strains A. g 13 TU 4793, A. g 13 TU 4799, K.p. 4841, K.p. 4844, E.c. 4842, 
E.c. 4843 
O = original extraction, R = re-extracted LPS, B = blank the negative control,  
1-A. g 13 TU 4793, 2-A. g 13 TU 4799, 3-K.p.4841, 4-K.p. 4844, 5-E.c. 4842, 6-E.c. 4843, O18- E. 
coli positive control for a smooth LPS, K12- E. coli positive control for a rough LPS. 
Figure 3.3 is of a similar layout to the previous two figures, again with LPS from 
different species. The two Acinetobacter genospecies 13 TU species both appear to be 
rough forms from their appearance on the figure but it is believed, that as in the 
Figure 3.1 they are in fact smooth. The two Klebsiella pneumoniae strains both show 
the characteristic streak pattern that is common for Klebsiella pneumoniae LPS. This 
streak is due to the small size of the repeating units i  Klebsiella pneumoniae’s 
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polysaccharide chain: many and homopolysaccharides. Thi  means that the different 
bands are very close together, as an increase of one repeating unit does not vary the 
molecular weight by much. The two E. coli strains have a traditional smooth LPS 
ladder pattern with multiple obvious bands. Both of the Klebsiella pneumoniae and E. 
coli strains are similar in both the original extraction and after the re-extractions. 
3.1.3 Colloidal Gold total protein stains of the LPS extractions 
These experiments were done to measure the total bacterial protein on the LPS 
extractions. This was to make sure that the LPS was properly purified and thus that 
the effects we observed, were due to the pure LPS and not due to any bacterial 
proteins attached to them. The Colloidal gold binds to any proteins present on the 
nitrocellulose membrane and stains them, so it is easy to see if there are any proteins 
still attached to the LPS. Figures 3.4, 3.5 and 3.6 below show the purities of the LPS 
extractions. The negative control is a blank, whilst the positive controls were the mark 






Figure 3.4: Colloidal Gold stain of A. genospecies 13 TU strains A. g 13 TU 4800, A. g 13 TU 4801, 
A. g 13 TU 4802, A. g 13 TU 4803, A. g 13 TU 4808, A. g 13 TU 4809 
O = original extraction, R = re-extracted LPS, B = blank the negative control,  
1-A. g 13 TU 4800, 2-A. g 13 TU 4801, 3-A. g 13 TU 4802, 4-A. g 13 TU 4803, 5-A. g 13 TU 4808, 6-
A. g 13 TU 4809, P – positive control Mark 12 protein marker (Sigma) 
As can be seen in Figure 3.4, the two positive controls both show that protein is 
present, whereas none of the LPS extractions had any protein appear on the figure and 




Figure 3.5: Colloidal Gold stain of strains P.a. 4789, P.a. 4845, H.i. 4790, H.i. 4838, H.i. 4839, H.i. 
4840 
Legend: O = original extraction, R = re-extracted LPS, 1-P.a. 4789, 2-P.a. 4845, 3-H.i. 4790, 4-H.i. 
4838, 5-H.i. 4839, 6-H.i. 4839, C – positive control Mark 12 protein marker (Sigma) 
In Figure 3.5 there is protein contamination in the original LPS extraction of P. 
aeruginosa 4845 (O2), but there is none in the re-extracted LPS (R2), so the re-
extraction process has cleaned this LPS up. The other LPSs have no protein 
contamination. The positive control is clearly positive, although it has run over into 
the negative control as well, making it look like the negative control is also positive 
when it is not. 
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Figure 3.6: Colloidal Gold stains of strains A. g 13 TU 4793, A. g 13 TU 4799, K.p. 4841, K..p 4844, 
E.c. 4842, E.c. 4843 
Legend: O = original extraction, R = re-extracted LPS, B = blank the negative control,  
1-A. g 13 TU 4793, 2-A. g 13 TU 4799, 3-K.p. 4841, -K.p. 4844, 5-E.c. 4842, 6-E.c. 4843, P – 
positive control Mark 12 protein marker (Sigma) 
As can be seen in Figure 3.6, the two positive controls both show that protein is 
present, whereas none of the LPS extractions had any protein in them and so it is 





3.1.4 Limulus Amoebocyte Lysate assay of the LPS extractions 
The Limulus Amoebocyte Lysate assay uses lysate extracted from the amoebocytes of 
Limulus polyphemus, the horseshoe crab. This lysate gels when it comes into contact 
with bacterial endotoxin (Lindsey et al, 1989). This gelation means that it can be used 
as an assay for measuring how endotoxic a particular LPS is. This is carried out by 
making a number of 10-fold dilutions on a plate andmeasuring how turbid they make 
the Lysate and then comparing this to a standard curve of LPS with known 
endotoxicity levels. It is thus possible to measure the endotoxicity units of an 
unknown LPS. All the results in Figure 3.7 below were carried out using re-extracted 
LPS and were duplicates. 
 
Figure 3.7: The Endotoxicity levels of the re-extracted LPS from the bacterial strains studied. 
Figure 3.7 shows the endotoxicity levels of the LPS from the bacterial strains. Half of 
the strains were around the 200 endotoxicity units/µg mark. Seven strains were below 
100 endotoxicity units/µg. Two strains however, Acinetobacter genospecies 13 TU 









A. g 13 TU  4800 A. g 13 TU  4801 A. g 13 TU  4802 A. g 13 TU  4803 A. g 13 TU  4808 A. g 13 TU  4809 A. g 13 TU  4793 A. g 13 TU  4799 
Hi 4790 Hi 4838 Hi 4839 Hi 4840 Pa 4789 Pa 4845 Ec 4842 Ec 4843 Kp 4841 Kp 4844 
Strains 
Endotoxicity units/ug of LPS 
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respectively. This shows that the majority of the strains tested had low endotoxicities, 
but that two of the strains had very high endotoxicities and thus were more likely to 
be more aggressive pathogens. 
 
3.2 Investigating how widespread antibodies to 
Acinetobacter genospecies 13 TU and Haemophilus 
influenzae Lipopolysaccharide are in the healthy 
population of Southeast Scotland  
 
3.2.1 Antibodies to Acinetobacter genospecies 13 TU LPS in the healthy 
population of Southeast Scotland 
 
3.2.1.1 ELISA results for antibody levels to the LPS of Acinetobacter 
genospecies 13 TU strains.  
Serum was isolated from 475 blood samples, given by blood donors to the Blood 
Transfusion Service of Southeast Scotland. The levels of antibodies in these blood 
donor samples to the LPS from eight different strains of A. genospecies 13 TU were 
measured by ELISA, following 100-fold dilution of the serum and reaction with the 
LPS-polymyxin complexes coated at 5µg/ml on a 96 well Nunc Medisorp plate. The 





















Histogram of A. g 13 TU 4793
 
Figure 3.8: Histogram of the frequency of OD results from ELISAs with the LPS of Acinetobacter 
genospecies 13 TU 4793. Frequency is the number of individual blood donors with a particular 
antibody level to Acinetobacter genospecies 13 TU 4793 in the range indicated on the horizontal axis. 
In Figure 3.8 the mean optical density (OD) range for antibody levels to the LPS of 
Acinetobacter genospecies 13 TU 4793 of 0.588 is greater when compared with 
several of the subsequently analyzed strains. Also the normal curve is very flat with a 
large standard deviation of 0.3529. All of this shows that the antibody levels in a 
healthy population of Southeast Scotland to Acinetobacter genospecies 13 TU 4793 
LPS are larger than those of some of the subsequently aal zed strains. The reason it 
is possible to say this is that with a larger mean and a higher standard deviation these 
indicate a greater frequency of high responders in the population, which partially 





















Histogram of A. g 13 TU 4799
 
Figure 3.9: Histogram of the frequency of OD results from ELISAs with the LPS of Acinetobacter 
genospecies 13 TU 4799. Frequency is the number of individual blood donors with a particular 
antibody level to Acinetobacter genospecies 13 TU 4799 in the range indicated on the horizontal axis. 
In Figure 3.9 the mean OD range for antibody levels to the LPS of Acinetobacter 
genospecies 13 TU 4799 of 0.5748 is very similar to those of Acinetobacter 
genospecies 13 TU 4793. The normal curve is very flat, with a similar standard 
deviation of 0.3838 to that of Acinetobacter genospecies 13 TU 4793 as shown in 
Figure 3.8. All of this indicates that exposure to Acinetobacter genospecies 13 TU 
4799 LPS in a healthy population of Southeast Scotland is very similar to that of 
























Histogram of A. g 13 TU 4800
 
Figure 3.10: Histogram of the frequency of OD results from ELISAs with the LPS of Acinetobacter 
genospecies 13 TU 4800. Frequency is the number of individual blood donors with a particular 
antibody level to Acinetobacter genospecies 13 TU 4800 in the range indicated on the horizontal axis. 
In Figure 3.10 the mean OD range for antibody levels to the LPS of Acinetobacter 
genospecies 13 TU 4800 of 0.4803 is lower than that of Acinetobacter genospecies 13 
TU 4793 and Acinetobacter genospecies 13 TU 4799. The normal curve is more 
pronounced, with a smaller standard deviation of 0.2465 than those of Acinetobacter 
genospecies 13 TU 4793 and Acinetobacter genospecies 13 TU 4799. All of this 
shows that exposure to Acinetobacter genospecies 13 TU 4800 LPS in a healthy 
population of Southeast Scotland is at a lower level than those of the two previous 























Histogram of A. g 13 TU 4801
 
Figure 3.11: Histogram of the frequency of OD results from ELISAs with the LPS of Acinetobacter 
genospecies 13 TU 4801. Frequency is the number of individual blood donors with a particular 
antibody level to Acinetobacter genospecies 13 TU 4801 in the range indicated on the horizontal axis. 
In Figure 3.11 the mean OD range for antibody levels to the LPS of Acinetobacter 
genospecies 13 TU 4799 of 0.5454 is very similar to those of Acinetobacter 
genospecies 13 TU 4793 and Acinetobacter genospecies 13 TU 4801. The normal 
curve is very flat, with a similar standard deviation of 2.804, which is less than that of 
Acinetobacter genospecies 13 TU 4793 and Acinetobacter genospecies 13 TU 4799, 
but greater than that of Acinetobacter genospecies 13 TU 4800.  This means that there 
is less variety of results and they are more tightly grouped around the mean. All of 
this indicates that exposure to Acinetobacter genospecies 13 TU 4801 LPS in a 
healthy population of Southeast Scotland is similar to, but slightly less than the 
exposure levels to Acinetobacter genospecies 13 TU 4793 and Acinetobacter 





















Histogram of A. g 13 TU 4802
 
Figure 3.12: Histogram of the frequency of OD results from ELISAs with the LPS of Acinetobacter 
genospecies 13 TU 4802. Frequency is the number of individual blood donors with a particular 
antibody level to Acinetobacter genospecies 13 TU 4802 in the range indicated on the horizontal axis. 
In Figure 3.12 the mean OD range for antibody levels to the LPS of Acinetobacter 
genospecies 13 TU 4802 of 0.3336 is lower than all of the previously described 
Acinetobacter genospecies 13 TU strains. The normal curve is much more 
pronounced, with a standard deviation of 0.2197, which whilst smaller than those of 
Acinetobacter genospecies 13 TU 4793 and Acinetobacter genospecies 13 TU 4799, 
was closer to that of Acinetobacter genospecies 13 TU 4800. All of this shows that 
exposure to Acinetobacter genospecies 13 TU 4802 LPS in a healthy population of 
Southeast Scotland is at a lower level than in all the previously described strains of 






















Histogram of A. g 13 TU 4803
 
Figure 3.13: Histogram of the frequency of OD results from ELISAs with the LPS of Acinetobacter 
genospecies 13 TU 4803. Frequency is the number of individual blood donors with a particular 
antibody level to Acinetobacter genospecies 13 TU 4803 in the range indicated on the horizontal axis. 
In Figure 3.13 the mean OD range for antibody levels to the LPS of Acinetobacter 
genospecies 13 TU 4803 of 0.3591 is lower than most of the previously described 
Acinetobacter genospecies 13 TU strains. The normal curve and the standard 
deviation of 0.2243 are very close to the normal curve and standard deviation of 
Acinetobacter genospecies 13 TU 4802. Thus the level of exposure in the healthy 
population of Southeast Scotland to Acinetobacter genospecies 13 TU 4803 LPS is 
very similar to that of Acinetobacter genospecies 13 TU 4802 LPS.  Thus these two 
Acinetobacter genospecies 13 TU strains seem to have lower exposure levels to their 























Histogram of A. g 13 TU 4808
 
Figure 3.14: Histogram of the frequency of OD results from ELISAs with the LPS of Acinetobacter 
genospecies 13 TU 4808. Frequency is the number of individual blood donors with a particular 
antibody level to Acinetobacter genospecies 13 TU 4808 in the range indicated on the horizontal axis. 
In Figure 3.14 the mean OD range for antibody levels to the LPS of Acinetobacter 
genospecies 13 TU 4808 of 0.4063 is lower than that of Acinetobacter genospecies 13 
TU 4800, but greater than those of Acinetobacter genospecies 13 TU 4802 and 
Acinetobacter genospecies 13 TU 4803. The normal curve is flatter than thse of 
Acinetobacter genospecies 13 TU 4802 and Acinetobacter genospecies 13 TU 4803, 
but has a smaller standard deviation of 0.208 than either of the two strains just 
mentioned. All of this shows that exposure to Acinetobacter genospecies 13 TU 4808 
LPS in a healthy population of Southeast Scotland is at a lower level than 
Acinetobacter genospecies 13 TU 4800 LPS, but higher than Aci etobacter 






















Histogram of A. g 13 TU 4809
 
Figure 3.15: Histogram of the frequency of OD results from ELISAs with the LPS of Acinetobacter 
genospecies 13 TU 4809. Frequency is the number of individual blood donors with a particular 
antibody level to Acinetobacter genospecies 13 TU 4809 in the range indicated on the horizontal axis. 
In Figure 3.15 the mean OD range for antibody levels to the LPS of Acinetobacter 
genospecies 13 TU 4809 of 0.4829 is very similar to that of Acinetobacter 
genospecies 13 TU 4800. The normal curve and the standard deviation of 0.2399 are 
also very similar to those of Acinetobacter genospecies 13 TU 4800. Thus exposure to 
Acinetobacter genospecies 13 TU 4809 LPS in a healthy population of Southeast 





































Normal distribution curves of all the A. g 13 TU strains used in the study
 
Figure 3.16: All the normal curves from the antibody levels to the LPSs of the eight Acinetobacter 
genospecies 13 TU strains placed on a graph together. T  graph has all the normal curves of the eight 
Acinetobacter genospecies 13 TU strains with their means and standard deviations.  
As can be seen in Figure 3.16, there is a wide variety of different normal curves with 
some being taller and narrower than others. There is also a variety of the wider lower 
normal curves seen in the figure. The reason that some of the normal curves are high 
and narrow is that the antibody levels to the LPS from those strains were much more 
grouped about the mean than for other strains. This leads to a greater frequency of 
these results and thus the normal curves are much higher and narrower. The wider, 
flatter normal curves have a greater distribution of results and thus have a lower 
frequency of certain results appearing, so the curves are wider and flatter. The normal 
curves when taken in conjunction with the means show t at the antibody levels to the 
LPSs of Acinetobacter genospecies 13 TU 4793 and Acinetobacter genospecies 13 
TU 4799 are very similar in their distribution and means, which implies that exposure 
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to them is similarly widespread in the healthy population of Southeast Scotland. The 
results of antibody levels to the LPSs of Acinetobacter genospecies 13 TU 4800 and 
4809 also have very similar normal curves and means, implying that there is a similar 
level of exposure to them across the healthy population of Southeast Scotland. Levels 
to the LPSs of Acinetobacter genospecies 13 TU 4802, 4803 and to a lesser extent 
4808 all have similar means and shapes of their normal curves, which again indicates 
that the exposure levels to these strains are similar in the healthy population of 
Southeast Scotland. The antibody levels to Acinetobacter genospecies 13 TU 4801 
LPS have a higher mean than those against Acinetobacter genospecies 13 TU 4802, 
4803, 4808, 4800 and 4809 LPSs, but are lower than those of Acinetobacter 
genospecies 13 TU 4793 and 4799 LPSs. So they are at th higher end of the exposure 
levels to these eight Acinetobacter genospecies 13 TU strains but not the highest. 
3.2.1.2 Comparison of results from Acinetobacter genospecies 13 TU with 
other organisms. 
The ELISA results of antibody levels from each serum specimen to LPSs were 
averaged across all the strains tested within a species. These averaged OD results 
were plotted in scatterplots against the averaged OD results of other species with 
well-characterised LPSs, Escherichia coli, Klebsiella pneumoniae and Pseudomonas 
aeruginosa. The means of these antibody levels to the LPSs of the different species 
were also included on the scatterplots and compared with each other. The first two 
species are common human gut commensals that are often also opportunistic 
pathogens. The last organism is a common environmental organism that is also a 
common opportunistic pathogen. The antibody levels are indicative of the level of 
exposure that the population has had to the LPS of this organism; thus it is possible to 
 100 
draw conclusions as to how widespread exposure to Acinetobacter genospecies 13 TU 
is in comparison to the other organisms in the healt y population of Southeast 
Scotland. 
 
Figure 3.17: Scatter plot of the averaged OD results of antibody levels to the LPSs of Acinetobacter 
genospecies 13 TU and E. coli against the serum sample number. The means of the averaged OD 
results are also plotted on the graph. 
As can be seen in Figure 3.17, the mean of the antibody levels to the LPSs of 
Acinetobacter genospecies 13 TU are significantly (p<0.001) lower than the mean of 
E. coli LPS and thus the spread of the responses to the lipopolysaccharides is very 
much higher for E. coli.  
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Figure 3.18: Scatter plot of the averaged OD results of antibody levels to the LPSs of Acinetobacter 
genospecies 13 TU and Klebsiella pneumoniae against the serum sample number. The means of the 
averaged OD results are also plotted on the graph. 
As Figure 3.18 shows, the mean of the antibody levels to the LPSs of Acinetobacter 
genospecies 13 TU is significantly (p<0.001) smaller than the mean of Klebsiella 
pneumoniae, but the means are much closer to each other then the mean of 
Acinetobacter genospecies 13 TU is to the mean of E. coli. When the points on the 
graph are compared, it is possible to see that Klebsiella pneumoniae LPS has a greater 
number of higher responders, but also has a greater number of lower responders, 





Figure 3.19: Scatter plot of the averaged OD results of antibody levels to the LPSs of Acinetobacter 
genospecies 13 TU and Pseudomonas pneumoniae against the serum sample number. The means of the 
averaged OD results are also plotted on the graph. 
Figure 3.19 demonstrates that, whilst the mean of antibody levels to the LPSs of
Acinetobacter genospecies 13 TU is significantly (p<0.001) smaller than that of 
Pseudomonas aeruginosa LPS, it is a smaller difference than between the means of 
antibody levels to the LPSs ofKlebsiella pneumoniae and Acinetobacter genospecies 
13 TU. When the points on the graph are compared, it is pos ible to see that antibody 
levels to the LPSs Pseudomonas aeruginosa and Acinetobacter genospecies 13 TU 
are very closely overlaid on top of each other indicating that the antibody response to 





3.2.2 Antibodies to Haemophilus influenzae  LPS in the healthy 
population of Southeast Scotland 
3.2.2.1 ELISA results for antibody levels to the LPS of Haemophilus 
influenzae strains.  
 
These experiments were carried out in exactly the same manner as for the 
Acinetobacter genospecies 13 TU strains. The results of the levels of antibodies to the 
LPS from four strains of Haemophilus influenzae were also compared with the levels 
of antibody to LPS from E. coli, K. pneumoniae and P. aeruginosa. This was done to 
allow conclusions to be drawn as to how widespread exposure to Haemophilus 


























Histogram of H.i. 4790
Normal 
 
Figure 3.20: Histogram of the frequency of OD results from ELISAs with the LPS of Haemophilus 
influenzae 4790. Frequency is the number of individual blood d nors with a particular antibody level to 
Haemophilus influenzae 4790 in the range indicated on the horizontal axis. 
In Figure 3.20 the mean OD range for antibody levels to Haemophilus influenzae 
4790 LPS of 0.9534. The normal curve is wide and flat and the standard deviation of 
0.6038 is very large, giving the normal curve its wide and flat appearance. There is a 
possibility of bimodal distribution with a second peak around an OD of 1.7, but this is 
much lower, so it is harder to say. Thus it is possible say that exposure to
Haemophilus influenzae 4790 LPS in a healthy population of Southeast Scotland is 
higher than all the other Haemophilus influenzae strains that were subsequently tested. 
The mean is much higher than those of the Acinetobacter genospecies 13 TU strains 






















Histogram of H.i. 4838
Normal 
 
Figure 3.21: Histogram of the frequency of OD results from ELISAs with the LPS of Haemophilus 
influenzae 4838. Frequency is the number of individual blood d nors with a particular antibody level to 
Haemophilus influenzae 4838 in the range indicated on the horizontal axis. 
In Figure 3.21 the mean OD range for antibody levels to Haemophilus influenzae 
4838 LPS of 0.7522; this mean is much lower than the mean of Haemophilus 
influenzae 4790. The normal curve is much more pronounced than with Haemophilus 
influenzae 4790 and the standard deviation of 0.3258 is much smaller, meaning that 
the data are much more closely grouped around the mean than in the previous figure. 
From the data presented in Figure 3.21 it is possible to say that exposure to 
Haemophilus influenzae 4838 LPS in a healthy population of Southeast Scotland is 






















Histogram of H.i. 4839
Normal 
 
Figure 3.22: Histogram of the frequency of OD results from ELISAs with the LPS of Haemophilus 
influenzae 4839. Frequency is the number of individual blood d nors with a particular antibody level to 
Haemophilus influenzae 4839 in the range indicated on the horizontal axis. 
In Figure 3.22 the mean OD range for antibody levels to Haemophilus influenzae 
4839  is 0.7480, which is very close to the mean of Haemophilus influenzae 4838. The 
normal curve is very similar to Haemophilus influenzae 4838 and the standard 
deviation of 0.3224 is also very close to that of Haemophilus influenzae 4838. Thus 
exposure to Haemophilus influenzae 4839 LPS in a healthy population of Southeast 
























Histogram of H.i. 4840
Normal 
 
Figure 3.23: Histogram of the frequency of OD results from ELISAs with the LPS of Haemophilus 
influenzae 4839. Frequency is the number of individual blood d nors with a particular antibody level to 
Haemophilus influenzae 4839 in the range indicated on the horizontal axis. 
In Figure 3.23 the mean OD range for antibody levels to Haemophilus influenzae 
4840 of 0.7324, this mean is very close to the means of Haemophilus influenzae 4838 
and Haemophilus influenzae 4839. The normal curve and the standard deviation of 
0.3859 are both very similar to Haemophilus influenzae 4838 and Haemophilus 
influenzae 4839. So it can be said exposure to Haemophilus influenzae 4840 LPS in a 
healthy population of Southeast Scotland is very similar to the exposure to both 






























Normal distribution curves of H.i. 4790, H.i. 4838, H.i. 4839, H.i. 4840
 
Figure 3.24: All the normal curves from the antibody levels to the LPSs of the four Haemophilus 
influenzae strains placed on a graph together. The graph has all the normal curves of the four 
Haemophilus influenzae strains with their means and standard deviations.  
 
In Figure 3.24 there is a smaller amount of variation between the normal distribution 
curves than there was for the Acinetobacter genospecies 13 TU strains. This is 
partially due to the smaller group size, but as can be seen Haemophilus influenzae 
4838, Haemophilus influenzae 4839 and Haemophilus influenzae 4840 have very 
similar distribution curves and also very similar means. The antibody levels to these 
three organisms can be said to be similar, since the distribution of the ELISA results is 
very close. Haemophilus influenzae 4790 LPS has a much higher mean and great 
distribution curve. So it seems that Haemophilus influenzae 4790 LPS antibody levels 
are higher than for the other three strains. 
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3.2.2.2 Comparison of Results from Haemophilus influenzae with other 
organisms. 
As before, the ELISA results from across the strains tested were averaged within each 
species and their OD results were tested against some other well characterised 
species, namely Escherichia coli, Klebsiella pneumoniae and Pseudomonas 
aeruginosa. These were again plotted with scatterplots and the means were also 
compared. The antibody levels to the LPS of these organisms are indicative of the 
level of exposure that the population has had to that organism. From this it is possible 
to draw conclusions as to how widespread exposure to Haemophilus influenzae is in 











Figure 3.25: Scatter plot of the averaged OD results of Haemophilus influenzae and E. coli LPSs 
against the serum sample number. The means of the averaged OD results are also plotted on the graph. 
In Figure 3.25 it can be seen that whilst the mean of Haemophilus influenzae LPS is 
significantly (p<0.001) larger than that of E. coli LPS, it is not massively so. Also the 
data plots of the two organisms can be seen to be overlying each other fairly closely 








Figure 3.26: Scatter plot of the averaged OD results of Haemophilus influenzae and Klebsiella 
pneumoniae LPSs against the serum sample number. The means of the averaged OD results are also 
plotted on the graph. 
As can be seen in Figure 3.26, the mean of Haemophilus influenzae LPS is 
significantly (p<0.001) greater than that of Klebsiella pneumoniae LPS. When the 
data plots of the two organisms are compared with eac  other, it is possible to see that 
Klebsiella pneumoniae LPS has much lower data points than Haemophilus influenzae 
LPS. This shows that antibody levels to Haemophilus influenzae LPSs are more 







Figure 3.27: Scatter plot of the averaged OD results of Haemophilus influenzae and Pseudomonas 
aeruginosa LPSs against the serum sample number. The means of the averaged OD results are also 
plotted on the graph. 
 The results show that the mean of Haemophilus influenzae LPSs is significantly 
(p<0.001) greater than that of Pseudomonas aeruginosa LPSs. Comparison between 
the two data plots also shows that Pseudomonas aeruginosa LPSs has induced a much 
lower antibody response than Haemophilus influenzae LPSs. This shows that antibody 
levels to Haemophilus influenzae LPSs are more widespread in the healthy population 





3.2.3 High and low responders in the healthy population of Southeast 
Scotland. 
In a healthy population there is normally a wide range of different levels antibody 
responses to the LPS, but some people just have a lower reaction to any antigen they 
are challenged with. Others have consistently higher levels of antibody response. This 
can be seen in Figure 3.28. 
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Each symbol represents up to 2 observations.
Dotplot of average antibody levels to the LPS from all species studied.
 
Figure 3.28: Dotplot of the average antibody level in the serum sa ples across all the LPS of the 
species studied. In this figure all the ELISA result  for each serum sample were averaged out across the 
species and placed on this dotplot. 
As can be seen in Figure 3.28 there are a wide range of possible antibody levels with 
the majority between an OD of 0.3 and 0.6. There are some individuals though that 
have a much higher level of response to all the diff rent LPS. There are five 
individuals with average antibody levels across the LPS isolated from the 18 strains, 
which lie between an OD of 1.5 and 2.0. These are the high responders. 
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3.2.4 ELISA inhibition assays 
These experiments were carried out to see if there was any cross-reactivity between 
any of the LPSs of the different strains. Since, if there were, it would mean that the 
ELISA results were likely to be due to reactions with the common regions of LPS and 
not to exposure to the strain-specific regions of the LPS of that strain. These 
experiments were to be carried out using inhibition assays as described below.  
Serum samples from 250 of the blood donors were pooled t gether. A 96 well Nunc 
Medisorp plate was coated with a 1 in 8 dilution of LPS (equivalent to 0.125µg/ml) 
from one of the strains of interest. LPS from several strains including the LPS from 
the strain that was used to coat the plate were incubated for 30 minutes at 37ºC in a 1 
in 50 dilution of the pooled serum at dilutions of: 1mg/ml, 200µg/ml, 40µg/ml, 
8µg/ml, 1.6µg/ml, 0.32µg/ml, 0.064µg/ml and 0.013µg/ml. These were then treated as 
a normal ELISA and the inhibited serum samples were placed onto the plate in rows 
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Figure 3.29: E. coli O18 inhibition assay. This experiment was carried out as a positive control with E. 
coli O18 to show that the t chnique worked. The optical densities of the results were read and put into 
the graph. The LPS was diluted in 8 5-fold dilutions. 
As can be seen in Figure 3.29, at high concentrations the O18 free-floating LPS in the 
pooled serum inhibited the serum by binding to the fre antibodies and thus reducing 
the amounts available. The other two E. coli LPSs which included a different O-type 
and a rough mutant had little or no inhibiting effect having the same results as the 
serum positive control. Thus it can be seen that the experiment works with E. coli. 
Unfortunately this technique does not appear to work with Acinetobacter genospecies 
13 TU. This is shown in Figure 3.30 below.  
. 
 116 








1000 200 40 8 1.6 0.32 0.064 0.013







A. g 13 TU
4808
A. g 13 TU
4809





Figure 3.30: Acinetobacter genospecies 13 TU 4808 inhibition assay. The optical densities of the 
results were read and put into the graph. The LPS was diluted in 8 5-fold dilutions. E. coli O18 was 
included as a positive control. 
 
In Figure 3.30, LPSs from three Acinetobacter genospecies 13 TU strains (including 
that from the coating strain) were used in an attempt to ascertain if there was any 
cross strain inhibition of LPS binding, which would show any structural similarities 
between the LPS of the different strains. As can be seen, there was no difference 
between the different Acinetobacter genospecies 13 TU strains including the coating 
and they lie on the serum-only positive control. This was included to show that the 
serum was in fact binding to the LPS bound to the plate. The E. coli O18 was also a 
positive control to show that the inhibition effect was working on the plate. The 
reason that it increases to above the serum only line is that it is an E. coli LPS and, as 
has been seen in the ELISA results, there is a greater amount of anti E. coli antibodies 
in the healthy population. So the above graph shows that there is no inhibition effect 
from any of the Acinetobacter genospecies 13 TU strains including the strain that was 
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coating the plate. Thus it seems that for some reason Acinetobacter genospecies 13 
TU LPS in soluble form is unable to bind to the same antibodies as Acinetobacter 
genospecies 13 TU LPS that is bound to the Nunc Medisorp plate. This experiment 
was attempted with the same LPSs six times successfully and each time the results 
were the same. This situation was also observed when tested with LPS from other 
Acinetobacter genospecies 13 TU strains.  
 
3.3 Results cytokine production induced by LPS with THP-
1 studied by quantitative polymerase chain reaction 
(QPCR) experiments  
3.3.1 Primer testing  
The primers had to be tested to make sure that the products that they gave were 
correct. The testing was carried out using standard PCR. The primers were tested with 
DNA isolated from THP-1 cells. The PCR preperations were then run using the 
protocol as described in experiment 2.5.5. The products were run on a 2% agarose gel 




Figure 3.31: The primer tests of the six genes with the 100bp ladder. 
1 - 100bp ladder, 2 - 18S ribosomal RNA, 3 - TNF-α, 4 - IFN γ, 5 - IL-1β, 6 - IL-8,    7 - IL-10, 8 - 
100bp ladder. 
As can be seen in Figure 3.31 the products of all the primers were the correct sizes.  
These were 151 bp for the 18S ribosomal RNA primers, 151bp for the TNF-α 
primers, 155bp for the IFN-γ primers, 151bp for the IL-1β primers, 151bp for the IL-8 
primers and 150bp for the IL-10 primers. So it can been seen that the primers are all 
within 5bps of each other, as it is necessary for the products to be of nearly the same 
size when attempting to carry out QPCR. 
3.3.2 Primer concentrations for QPCR 
The optimal concentration of the primers had to be ascertained for the different genes. 
This was carried out by trying out four different con entrations of the primers: 50nM, 
100nM, 200nM and400nM. These concentrations were run in a QPCR experiment as 
described in chapter 2.5.6.1 with THP-1 DNA, and the concentration that gave the 
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best response was chosen. The concentration that gave the best response for 18S 
ribosomal RNA, IFN-γ, IL-1β, IL-8 and IL-10 was the 200nM concentration. The best 
concentration for TNF-α was 400nM. 
3.3.3 cDNA selection. 
THP-1 cells had been grown and differentiated using v tamin D3 as described in 
chapter 2.4.2. The cells were then challenged with seven concentrations of LPS from 
five species of bacteria with two strains from each bacterial species to make a total of 
10 LPSs. The species and strains used were Acinetobacter genospecies 13 TU 4802 
and 4809, Haemophilus influenzae 4838 and 4839, Pseudomonas aeruginosa 4789 and 
4845, Klebsiella pneumoniae 4841 and 4844 and finally E. coli 4842 and 4843. The 
concentrations of LPS used were 100ng/ml, 10ng/ml, 1ng/ml, 100pg/ml, 10pg/ml, 
1pg/ml and 0.1pg/ml. This procedure is described in full in chapter 2.4.3. The 
messenger RNA (mRNA) was extracted from the THP-1 cells that had been 
challenged with the different concentrations of LPS as described in chapter 2.5.3. The 
mRNA that had been extracted was turned into cDNA as described in chapter 2.5.4. 
The cDNA from Acinetobacter genospecies 13 TU 4809 was used as a guide to work 
out which two cDNAs, of the seven potential candidates, would give the best results. 
The cDNAs were run as described in chapter 2.5.6.2. The data from the QPCR 
experiment showed that for the 18S ribosomal RNA, TNF-α, IL-1β and IL-10 the 
cDNA from the cells challenged by 10ng/ml and 1ng/ml concentrations of LPS gave 
the best results, whilst for IFN-γ and IL-8, the cDNA from the cells challenged by 
100ng/ml and 10ng/ml concentrations of LPS gave the best results.  
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3.3.4 Comparison of mRNA production between the bacterial species. 
LPS from each strain of the species was used to measur  the levels of production of 
mRNA from all the six genes of interest. The 18S ribosomal RNA was used as a 
positive control and also as the base line level of gene production in the THP-1 cells. 
The cycle threshold (Ct) value generated from the cDNA of the THP-1 cells 
challenged by the LPS from the different bacterial species and strains, for the 18S 
ribosomal RNA was used to normalise all the other genes’ Ct values. The 
normalisation was carried out by dividing each ct value, from the cDNA generated by 
challenge with the LPS from the different bacteria, for each gene by the ct value of 
the 18S ribosomal RNA, cDNA from the same bacterial strain, to give a normalised 
Ct value. The results for the two Acinetobacter genospecies 13 TU strains tested are 
shown in Figure 3.31. 
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Figure 3.31: Levels of mRNA product from THP-1 cells for the genes of interest generated by 
challenge with LPS from Acinetobacter genospecies 13 TU 4802 and Acinetobacter genospecies 13 TU 
4809. The results for both strains for each gene are plotted next to each other.  
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When analysing the results presented in Figure 3.31, it needs to be remembered that 
the smaller the bars the greater the amount of mRNA for that particular gene was 
extracted from the THP-1 cells. This is because the Ct value is the cycle at which the 
amount of RNA amplified has reached a threshold level and is now large enough to 
measure effectively. Thus the greater amount of mRNA in the sample, the faster this 
threshold is reached and so the Ct value is correspondingly lower. If the Ct value is 
zero though this means that the Ct value was not sufficiently greater than the negative 
control so the value is counted as zero since no detectable levels of cytokines were 
produced. The results were compared statistically through the use of 2-samples t-tests 
carried out in Minitab 15.  Thus in Figure 3.31 it is possible to see that Acinetobacter 
genospecies 13 TU 4802 LPS generated a greater cytokine response than 
Acinetobacter genospecies 13 TU 4809 LPS. The difference between the levels of 
cytokine responses generated by the LPS of the two s rains was not significant at 
p<0.05. This is probably due to the low number of data points involved in the 
experiments. Acinetobacter genospecies 13 TU 4809 LPS generated low level 
responses to IL-8 and IL-10 with lower responses to TNF-α than the Acinetobacter 
genospecies 13 TU 4802 LPS was able to generate. Acinetobacter genospecies 13 TU 
4809 LPS was unable to induce a high enough cytokine response for IFN-γ and IL-1β, 
compared with the negative control for it to be considered anything but a zero level 
response. On the other hand Acinetobacter genospecies 13 TU 4802 LPS was able to 
generate a cytokine response to all the genes at a higher level than the LPS from 
Acinetobacter genospecies 13 TU 4809. 
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Figure 3.32: Levels of mRNA product from THP-1 cells for the genes of interest generated by 
challenge with LPS from Haemophilus influenzae 4838 and Haemophilus influenzae 4839. The results 
for both strains for each gene are plotted next to each other.  
In Figure 3.32 it is possible to see that Haemophilus influenzae 4838 LPS generated a 
slightly higher, but not significantly so at p<0.05, cytokine response when compared 
with Haemophilus influenzae 4839 LPS. There was no significant production of 
mRNA for IFN-γ, IL-1β and IL-8 100ng/ml, when compared with the negative 
controls. There was a small amount of mRNA production in IL-8 10ng with 
Haemophilus influenzae 4839.  
Although there is a difference between the two Haemophilus influenzae LPSs, it is not 
significant and it is less than the difference between the two Acinetobacter 
genospecies 13 TU LPSs in Figure 3.31. There was a significant difference p<0.001 
between the cytokine production levels of the Acinetobacter genospecies 13 TU LPS 
and Haemophilus influenzae LPS. This is probably due to the fact that the 
Haemophilus influenzae LPS is unable to generate a response from either INF-γ or IL-
1β and only LPS from Haemophilus influenzae 4839 was able to generate an IL-8 
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response. Thus whilst Haemophilus influenzae LPS seems to have generated higher 
levels of cytokine production of TNF-α and IL-10 than the Acinetobacter genospecies 
13 TU LPS was able to, they were not able to generate production of the other 
cytokines as effectively as Acinetobacter genospecies 13 TU LPS. 


























































































Figure 3.33: Levels of mRNA product from THP-1 cells for the genes of interest generated by 
challenge with LPS from Pseudomonas aeruginosa 4789 and Pseudomonas aeruginosa 4845. The 
results for both strains for each gene are plotted next to each other.  
In Figure 3.33 it can be seen that Pseudomonas aeruginosa 4789 LPS generated a 
higher cytokine response than Pseudomonas aeruginosa 4845 LPS, but again this 
difference was not significant. The levels of IFN-γ, IL-1β 10ng/ml and IL-8 100ng/ml 
mRNA created in the cells at the time of RNA extraction, was not significantly 
different to those of the negative controls. There was a small amount of mRNA 
production for IL-1β from the cells challenged with 10ng of Pseudomonas aeruginosa 
4845 LPS. LPS from both strains produced mRNA for IL-8 at 10ng/ml concentration 
of LPS, with Pseudomonas aeruginosa 4789 LPS inducing the highest levels. 
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There was no significant difference between the mRNA levels generated by 
Pseudomonas aeruginosa LPS and Haemophilus influenzae LPS. Whilst 
Pseudomonas aeruginosa LPS did not generate a significantly greater respone than 
Acinetobacter genospecies 13 TU LPS, it can be seen that it generates greater 
cytokine levels than those generated by the Pseudomonas aeruginosa LPS.  


























































































Figure 3.34: Levels of mRNA product from THP-1 cells for the genes of interest generated by 
challenge with LPS from Klebsiella pneumoniae 4841 and Klebsiella pneumoniae 4844. The results for 
both strains for each gene are plotted next to eachother. 
Figure 3.34 shows that Klebsiella pneumoniae 4844 LPS is able to induce an mRNA 
response to all the genes of interest. Klebsiella pneumoniae 4841 LPS was unable to 
induce mRNA production in IFN-γ. The levels of mRNA production between the LPS 
of the two strains were not significantly different, but Klebsiella pneumoniae 4844 
LPS had very slightly higher levels of production.  
The Klebsiella pneumoniae LPS induces mRNA levels at a lower levels than 
Pseudomonas aeruginosa and Haemophilus influenzae LPS for the cytokines that 
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were produced by all the strains. Due to the fact that Klebsiella pneumoniae LPS was 
able to generate cytokine production for all the cytokines, there was a significant 
difference p<0.05 between Klebsiella pneumoniae LPS and Haemophilus influenzae 
4838 and Pseudomonas aeruginosa 4790 LPS. It also generated a greater mRNA 
production than Acinetobacter genospecies 13 TU LPS, especially Acinetobacter 
genospecies 13 TU 4809, but not significantly so. 


























































































Figure 3.35: Levels of mRNA product from THP-1 cells for the genes of interest generated by 
challenge with LPS from E. coli 4842 and E. coli 4843. The results for both strains for each gene are 
plotted next to each other.  
As Figure 3.35 shows, there was no significant difference between the LPS from E. 
coli 4842 and E. coli 4843; E. coli 4842 LPS generated a slightly higher level of 
cytokine production. Both strains of E. coli LPS were unable to induce mRNA 
production with IFN-γ, IL-1β and IL-8 100ng/ml.  
The mRNA levels induced by E. coli, Pseudomonas aeruginosa and Haemophilus 
influenzae LPS were not significantly different. The E. coli LPS generates 
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significantly different p<0.01 levels of mRNA production with Klebsiella 
pneumoniae 4844 LPS. This is because Klebsiella pneumoniae 4844 LPS is able to 
induce cytokine production for all the cytokines, whilst the E.coli LPSs was only able 
to induce cytokine production in half the cytokines looked at in the study. When the 
level of cytokine production was compared for the cytokines that the E. coli LPS was 
able to induce, there was no significant difference between the LPSs from the two 
organisms. This is why there is no significant difference between Klebsiella 
pneumoniae 4841 LPS and the E.coli LPS. When compared with Acinetobacter 
genospecies 13 TU LPS there was no significant difference between these and the E. 
coli LPS, but it can be seen that E. coli LPS does induce higher cytokine levels 
especially when compared with those of Acinetobacter genospecies 13 TU 4809 LPS. 
3.3.5 Comparison of mRNA production between genes of interest 
The same results used to generate the previous five figures were used to generate a 














































































Figure 3.36: The normalised Ct values of TNF-α from cDNA taken from THP-1 cells challenged with 
either 10ng/ml or 1ng/ml of one of the ten different LPSs from the strains of bacteria.  
Figure 3.36 shows that whilst there is some variation between the cytokine levels 
induced by the LPS of the strains, they are not significant. It can be seen that the two 
Haemophilus influenzae LPSs and the LPS from Pseudomonas aeruginosa 4789 are 
the highest inducers of TNF-α, whilst TNF-α mRNA level induced by LPS from 
Acinetobacter genospecies 13 TU 4802, Pseudomonas aeruginosa 4845, Klebsiella 
pneumoniae 4842 and E. coli 4843 was lower than the other LPSs. The final three 
LPSs again induced mid levels of mRNA for TNF-α production. 
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Figure 3.37: The normalised Ct values of IFN-γ from cDNA taken from THP-1 cells challenged with 
either 100ng/ml or 10ng/ml of one of the ten different LPSs from the strains of bacteria.  
In Figure 3.37 it is possible to see that LPS from only a very small number of 
organisms were able to induce IFN-γ mRNA production. The sole exceptions to this 
were Acinetobacter genospecies 13 TU 4802 LPS,which induced the THP-1 cells to 
produce mRNA for IFN-γ when used at 10ng/ml, and Klebsiella pneumoniae 4844 
LPS which was able to induce mRNA for INF-γ at both 100ng/ml and 10ng/ml. The 
two concentrations of LPS tested showed no significant difference between them. 
The levels of mRNA isolated from the cells where IFN-γ mRNA was produced was 
significantly (p<0.001) lower than for the TNF-α mRNA. 
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Figure 3.38: The normalised Ct values of IL-1β from cDNA taken from THP-1 cells challenged with 
either 10ng/ml or 1ng/ml of one of the ten different LPSs from the strains of bacteria.  
In Figure 3.38 it can be seen that once again very few of the LPSs were able to induce 
mRNA production. The exceptions were again Acinetobacter genospecies 13 TU 
4802 LPS, which was able to induce mRNA production for IL-1β at both 10ng/ml and 
1ng/ml, and Klebsiella pneumoniae 4844 LPS which was also able to induce mRNA 
for IL-1β for both 10ng/ml and 1ng/ml. Moreover Klebsiella pneumoniae 4841 LPS 
was able to induce mRNA for IL-1β for both 10ng/ml and 1ng/ml, whilst 
Pseudomonas aeruginosa 4845 induced mRNA production at 1ng/ml. There was also 
no significant difference between the two concentrations of LPS used to stimulate the 
cells. 
There was no significant difference between the cytokine production levels from IL-
1β and IFN-γ, but there was a significant difference (p<0.01) between the cytokine 
levels produced for IL-1β and TNF-α. 
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Figure 3.39: The normalised Ct values of IL-8 from cDNA taken from THP-1 cells challenged with 
either 100ng/ml or 10ng/ml of one of the ten different LPSs from the strains of bacteria.  
Figure 3.39 shows that nearly all the LPSs were ablto induce levels of mRNA 
production at 10ng/ml, but only Klebsiella pneumoniae 4841 and Klebsiella 
pneumoniae 4844 LPSs were able to generate mRNA production with 100ng/ml. 
There is a very wide variation in levels of mRNA production generated by the LPS 
from the different strains. Acinetobacter genospecies 13 TU 4802 and Pseudomonas 
aeruginosa 4789 LPSs had the highest mRNA responses and Acinetobacter 
genospecies 13 TU 4809 LPS had the lowest mRNA response. There is a significant 
difference (p<0.01) between the two concentrations of LPS used to stimulate the cells.  
When compared with the other genes, it is possible to see that IL-8 at 10ng/ml was 
produced at significantly higher levels (p<0.01) than both IL-1β and IFN-γ. There was 
no significant difference between IL-8 at 10ng/ml and TNF-α production. For IL-8 at 
100ng/ml though these results were inversed and there was no significant difference 
between it and IFN-γ and IL-1β. There was a significant difference (p<0.01) with 
TNF-α  
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Figure 3.40: The normalised Ct values of IL-10 from cDNA taken from THP-1 cells challenged with 
either 10ng/ml or 1ng/ml of one of the ten different LPSs from the strains of bacteria.  
In Figure 3.40 it can be seen that IL-10 was induce by all the LPSs at all dilutions. 
Haemophilus influenzae 4838 and Pseudomonas aeruginosa 4789 induced the highest 
levels of mRNA production, whilst easily the lowest level of mRNA production was 
Acinetobacter genospecies 13 TU 4809. The other LPSs fall in betwe n these two 
extremes. There was no significant difference betwen the two concentrations of LPS. 
When compared with the other genes, it can be seen that there is no significant 
difference between the levels of mRNA production for IL-10, TNF-α and IL-8 when 
stimulated with 10ng/ml of LPS. There was a significant difference (p<0.05) between 
the levels of production of mRNA for Il-10 and IFN-γ, there was also a significant 
difference (p<0.05) with IL-10 and IL-1β and IL-8 when the last two were stimulated 




4.1 LPS structures 
There are a wide variety of different types of LPS structures. As was covered in the 
Introduction there are traditionally three parts to the LPS: the O-polysaccharide chain, 
the core polysaccharide region consisting of the inn r and outer cores and the Lipid A 
moiety. The structures of the LPSs of the species investigated in this Thesis need to be 
described.  
E. coli traditionally has a smooth LPS i.e. with an O-polysaccharide chain. The two 
strains of E. coli investigated here both had a typical smooth LPS type with easily 
identifiable repeating units. The Klebsiella pneumoniae strains also followed the 
traditional types for their species, both having smooth LPS with large numbers of 
small repeating units, so they appeared as a continuous smear on the ammoniacal 
silver stain gel. The Pseudomonas aeruginosa LPSs seemed to have rough LPS 
strains i.e. where only the Lipid A moiety and the core polysaccharide are present. As 
to whether these are in fact rough LPS types is discussed in greater detail below 
(Erridge et al, 2002).  
Haemophilus influenzae LPSs are often found in the rough or smooth-rough forms. A 
smooth-rough form is an LPS that has a shortened O-polysaccharide chain attached to 
the core polysaccharide. The LPS from the Haemophilus influenzae strain 
investigated in this study are all of the smooth-rough type. The Acinetobacter 
genospecies 13 TU strains investigated in the study appeared to be of the rough LPS 
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type, but this is unlikely to be the case as Acinetobacter genospecies 13 TU is 
normally a smooth LPS. This is considered in Part 4.2 of the Discussion. 
4.2 The LPS extractions. 
As was seen in the ammoniacal silver stained PAGE gels and the colloidal gold stains,    
the re-extraction of LPS removed the residual protein from the LPSs. When the 
ammoniacal silver stain was carried out on Acinetobacter genospecies 13 TU LPS, 
these appeared to be rough LPS, as there was no banding pattern seen. This seemed 
strange, as so far all the published structures of Acinetobacter genospecies 13 TU LPS 
have been smooth LPS (Haseley et al, 1997a; Haseley et al, 1997b; Haseley et al, 
1997c; Haseley et al, 1998; Pantophlet et al, 2001; Vinogradov et al, 2002; 
Vinogradov et al, 2003; MacLean et al 2009). The reason that this occurred, is most 
likely due to the fact that the sugar composition of the O-polysaccharide chain is 
lacking in periodic-hydroxyls.This means that the oxidising agent, periodic acid, is 
unable to cleave to any of the sugars of the O-chain and open up sites in the repeating 
unit to the ammoniacal silver, which is then unable to bind to the O-polysaccharide 
repeating units (Kropinski et al, 1985; cited by Kropinski et al, 1986). Thus when the 
developer is added to the gel there is no ammoniacal silver in the O-polysaccharide 
for it to react with. This is why there is no bandig pattern with Acinetobacter 
genospecies 13 TU LPS on the PAGE gels stained with ammoniacal silver stain. The 
two Pseudomonas aeruginosa strains are also possibly smooth LPS that appear to be
rough LPS, as they also sometimes lack periodic-hydroxyls in their O-polysaccharides 
(Kropinski et al, 1985; cited by Kropinski et al, 1986), but there are also many rough 
LPS strains of Pseudomonas aeruginosa. The other three species LPSs were perfectly 
normal for their species types. 
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4.3 Limulus Amoebocyte Lysate (LAL) assay 
The results of this experiment showed that the endotoxic activities of the majority of 
the LPSs extracted were at very similar levels, falling between 100 endotoxicity 
units/µg of LPS and 300 endotoxicity units/µg of LPS. For these units to be best 
understood, it must be remembered that 1 endotoxiciy unit is equal to 0.2ng of a 
standard E. coli LPS. However, several of the LPSs were below the 100 endotoxicity 
unit/µg of LPS. These were largely from Acinetobacter genospecies 13 TU with four 
of the seven strains coming from this species. The ot r species were Haemophilus 
influenzae; Pseudomonas aeruginosa and E. coli with one strain each falling below 
100 endotoxicity units/µg of LPS. Two strains though had much higher levels of 
endotoxicity than the rest, namely Acinetobacter genospecies 13 TU 4802 and 
Klebsiella pneumoniae 4841, which had 600 and 1000 endotoxicity units/µg of LPS 
respectively. This was more than twice as large as the next highest endotoxicity level. 
The endotoxicity units are an indication of how “aggressive” the LPS is, so the higher 
the endotoxicity units are, the more potent they ar at stimulating the immune system. 
Thus it can be said that the LPSs from Acinetobacter genospecies 13 TU 4802 and 
Klebsiella pneumoniae 4841 seem to be the most potent stimulators of the immune 
system of these LPSs extracted.  
Half of the LPSs isolated from strains of Acinetobacter genospecies 13 TU were at a 
very low endotoxicity level and so will not stimulate the immune system very 
strongly. These were very close in levels to those of LPSs extracted from one of the 
strains of Pseudomonas aeruginosa, one of the Haemophilus influenzae strains and 
one of the strains of E. coli. This is as expected, since Acinetobacter genospecies 13 
TU is more of an opportunistic pathogen than a truly pathogenic species. The low 
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endotoxicity level of E. coli and Haemophilus influenzae LPSs is possibly due to the 
fact that they might be from strains that are less pathogenic as well or have other 
virulence factors, such as toxin etc. It is also possible that the some of the results are 
incorrect due to the poor solubility of LPS in water. LPS when dissolved in water 
forms clumps which means that when some of the mixture is removed the amount of 
LPS within is not indicative of the true amount of LPS in the solution. This is because 
it is possible to obtain either large amounts of LPS in clumps or nearly no LPS if a 
clump is not drawn up.  The way this problem was attempted to be limited was to 
dissolve the LPS in 0.2% Triethylamine (TEA). This molecule helps the LPS dissolve 
and stops the formation of clumps, thus allowing the LPS to diffuse fully through the 
liquid. 
As is discussed above, Acinetobacter genospecies 13 TU 4802 has a very high 
endotoxicity level possibly meaning that it is from a strain more suited to actively 
infecting people. The other three LPSs from Acinetobacter genospecies 13 TU were at 
similar levels of endotoxicity to LPS from three of the Haemophilus influenzae strains 
and close to those of half of the LPSs from Klebsiella pneumoniae and E. coli strains. 
This indicates that these strains are possibly entering niches closer to those occupied 
by these more specialised human commensals. These tree LPSs of Acinetobacter 
genospecies 13 TU are also very close in level to that of Pseudomonas aeruginosa 
4789 LPS, although slightly higher than it. Pseudomonas aeruginosa LPS is often 
thought to be less endotoxic than many other pathogenic Gram-negative organisms 
(Goldberg & Pier, 1996; Erridge et al, 2007). As was shown by Erridge et al (2007) 
Acinetobacter genospecies 13 TU LPS is a potent stimulator of the immune system 
and is able to stimulate TNF-α and IL-8 production at the same level as LPS from E. 
coli signalling through TLR-4. Thus whilst the endotoxicity levels from the LAL 
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assay vary between very high levels and other much lower levels, the LPS has always 
stimulated a response. 
The LPS from the Haemophilus influenzae 4789, 4838 and 4839 strains is mostly at 
the middle level lying between 100 and 300 endotoxicity units/µg of LPS, with LPS 
from 4838 and 4839 being closer to 300 endotoxicity units/µg of LPS and the LPS 
from 4789 being closer to 100 endotoxicity units/µg of LPS. Haemophilus influenzae 
4840 had very low levels of LPS endotoxicity. So the LPSs from the three higher 
strains are more endotoxic than the LPS belonging to the low level strain. It is 
possible that the low endotoxicity strain is less pathogenic than the other three, 
although it is likely to have some pathogenic potential, as it and all the other strains 
tested here were isolated from patients with respiratory tract infections. 
4.4 Range of antibodies to Acinetobacter genospecies 13 
TU LPS in a healthy population of Southeast Scotland 
4.4.1 Inter strain comparisons 
Acinetobacter genospecies 13 TU is now a fairly common hospital acquired 
bacterium and infections caused by it have been on the rise over the last twenty years 
(Giamarellou et al, 2008). There has never been a study to attempt to see how 
widespread exposure to this organism is in the wider healthy population. To attempt 
to ascertain this, it was decided to investigate the levels of antibody to LPS from eight 
Acinetobacter genospecies 13 TU strains isolated from patients in he Royal Infirmary 
Edinburgh. The measurement of the antibody levels to Acinetobacter genospecies 13 
TU LPS might serve as an indicator of how widespread xposure to Acinetobacter 
genospecies 13 TU is. It does need to be noted that very little is known about the 
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differences between the different structures of LPS within the genus Acinetobacter. 
So it is quite possible that antibody levels to Acinetobacter genospecies 13 TU LPS 
are in fact due to exposure to a different species of Acinetobacter. Since the higher the 
antibody levels, the greater is the number of people that will have been exposed to the 
LPS. Since exposure to the LPS normally occurs withexposure to the bacterium as 
well. So LPS exposure can be used as a rough estimate on the levels of exposure to 
the bacteria. The LPSs were used to assess the antibody levels in serum samples from 
475 blood donors by ELISAs. Blood donors are likely to represent the healthy 
population, since one must be in good health to be allowed to give blood. It was 
decided to use 475 blood donors since this was considered a large enough number to 
act as a reasonable indicator of the wider healthy population as a whole. 
There are some issues with the above assumption, in that there is not a direct 
correlation between the antibody levels to LPS and exposure to the organism itself. 
Since some LPSs appear to generate a much greater antibody response than others. 
This means that if 50% of the population has been exposed to the potent LPS then 
each individual that has been exposed to it will have  higher response and so the 
mean of the overall response would be much higher, t an the mean antibody response 
to an LPS from a different species or strain that is much less potent, but with an 
exposure rate of 70%. In the above case when the antibody levels are observed, it will 
appear that the strain with a 50% exposure will have  much higher mean and seem to 
have a much higher exposure rate than the strain with a 70% exposure rate. Alongside 
this issue is the problem of cross-reactivity, which is where the antigen closely 
resembles another antigen and so the antibodies will be able to bind to both of them. 
So in this case this would mean that an LPS to a more c mmon strain has some 
similarities in binding sites to the stain of investigation. This can artificially increase 
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the apparent antibody levels to the specific LPS, as there are now not only whatever 
antibodies that would normally be present in the serum against the specific LPS, but 
also any antibodies that would bind to the other LPSs as well. To overcome these 
problems it was necessary to observe all the data in one go and not just take the mean 
as the only important factor. Also inhibition ELISAs were carried out to measure the 
rate of cross-reactivity between the strains. Unfortunately the inhibition ELISAs did 
not work effectively and so were unable to be completed. This will be covered in a 
later part of the Discussion. 
The results showed that there was a definite variation in antibody levels to the 
different LPSs from the eight Acinetobacter genospecies 13 TU strains. This suggests 
that the different strains have different exposure rat s within the healthy population of 
Southeast Scotland. LPS from Acinetobacter genospecies 13 TU strains 4793, 4799 
and 4801 generated the highest mean levels of antibody, but also had the widest base 
of antibody results with a good mixture of results, making it likely that the higher 
mean is in fact due to a wider exposure to the LPS of the organism. The LPS from 
Acinetobacter genospecies 13 TU strains 4800 and 4809 generated an ibody responses 
whose means are very close to each other and also hve a wide range of antibody 
responses. This indicates that the exposure to the two Acinetobacter genospecies 13 
TU strains is not a bi-modal distribution, which would indicate a smaller exposure, 
but a higher antibody response from those that wereexposed. The means are lower 
than those to the LPS of the previous three strains, which would indicate that the 
exposure to Acinetobacter genospecies 13 TU 4800 and 4809 is lower than the 
previous strains. The LPS from Acinetobacter genospecies 13 TU 4808 generates a 
lower mean antibody response than the previous five strains. Once again though there 
is no bi-modality so the mean can be read as an accur te exposure rate over the 
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population. Again this strain has less exposure within the population than the previous 
Acinetobacter genospecies 13 TU strains. The LPS from the final two Acinetobacter 
genospecies 13 TU strains 4802 and 4803 have the lowest means of all and have very 
high numbers of antibody results between 1.5-3.5 OD 405nm; these are the lowest 
levels of antibody response to the LPSs out of all the Acinetobacter genospecies 13 
TU strains. The results indicate that these two strains have the lowest exposure in the 
healthy population of Southeast Scotland. So as can be seen there is a definite 
variation in the exposure rate to the different strains, with some strains having a 
higher rate of exposure whilst some having a low rate of exposure. In fact, the strain 
of Acinetobacter genospecies 13 TU with the highest endotoxic activity is also the 
strain with the lowest exposure rate of its LPS to the healthy population, possibly 
indicating that it is a more specialised pathogenic strain, which is more commonly 
found in hospitals and not in the healthy population.  
4.4.2 Inter species comparisons 
The antibody levels to the LPS from the Acinetobacter genospecies 13 TU strains 
were also compared with antibody levels generated by LPS from three organisms that 
commonly cause respiratory tract infections (Dupont et al, 2003). These organisms 
were Pseudomonas aeruginosa, Klebsiella pneumoniae and E. coli, and two strains of 
each were tested. Each serum sample was averaged across the eight Acinetobacter 
genospecies 13 TU, the two Pseudomonas aeruginosa, the two Klebsiella pneumoniae 
and the two E. coli strains and the mean antibody levels to the LPSs from these 
different species were compared. 
The comparison of the mean antibody levels to Pseudomonas aeruginosa and 
Acinetobacter genospecies 13 TU showed that there was a significat difference 
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between the two means. But even with this significant difference the means were 
much closer to each other than they were for the antibody levels to the LPS 
Acinetobacter genospecies 13 TU and E. coli. The points also overlay each other 
fairly well thus also showing a similarity between the two sets of data. Acinetobacter 
genospecies 13 TU is a human pathogen, unlike Pseudomonas aeruginosa, but as is 
discussed below a closely related species to this organism is a common environmental 
organism. Otherwise if that is not what the organism i  responding to, then a common 
nosocomial infection will have a lower exposure in a healthy population. This is 
because they will not have been exposed to it as regularly, since it isn’t really found 
outside of hospitals. 
As covered in the Introduction there is currently some discussion as to whether 
Acinetobacter baumannii is in fact an environmental organism or indeed as common 
in hospitals as it appears to be. So the natural reservoir for the organisms has never 
been discovered (Van looveren t al, 2004; Perez et al, 2007; Peleg et al, 2008). The 
majority of the literature though asserts that Acinetobacter baumannii is an 
environmental organism (Paterson, 2006; Giamallerou t al, 2008). The probable 
reason that is put forward as to why it is possible for the majority of the papers to 
claim the Acinetobacter baumannii is an environmental organism, is that until 
recently Acinetobacter baumannii was not easily differentiable from other closely 
related Acinetobacter spp. by normal phenotypic methods. The development of 16s-
23S DNA/DNA hybridisation by Tjernborg & Ursing in 1989 allowed the 
differentiation between the different species, which allowed for a more complete 
phylogenetic picture of Acinetobacter spp. to be developed. There are now 32 
genomic species within the group (Van Looveren et al, 2004). Acinetobacter 
baumannii and Acinetobacter calcoaceticus and two other genospecies 3 and 13 TU 
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make up a very closely related group of species often referred to as the Acinetobacter 
calcoaceticus - Acinetobacter baumannii complex. These species are almost 
impossible to differentiate from each other by normal phenotypic methods and thus it 
is likely that a number of the species previously described as Acinetobacter 
baumannii may in fact have been Acinetobacter calcoaceticus isolates that were 
misidentified as Acinetobacter baumannii. Acinetobacter calcoaceticus is in fact a 
common environmental organism that is found ubiquitously throughout nature (Peleg 
et al, 2008). So the argument put forward is that the majority of strains that have been 
previously identified in nature as being Acinetobacter baumannii are in fact 
Acinetobacter calcoaceticus. So now it has entered the general consciousness that 
Acinetobacter baumannii is an environmental organism all papers state this without 
checking to whether this is true. This has led to the probable mis-representation of 
Acinetobacter baumannii as an environmental organism. Whilst this means that 
Acinetobacter baumannii is not as commonly isolated as thought, the organisms are 
extremely closely related so it is likely that the data isolated for the Acinetobacter 
genospecies 13 TU can be also be applied to Acinetobacter baumannii. 
Thus it has been established that there are great similarities between these species of 
Acinetobacter, which means that it is probably likely that they share the same basic 
core and lipid A structure of the LPS. This obviously would mean that the antibody 
levels we are detecting to the Acinetobacter genospecies 13 TU LPS could in fact be 
antibodies developed against the core of Acinetobacter calcoaceticus LPS. This could 
mean that the actual level of antibody to Acinetobacter genospecies 13 TU LPS is 
lower than these results would suggest.  
 142 
The comparison between the means of the antibody levels against LPS from 
Klebsiella pneumoniae and Acinetobacter genospecies 13 TU showed that there was a 
significant difference between the means. The difference was slightly higher than the 
difference between the means of the antibody levels against LPS from Pseudomonas 
aeruginosa and Acinetobacter genospecies 13 TU. The means of the antibody levels 
against LPS from Klebsiella pneumoniae and Pseudomonas aeruginosa were not 
significantly different. This is not what would be expected normally, as Pseudomonas 
aeruginosa is a common environmental organism, whilst Klebsiella pneumoniae is a 
common commensal organism of the gut. So it is odd t  have the mean antibody 
results against the LPS from the organism being so close, as it would be expected for 
Klebsiella pneumoniae to have a much higher level of exposure in the healthy 
population. When the individual points on the graph re compared, it is possible to see 
that whilst Klebsiella pneumoniae has much greater number of higher responses it 
also has a much greater number of lower responses. This could be taken as an 
indication that Klebsiella pneumoniae has been exposed to a smaller part of the of the 
population, but has generated a higher response in veral individuals that were 
exposed to the organism, thus giving a mean that is higher than that against the LPS 
of Acinetobacter genospecies 13 TU. This is one possibility, but another is that, when 
the two strains that were averaged to make the results for Klebsiella pneumoniae, are 
looked at, then it is easy to see that they are significantly different (p<0.01) from each 
other, with Klebsiella pneumoniae 4841 having a much higher mean than that of 
Klebsiella pneumoniae 4844. The reason for this discrepancy between the two strains 
is possibly due to one of the strains being a more specialised pathogenic strain as 
opposed to a more common gut commensal. The more specialised pathogen would be 
more common in hospitalised patients and so be less likely to have exposure in the 
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healthy population. Exposure to the common gut commensal would be much more 
widespread as it will be commonly found in the gut of he population. The mean of 
the higher antibody response of 0.623 is much closer to the mean of E. coli at 0.689 
than it is to the mean of Klebsiella pneumoniae 4844 of 0.538, which is definitely 
closer to that of Acinetobacter genospecies 13 TU which is 0.471. Another possibility 
is that with only two strains of Klebsiella pneumoniae LPS being used, it means that 
the antibody level to them will be a combination of anti-core and anti-O chain, 
specific for each particular LPS antibody. This could lead to the discrepancy between 
the LPS of the two strains. There was a greater number of Acinetobacter genospecies 
13 TU LPSs tested which will be likely to reduce thimportance of the specific 
antibodies, as the anti-core antibodies are enhanced, since there will be more of them 
across the strains. To try and see what the actual reason is for this discrepancy, it 
would be best to obtain a number of extra Klebsiella pneumoniae strains and measure 
the antibody response to their LPSs. These responses could then be used to see if this 
is a common feature for Klebsiella pneumoniae or is something that just affects the 
two strains isolated here.  
When the means of the antibody responses to LPS from E. coli and Acinetobacter 
genospecies 13 TU were compared, it was possible to s e that there was a significant 
difference between the two means. When the scatterplo  was also investigated it could 
also be seen that the E. coli points were much more often above the points from 
Acinetobacter genospecies 13 TU. As with Klebsiella pneumoniae strains above there 
were only two strains of E. coli used in the experiment. So as above there could be a 
great discrepancy between the more general core antibodies and the specific O-chain 
antibodies. Also E. coli has 5 core types and with only two samples it is impossible 
for them all to have been represented in the experiments carried out. Again an 
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increased number of organisms could have helped even out the results.  However, 
they would probably still have been similar to the results currently here. This is as was 
expected, since Acinetobacter genospecies 13 TU is, as has been discussed above, a 
nosocomial infection, whilst E. coli is the most common facultative anaerobic gut 
organism in the majority of the population.  
So it can be said that the antibody levels to Acinetobacter genospecies 13 TU LPS are 
at a similar level to those of Pseudomonas aeruginosa LPS. It is at a much lower level 
of exposure when compared to E. coli LPS, but again this is as expected. With 
Klebsiella pneumoniae it was odd as it is also a common gut organism and the 
antibody levels were close, but there are a variety of reasons for this as discussed 
above. Overall then it is possible to say that exposure to Acinetobacter genospecies 13 
TU is about as widespread in the healthy population of Southeast Scotland as 
Pseudomonas aeruginosa and at least one strain of Klebsiella pneumoniae. 
4.5 Inhibition assays 
These experiments were carried out to attempt to ascertain the level of cross-reactivity 
between the strains. This was carried out firstly with three different E. coli LPSs to 
test the theory. This experiment was successful. When t e same method was 
attempted using Acinetobacter genospecies 13 TU LPSs there was no inhibition at all; 
in fact even the strain that was bound to the plate seemed to have no inhibitory action 
against itself. A reason as to why this may have happened is that in solution the 
Acinetobacter genospecies 13 TU LPS changes confirmation in such a way that it 
deforms the binding sites where the antibodies would normally bind to in the normal 
confirmation of the LPS. Possible ways to test thiseory would be to obtain 
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microbeads and bind the lipid A moiety to these. These LPS coated microbeads could 
then be incubated with the serum as the solubilised LPS was in the original 
experiment. The ELISA would then be carried out as normal. Another option would 
be using whole heated killed bacteria, but this has other risks involved, such as a 
much greater chance of cross reactivity between the LPS and other surface antigens 
and so the experiment would be less certain in its conclusions. 
4.6 Range of antibodies to Haemophilus influenzae LPS in 
a healthy population of Southeast Scotland 
4.6.1 Inter strain comparisons 
The antibody levels to the LPSs of three of the Haemophilus influenzae strains 4838, 
4839, and 4840, were very similar with the ranges of their antibody levels having a 
very similar mean and standard deviation. This indicates that either their LPSs are 
similarly widespread within the healthy population f Southeast Scotland or that there 
is a common determinant (the core) across the LPS of the strains that they are all 
responding to. The antibody levels to the LPS from Haemophilus influenzae 4790 on 
the other hand have a much greater mean and greater st ndard deviation. This is due 
to the extra group of donors with an OD at 405nm of 1.7-1.8, to the LPS of 
Haemophilus influenzae 4790. This extra peak seems to indicate a number of 
individuals who have developed a much greater amount f antibody to this LPS. The 
reason for this could be that these individuals have been exposed to a higher level of 
the LPS than other people indicating a more recent and greater exposure to the 
bacterial strain itself. Alternatively this particular LPS induces a stronger antibody 
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response from the immune system of certain individuals, which is why they have high 
levels of antibody to it.  
The shape of the curve Figure 3.20 suggests a certain level of bimodality to the 
antibody levels generated by the LPS to Haemophilus influenzae 4790. This is where 
the normal distribution is not strictly accurate as the graph has two peaks rather than 
just the one that a normally distributed graph would have. This means that a normal 
distribution will not work on this type of graph. In Figure 3.20 though this is likely to 
be the case as the second peak is much smaller than the first peak and it is more likely 
that this occurred because of a difference in which region of the LPS that the 
antibodies bound to than a true bimodal population. Different parts of the LPS can 
induce a greater antibody response than others and if some of a population responded 
to one of these areas they would have a much greater l vel of response than other 
individuals who were responding to another part of the LPS that induced a lower 
response.  Even with this second peak, the results of the antibody levels to the LPS 
from Haemophilus influenzae 4790 are consistently higher than those of the othr 
three strains. So it seems that Haemophilus influenzae 4790 is the strain which has the 
most widespread exposure in the healthy population of Southeast Scotland.  
4.6.2 Inter species comparisons 
The antibody levels to the LPSs from all the Haemophilus influenzae strains were 
analyzed in the same manner as with the antibody levels to all the Acinetobacter 
genospecies 13 TU strains. The antibody levels to Haemophilus influenzae LPS when 
averaged across all four strains were compared with the antibody levels to the LPS 
from the same three reference species as before, namely Pseudomonas aeruginosa, 
Klebsiella pneumoniae and E. coli.  
 147 
When the antibody levels to LPS isolated from Pseudomonas aeruginosa and 
Haemophilus influenzae are compared, it can be seen that there is a significa t 
difference between them, with Haemophilus influenzae having by far the greater 
antibody level. This is as expected, since Haemophilus influenzae is a very common 
commensal respiratory tract organism (World Health Organisation, 2005) and 
Pseudomonas aeruginosa is a common environmental organism. So it is expected for 
the common commensal to have a higher presence in th  healthy population than an 
environmental organism. 
The comparison between the antibody levels to the LPS from Klebsiella pneumoniae 
and Haemophilus influenzae, showed that there was a significant difference betwe n 
the antibody levels, with antibody levels to Haemophilus influenzae LPS being much 
greater than those of Klebsiella pneumoniae. Although both are commensals as was 
affirmed in Part 4.3.2 of the Discussion the two strains of Klebsiella pneumoniae are 
hugely varied, thus it is hard to draw definite conlusions from these two results. Even 
when looking at the means of antibody levels to the LPS from the two Klebsiella 
pneumoniae strains, they were both significantly lower than the antibody levels of 
LPS from Haemophilus influenzae. Currently then it seems that exposure to 
Haemophilus influenzae is much more widespread than Klebsiella pneumoniae in the 
healthy population of Southeast Scotland. 
When the antibody levels to the LPS from E. coli and Haemophilus influenzae were 
compared, they showed that there was a significant difference between the antibody 
levels. However, the difference between their means was much smaller than it was 
between the other two species. Thus it seems that exposure to these two organisms is 
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roughly the same. This is also as expected, since both are common commensal 
organisms. 
Thus it is possible to say that exposure to Haemophilus influenzae is slightly more 
widespread than that of E. coli in the healthy population of Southeast Scotland. It is 
more widespread than either Pseudomonas aeruginosa or Klebsiella pneumoniae. 
4.7 High responders 
As was seen in Figure 3.28 there are some individuals, who have high antibody 
responses to all LPS antigens they are exposed to. These high responders could 
possibly be used to act as donors for passive vaccin tions for people in high risk 
situations. These could include people who are about to ndergo surgery or people in 
the ICU on ventilator machines. There has been some thought of using anti-endotoxin 
antibodies to help treat people suffering from Gram-negative infections (Ziegler et al, 
1982; Baumgartner et al, 1985; Teng et al, 1985; Kirkland et al, 1986; Charalambous 
et al, 2007). The antibodies from these high responders, if u ed very carefully, could 
be of great benefit, with the massive increases in antibiotic resistance, as it much more 
unlikely that resistance will be developed to these. On the other hand, it is possible for 
antibodies to “accidentally” have cross-reactivity with common antigens from the 
patient being treated and start an auto-immune reaction. There is also the risk of blood 
borne viruses, such as HIV or Hepatitis B+C being spread by contaminated blood. 
This is why any use of this vaccine would have to be carefully monitored and all the 
blood fully screened for infections before it could be used. 
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4.8 Cytotoxin production from THP-1 cells with LPS 
There was a great deal of variation between the diff rent levels of cytokines induced 
by the different LPSs. Some cytokines were barely produced at all, whilst other 
cytokines were produced at higher levels. The cytokine which had the highest level of 
production was TNF-α. This cytokine was induced by the LPSs of all the bacterial 
strains studied. When the different levels of TNF-α productions were compared across 
the species and strains there was no significant difference between them; but with 
only ten data points in each group it is highly unlikely that this analysis is truly 
significant; for this to be so there would need to be a greater number of points. The 
reason statistics were used to analyse the results though was just in case they showed 
that there was a significant difference between the species or genes. However, when 
viewed “by eye” it is possible to see that Haemophilus influenzae had the highest 
level of production of TNF-α, with one of the Pseudomonas aeruginosa strains. TNF-
α being the highest produced cytokine was not particularly surprising as the LPS had 
been incubated with the cells for 4 hours, which is enough time for TNF-α to have 
started being produced, whilst a number of other cytokines have not really started to 
be produced yet (Agarwal et al, 1995). This is because TNF-α is a potent pro-
inflammatory cytokine, which is normally the first produced by the immune system 
when it comes into contact with an invading organism.  
For IFN-γ there were very low levels of production. Only Acinetobacter genospecies 
13 TU 4802 and Klebsiella pneumoniae 4844 actually induced any and even then it 
was produced at significantly lower levels than were p oduced for TNF-α. This is 
again as expected, since IFN-γ only normally starts to be produced after 10-18 hours, 
so low levels of production are perfectly normal (Chan et al 1991; Janskỳ et al, 2003).  
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IL-1β also had very low levels of production with only four strains producing it, 
namely the two Klebsiella pneumoniae strains, Pseudomonas aeruginosa 4845 and 
Acinetobacter genospecies 13 TU 4802. Again the production levels w re 
significantly below the production of the TNF-α. This result was not expected as IL-
1β is normally produced at the same time as TNF-α (Baron et al, 1993; Agarwal et al 
1995). This could be due to these LPSs not being able to stimulate the cells for IL-1β 
production. 
IL-8 though has a significantly larger amount being produced than either IL-1β or 
IFN-γ and there is no significant difference with TNF-α. It is induced by all strains 
except Haemophilus influenzae 4838. This is what is expected as well, since it is also 
a potent pro-inflammatory cytokine that is often stimulated within four hours (Baron 
et al, 1993; Agarwal et al 1995).  
IL-10 is an anti-inflammatory cytokine that acts as a control mechanism on pro-
inflammatory cytokines such as TNF-α and IL-8. It is often produced alongside the 
pro-inflammatory cytokines to control the immune response and make sure it doesn’t 
become too potent and start to cause damage to the host (D’Andrea et al, 1993). There 
was no significant difference between IL-10, IL-8 and TNF-α, but it could be seen 
that IL-10 was produced at a slightly lower level than either IL-8 or TNF-α, but not 
significantly so. All species and strains induced this cytokine. It has been shown by 
Janskỳ et al, (2003) that there is a peak of IL-10 production after 4 hours followed by 
a reduction in production until 12 hours have passed, when there is a much larger 
production of IL-10. The initial peak is probably to reduce the initial immune 
response to make sure it does not increase too rapidly; the second peak is what keeps 
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the main immune response under control and shuts it down before any histological 
damage can be caused. 
Haemophilus influenzae LPS induced the highest levels of production of the 
cytokines, in the cytokines that it could induce i.e. TNF-α and IL-10. IL-8 was also 
able to be induced at high levels by Haemophilus influenzae 4839 LPS. When 
compared with Klebsiella pneumoniae LPS which was able to induce production of 
all the cytokines, there was a significant differenc  between them. Acinetobacter 
genospecies 13 TU 4802 LPS was able to induce producti n of all the cytokines, 
whereas Acinetobacter genospecies 13 TU 4809 LPS was unable to induce producti n 
of either IFN-γ or IL-1β and the ones it could induce were at lower levels when 
compared with Acinetobacter genospecies 13 TU 4802 LPS. Pseudomonas 
aeruginosa and E. coli LPSs did not have significantly different production levels to 
each other or to Haemophilus influenzae LPS as they were able to induce mostly the 
same cytokines. Pseudomonas aeruginosa LPS was also able to induce production of 
IL-1β at low levels.  
From the data seen here and when compared with the endotoxicity levels calculated 
using the LAL assays, it would be assumed that Acinetobacter genospecies 13 TU 
4802 and Klebsiella pneumoniae 4841 would be the two most potent stimulators of 
the immune system and thus stimulate greater production of cytokines. This does not 
seem to be the case as there is no significant difference between the abilities of the 
LPS from the same strains to stimulate different production rates of the cytokines also 
whilst Acinetobacter genospecies 13 TU 4802 LPS induced higher production levels 
of cytokines than Acinetobacter genospecies 13 TU 4809 LPS. Klebsiella pneumoniae 
4841 LPS in fact induced less cytokine production than Klebsiella pneumoniae 4844 
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LPS , but not significantly so, despite Klebsiella pneumoniae 4841 LPS having five 
times the endotoxicity levels by LAL. Thus it seems that endotoxicity levels 
calculated by the LAL assay were not indicative of h w potent a cytokine stimulator a 
particular LPS is.  
There was only one time point used in this experiment due to problems growing the 
cells which led to a long wait for viable cells to be grown to sufficient numbers to be 
able to experiment on them properly. With more time for the project, extra time points 
at 12 hours, 18 hours, 24 hours and 48 hours for all the LPS samples would have been 
included to allow for better understanding of the production of the cytokines that had 
not started to be produced after 4 hours.  
4.9 Conclusions 
So in conclusion it can be said that exposure to Acinetobacter and Haemophilus 
influenzae LPSs in a healthy population varies within the species. This is due to the 
fact that some strains with in the species had higher levels of antibody to the LPS in 
the healthy population than others. Apparent exposure to Acinetobacter genospecies 
13 TU LPS was at a similar level of exposure to Pseudomonas aeruginosa LPS and 
also to at least one LPS from one of the studied strains of Klebsiella pneumoniae in a 
healthy population. Haemophilus influenzae LPS on the other hand had a similar level 
of exposure to E. coli LPS in a healthy population. This is useful to know as it has 
previously been unknown how widespread exposure to Acinetobacter LPS is outside a 
hospital setting. The level of exposure to Acinetobacter LPS is similar to that of 
Pseudomonas aeruginosa LPS, which suggests that it is not a commensal organism 
and could possibly be an environmental organism.  
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TNF-α is the most produced cytokine along with IL-8 and IL-10 close behind it in 
production levels. IFN-γ and IL-1β were at a lower level, but are not normally 
activated till 18 hours or so after the initial contact with the foreign antigen. 
Haemophilus influenzae LPS did not induce production of many of the cytokines, 
whilst Klebsiella pneumoniae LPS was able to induce production in all the cytokines 
investigated. Acinetobacter genospecies 13 TU LPS varied between the two strain 
with one being a potent inducer of cytokine production, whilst the other was not a 
very potent inducer. It was also seen that endotoxic activity is not necessarily linked 
to being a more potent stimulator of cytokine production. 
The findings presented in this thesis indicate that it may well be possible to use serum 
from selected “high titre” blood donors to prepare intravenous IgG to treat patients 
suffering from pneumonia caused by a range of Gram-negative bacteria such as 
Acinetobacter spp, Haemophilus influenzae, Klebsiella pneumonia and Pseudomonas 
aeruginosa. When the data was viewed it could be seen that some of the blood donors 
had a high level of response to the LPS of all the organisms. In general this showed 
that there were people who were able to mount an effective response to all the 
organisms and their serum would be the most appropriate to be used as it would 
provide the greatest protection from these organisms. Although such an approach is 
not new; it has been proposed for treating patients suffering from sepsis and other 
nosocomial infections (Braude et al, 1981; Ziegler et al, 1982) and for burns patients 
(Jones et al, 1980), it could also employ specific monoclonal antibodies (di Padova et 
al, 1993). 
Future work could also investigate whether patients suffering from VAP show 
changes in anti-LPS antibodies similar to those seen in sepsis patients (Barclay et al, 
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1989), and those patients who have high levels of specific anti-LPS antibodies may be 
protected from developing VAP. If they do, active vaccination with a vaccine 
containing the relevant LPSs incorporated into liposomes would probably be most 
appropriate. This would be similar to the vaccine developed by Bennett-Guerrero and 












































 Agarwal, S., N. P. Piesco, L. P. Johns, and A. E. Riccelli. 1995. Differential 
expression of IL-1 beta, TNF-alpha, IL-6, and IL-8 in human monocytes in 
response to lipopolysaccharides from different microbes. J Dent Res 74:1057-
65. 
 Akira, S., S. Uematsu, and O. Takeuchi. 2006. Pathogen recognition and 
innate immunity. Cell 124:783-801. 
 Alekshun, M. N., and S. B. Levy. 2006. Commensals upon us. Biochem 
Pharmacol 71:893-900. 
 Alexander, C., and E. T. Rietschel. 2001. Bacterial lipopolysaccharides and 
innate immunity. J Endotoxin Res 7:167-202. 
 Allan, E., I. R. Poxton, and G. R. Barclay. 1995. Anti-bacteroides 
lipopolysaccharide IgG levels in healthy adults andsepsis patients. FEMS 
Immunol Med Microbiol 11:5-12. 
 Ancuta, P., T. Pedron, R. Girard, G. Sandstrom, and R. Chaby. 1996. 
Inability of the Francisella tularensis lipopolysaccharide to mimic or to 
antagonize the induction of cell activation by endotoxins. Infect Immun 
64:2041-6. 
 Antal-Szalmas, P. 2000. Evaluation of CD14 in host defence. Eur J Clin
Invest 30:167-79. 
 Appelmelk, B. J., M. A. Monteiro, S. L. Martin, A. P. Moran, and C. M. 
Vandenbroucke-Grauls. 2000. Why Helicobacter pylori has Lewis antigens. 
Trends Microbiol 8:565-70. 
 Aravind, L., V. M. Dixit, and E. V. Koonin.  1999. The domains of death:   
evolution of the apoptosis machinery. Trends Biochem Sci 24:47-53. 
           Barclay, G. R., B. B. Scott, I. H. Wright, P. N. Rogers, D. G. Smith, and I. 
R. Poxton. 1989. Changes in anti-endotoxin-IgG antibody and eotoxaemia 
in three cases of gram-negative septic shock. Circ Shock 29:93-106. 
 Baron, P., G. Constantin, A. D'Andrea, D. Ponzin, E. Scarpini, G. 
Scarlato, G. Trinchieri, F. Rossi, and M. A. Cassatella. 1993. Production of 
tumor necrosis factor and other proinflammatory cytokines by human 
mononuclear phagocytes stimulated with myelin P2 protein. Proc Natl Acad 




            Basset, C., J. Holton, R. O'Mahony, and I. Roitt. 2003. Innate immunity 
and pathogen-host interaction. Vaccine 21 Suppl 2:S12-23. 
 Baumgartner, J. D., M. P. Glauser, J. A. McCutchan, E. J. Ziegler, G. van 
Melle, M. R. Klauber, M. Vogt, E. Muehlen, R. Luethy, R. Chiolero, and 
et al. 1985. Prevention of gram-negative shock and death in surgical patients 
by antibody to endotoxin core glycolipid. Lancet 2:59-63. 
            Beardsley, J. R., J. C. Williamson, J. W. Johnson, C. A. Ohl, T. B. 
Karchmer, and D. L. Bowton. 2006. Using local microbiologic data to 
develop institution-specific guidelines for the treatment of hospital-acquired 
pneumonia. Chest 130:787-93. 
 Bennett-Guerrero, E., G. R. Barclay, M. E. Youssef, S. Hossain, F. Vela-
Cantos, L. A. Andres, and I. R. Poxton. 2000. Exposure to bacteroides 
fragilis endotoxin during cardiac surgery. Anesth Analg 90:819-23. 
           Bennett-Guerrero, E., T. J. McIntosh, G. R. Barclay, D. S. Snyder, R. J. 
Gibbs, M. G. Mythen, and I. R. Poxton. 2000a. Preparation and preclinical 
evaluation of a novel liposomal complete-core lipopolysaccharide vaccine. 
Infect Immun 68:6202-8. 
 Berba, R., M. Alejandria, J. Rosaros, I. Reside, C. Ang, C. Cordero, J. 
Chavez, and M. Mendoza. 1999. Incidence, Risk factors and outcome of 
Hospital-Acquired Pneumonia in critically-ill patients at the Philippine general 
hospital. Philippine Journal of microbiology and infectious disease 28:29-38. 
 Bergeron, M. G., P. Simard, and P. Provencher. 1987. Influence of growth 
medium and supplement on growth of Haemophilus influenzae and on 
antibacterial activity of several antibiotics. J Clin Microbiol 25:650-5. 
 Bergogne-Bérézin E, and Towner. KJ. 1996. Acinetobacter spp. as 
nosocomial pathogens: microbiological, clinical, and epidemiological features. 
Clincal microbiology reviews 9:148-165. 
 Berlau, J., H. Aucken, E. Houang, and T. Pitt. 1999. Isolation of 
Acinetobacter spp. including A. genospecies 13 TU from vegetables: 
implications for hospital-acquired infections. Journal of Hospital Infection 
42:201-204. 
 Beutler, B. 2004. Innate immunity: an overview. Mol Immunol 40:845-59. 
 Beutler, B., I. W. Milsark, and A. C. Cerami. 1985. Passive immunization 
against cachectin/tumor necrosis factor protects mice from lethal effect of 
endotoxin. Science 229:869-71. 
 Beutler, B., and A. Poltorak. 2001. The sole gateway to endotoxin response: 
how LPS was identified as Tlr4, and its role in innate immunity. Drug Metab 
Dispos 29:474-8. 
 Beutler, B., and E. T. Rietschel. 2003. Innate immune sensing and its roots: 
the story of endotoxin. Nat Rev Immunol 3:169-76. 
 157 
 Bos, M. P., V. Robert, and J. Tommassen. 2007. Biogenesis of the gram-
negative bacterial outer membrane. Annu Rev Microbiol 61:191-214. 
 Bou, G., G. Cervero, M. A. Dominguez, C. Quereda, and J. Martinez-
Beltran. 2000. Characterization of a nosocomial outbreak caused by a 
multiresistant Acinetobacter genospecies 13 TU strain with a carbapenem-
hydrolyzing enzyme: high-level carbapenem resistance i  A. genospecies 13 
TU is not due solely to the presence of beta-lactamases. J Clin Microbiol 
38:3299-305. 
            Bou, G., A. Oliver, and J. Martinez-Beltran. 2000a. OXA-24, a novel class 
D beta-lactamase with carbapenemase activity in an Aci etobacter baumannii 
clinical strain. Antimicrob Agents Chemother 44:1556-61.  
            Bowton, D. L. 1999. Nosocomial pneumonia in the ICU--year 2000 and 
beyond. Chest 115:28S-33S. 
 Brade, H., L. Brade, and F. E. Nano. 1987. Chemical and serological 
investigations on the genus-specific lipopolysaccharide epitope of Chlamydia. 
Proc Natl Acad Sci U S A 84:2508-12. 
           Braude, A. I., E. J. Ziegler, J. A. McCutchan, and H. Douglas. 1981. 
Immunization against nosocomial infection. Am J Med 70:463-6. 
 Brandenburg, K., and A. Wiese. 2004. Endotoxins: relationships between 
structure, function, and activity. Curr Top Med Chem 4:1127-46. 
 Branger, J., J. C. Leemans, S. Florquin, P. Speelman, D. T. Golenbock, 
and T. van der Poll. 2005. Lipopolysaccharide binding protein-deficient mice 
have a normal defense against pulmonary mycobacteril infection. Clin 
Immunol 116:174-81. 
 Brightbill, H. D., D. H. Libraty, S. R. Krutzik, R.  B. Yang, J. T. Belisle, J. 
R. Bleharski, M. Maitland, M. V. Norgard, S. E. Plevy, S. T. Smale, P. J. 
Brennan, B. R. Bloom, P. J. Godowski, and R. L. Modlin.  1999. Host 
defense mechanisms triggered by microbial lipoproteins through toll-like 
receptors. Science 285:732-6. 
 Brown, S.. Young, H-K and Amyes, S. G. B.2005. Characterisation of OXA-
51, a novel class D carbapenemase found in genetically unrelated clinical 
strains of Acinetobacter baumannii from Argentina. Clin.Microbiol.Infect. 
11:15-23. 
 Cadenas, S., and A. M. Cadenas. 2002. Fighting the stranger-antioxidant 
protection against endotoxin toxicity. Toxicology 180:45-63. 
 Caroff, M., D. Karibian, J. M. Cavaillon, and N. Haeffner-Cavaillon. 
2002. Structural and functional analyses of bacterial lipopolysaccharides. 
Microbes Infect 4:915-26. 
 158 
 CDC. 2004. Acinetobacter genospecies 13 TU infections among patients at 
military medical facilities treating injured U.S. service members, 2002-2004. 
MMWR Morb Mortal Wkly Rep 53:1063-6. 
 Chan, S. H., B. Perussia, J. W. Gupta, M. Kobayashi, M. Pospisil, H. A. 
Young, S. F. Wolf, D. Young, S. C. Clark, and G. Trinchieri. 1991. 
Induction of interferon gamma production by natural killer cell stimulatory 
factor: characterization of the responder cells and synergy with other inducers. 
J Exp Med 173:869-79. 
 Charalambous, B. M., R. C. Stephens, I. M. Feavers, and H. E. 
Montgomery. 2007. Role of bacterial endotoxin in chronic heart f ilure: the 
gut of the matter. Shock 28:15-23. 
 Christian R. H. Raetz, and C. Whitfield. 2002. Lipopolysaccharide 
Endotoxins. Annual Review of Biochemistry 71:635-700. 
 Coelho, J., N. Woodford, M. Afzal-Shah, and D. Livermore. 2006. 
Occurrence of OXA-58-like carbapenemases in Acinetobacter spp. collected 
over 10 years in three continents. Antimicrobical Agents and Chemotherapy 
20:756-758. 
 Conrad, R. S., and C. Galanos. 1989. Fatty acid alterations and polymyxin B 
binding by lipopolysaccharides from Pseudomonas aeruginosa adapted to 
polymyxin B resistance. Antimicrob Agents Chemother 33:1724-8. 
 Corbella, X., l. M. Pujo, J. Ayats, M. Sendra, C. Ardanuy, M. Domínguez, 
J. Liñares, J. Ariza, and F. Gudiol. 1996. Relevance of digestive tract 
colonization in the epidemiology of nosocomial infections due to 
multiresistant Acinetobacter genospecies 13 TU. Clinical infectious diseases 
23:329-334. 
 Corvec, S., N. Caroff, E. Espaze, C. Giraudeau, H. Drugeon, and A. 
Reynaud. 2003. AmpC cephalosporinase hyperproduction in Acinetobacter 
genospecies 13 TU clinical strains. J Antimicrob Chemother 52:629-35. 
 Couturier, C., N. Haeffner-Cavaillon, M. Caroff, and M. D. Kazatchkine. 
1991. Binding sites for endotoxins (lipopolysaccharides) on human 
monocytes. J Immunol 147:1899-904. 
 Cunningham, M. D., J. Bajorath, J. E. Somerville, and R. P. Darveau. 
1999. Escherichia coli and Porphyromonas gingivalis lipopolysaccharide 
interactions with CD14: implications for myeloid and onmyeloid cell 
activation. Clin Infect Dis 28:497-504. 
 D'Andrea, A., M. Aste-Amezaga, N. M. Valiante, X. Ma, M. Kubin, and 
G. Trinchieri.  1993. Interleukin 10 (IL-10) inhibits human lymphocyte 
interferon gamma-production by suppressing natural killer cell stimulatory 
factor/IL-12 synthesis in accessory cells. J Exp Med 178:1041-8. 
 159 
 Dehus O, Hartnung T, and H. C. 2006. Endotoxin evaluation of eleven 
lipopolysaccharides by whole blood assay does not always correlate with 
Limulus amebocyte lysate assay. Journal of Endotoxin Research 12:171-180. 
 Dentener, M. A., A. C. Vreugdenhil, P. H. Hoet, J. H. Vernooy, F. H. 
Nieman, D. Heumann, Y. M. Janssen, W. A. Buurman, and E. F. 
Wouters. 2000. Production of the acute-phase protein lipopolysaccharide-
binding protein by respiratory type II epithelial cells: implications for local 
defense to bacterial endotoxins. Am J Respir Cell Mol Biol 23:146-53. 
 Di Padova, F. E., H. Brade, G. R. Barclay, I. R. Poxton, E. Liehl, E. 
Schuetze, H. P. Kocher, G. Ramsay, M. H. Schreier, D. B. McClelland, 
and et al. 1993. A broadly cross-protective monoclonal antibody binding to 
Escherichia coli and Salmonella lipopolysaccharides. Infect Immun 61:3863-
72. 
           Dijkshoorn, L., A. Nemec, and H. Seifert. 2007. An increasing threat in 
hospitals: multidrug-resistant Acinetobacter baumannii. Nat Rev Microbiol 
5:939-51. 
 Dixon, D. R., and R. P. Darveau. 2005. Lipopolysaccharide heterogeneity: 
innate host responses to bacterial modification of lipid a structure. J Dent Res 
84:584-95. 
 Dobrovolskaia, M. A., and S. N. Vogel. 2002. Toll receptors, CD14, and 
macrophage activation and deactivation by LPS. Microbes Infect 4:903-14. 
           Dolzani, L., E. Tonin, C. Lagatolla, L. Prandin, and C. Monti-Bragadin. 
1995. Identification of Acinetobacter isolates in the A. calcoaceticus-A. 
baumannii complex by restriction analysis of the 16S-23S rRNA intergenic-
spacer sequences. J Clin Microbiol 33:1108-13. 
 
 Donald, H. M., W. Scaife, S. G. Amyes, and H. K. Young. 2000. Sequence 
analysis of ARI-1, a novel OXA beta-lactamase, respon ible for imipenem 
resistance in Acinetobacter baumannii 6B92. Antimicrob Agents Chemother 
44:196-9. 
            Dupont, H., P. Montravers, R. Gauzit, B. Veber, J. L. Pouriat, and C. 
Martin.  2003. Outcome of postoperative pneumonia in the Eol study. 
Intensive Care Med 29:179-88. 
 Dupont, M., J. M. Pages, D. Lafitte, A. Siroy, and C. Bollet. 2005. 
Identification of an OprD homologue in Acinetobacter g nospecies 13 TU. J 
Proteome Res 4:2386-90. 
 Elsbach, P. 2000. Mechanisms of disposal of bacterial lipopolysaccharides by 
animal hosts. Microbes Infect 2:1171-80. 
 Erridge, C., E. Bennett-Guerrero, and I. R. Poxton. 2002. Structure and 
function of lipopolysaccharides. Microbes Infect 4:837-51. 
 160 
           Erridge, C., J. Stewart, E. Bennett-Guerrero, T. J. McIntosh, and I. R. 
Poxton. 2002a. The biological activity of a liposomal complete core 
lipopolysaccharide vaccine. J Endotoxin Res 8:39-46. 
 
 Erridge, C., O. L. Moncayo-Nieto, R. Morgan, M. Young, and I. R. 
Poxton. 2007. Acinetobacter genospecies 13 TU lipopolysacch rides are 
potent stimulators of human monocyte activation via Toll-like receptor 4 
signalling. J Med Microbiol 56:165-71. 
 
 Erridge, C., A. Pridmore, A. Eley, J. Stewart, and I. R. Poxton. 2004. 
Lipopolysaccharides of Bacteroides fragilis, Chlamydia trachomatis and 
Pseudomonas aeruginosa signal via toll-like receptor 2. J Med Microbiol 
53:735-40. 
 
 Erwin, A. L., and R. S. Munford. 1990. Deacylation of structurally diverse 
lipopolysaccharides by human acyloxyacyl hydrolase. J Biol Chem 
265:16444-9. 
 
 Falagas, M. E., P. I. Rafailidis, D. K. Matthaiou, S. Virtzili, D. Nikita, and 
A. Michalopoulos. 2008. Pandrug-resistant Klebsiella pneumoniae, 
Pseudomonas aeruginosa and Acinetobacter genospecie 13 TU infections: 
Characteristics and outcome in a series of 28 patients. Int J Antimicrob Agents 
32:450-4 
 
 Fournier, P. E., and H. Richet. 2006. The epidemiology and control of 
Acinetobacter genospecies 13 TU in health care facilities. Clin Infect Dis 
42:692-9. 
 
 Freudenberg, M. A., D. Keppler, and C. Galanos. 1986. Requirement for 
lipopolysaccharide-responsive macrophages in galactos mine-induced 
sensitization to endotoxin. Infect Immun 51:891-5. 
 
 Freudenberg, M. A., T. Merlin, M. Gumenscheimer, C. Kalis, R. 
Landmann, and C. Galanos. 2001. Role of lipopolysaccharide susceptibility 
in the innate immune response to Salmonella typhimurium infection: LPS, a 
primary target for recognition of Gram-negative bacteria. Microbes Infect 
3:1213-22. 
 
 Fujimoto, Y., Y. Adachi, M. Akamatsu, Y. Fukase, M. Kataoka, Y. Suda, 
K. Fukase, and S. Kusumoto. 2005. Synthesis of lipid A and its analogues 




            Funda, D. P., L. Tuckova, M. A. Farre, T. Iwase, I. Moro, and H. 
Tlaskalova-Hogenova. 2001. CD14 is expressed and released as soluble 
CD14 by human intestinal epithelial cells in vitro: lipopolysaccharide 
activation of epithelial cells revisited. Infect Immun 69:3772-81. 
 
 161 
 Galanos, C., V. Lehmann, O. Luderitz, E. T. Rietschel, O. Westphal, H. 
Brade, L. Brade, M. A. Freudenberg, T. Hansen-Hagge, T. Luderitz, and 
et al. 1984. Endotoxic properties of chemically synthesizd lipid A part 
structures. Comparison of synthetic lipid A precursor and synthetic analogues 
with biosynthetic lipid A precursor and free lipid A. Eur J Biochem 140:221-
7. 
 
 Galanos, C., O. Luderitz, E. T. Rietschel, O. Westphal, H. Brade, L. 
Brade, M. Freudenberg, U. Schade, M. Imoto, H. Yoshimura, and et al. 
1985. Synthetic and natural Escherichia coli free lipid A express identical 
endotoxic activities. Eur J Biochem 148:1-5. 
 
 Gales, A. C., R. N. Jones, and H. S. Sader. 2006. Global assessment of the 
antimicrobial activity of polymyxin B against 54 731 clinical isolates of 
Gram-negative bacilli: report from the SENTRY antimicrobial surveillance 
programme (2001-2004). Clin Microbiol Infect 12:315-21. 
 
 Giamarellou H. 2006. Treatment options for multidrug-resistant bacteria. 
Expert review of anti-infective therapy 4:601-618. 
 
 Giamarellou H, Antoniadou A, and K. K. 2008. Acinetobacter genospecies 
13 TU: a universal threat to public health? Internation journal of antimicrobial 
agents 32:106-19. 
 
 Girard, R., T. Pedron, S. Uematsu, V. Balloy, M. Chignard, S. Akira, and 
R. Chaby. 2003. Lipopolysaccharides from Legionella and Rhizob um 
stimulate mouse bone marrow granulocytes via Toll-like receptor 2. J Cell Sci 
116:293-302. 
 
 Goldberg, J. B., and G. B. Pler. 1996. Pseudomonas aeruginosa 
lipopolysaccharides and pathogenesis. Trends Microbiol 4:490-4. 
 
 Gronow, S., and H. Brade. 2001. Lipopolysaccharide biosynthesis: which 
steps do bacteria need to survive? J Endotoxin Res 7:3-23. 
 
 Gur, D., M. Ozalp, B. Sumerkan, A. Kaygusuz, K. Toreci, I. Koksal, U. 
Over, and G. Soyletir. 2002. Prevalence of antimicrobial resistance in 
Haemophilus influenzae, Streptococcus pneumoniae, Moraxella catarrhalis 
and Streptococcus pyogenes: results of a multicentre study in Turkey. Int J 
Antimicrob Agents 19:207-11. 
 
 Hajishengallis, G., R. I. Tapping, E. Harokopakis, S. Nishiyama, P. Ratti, 
R. E. Schifferle, E. A. Lyle, M. Triantafilou, K. Triantafilou, and F. 
Yoshimura. 2006. Differential interactions of fimbriae and lipopolysaccharide 
from Porphyromonas gingivalis with the Toll-like receptor 2-centred pattern 
recognition apparatus. Cell Microbiol 8:1557-70. 
 
 Hancock IC, and P. IR. 1988. Modern microbiology methods: Bacterial cell 
surface techniques. John Wiley and sons. 
 
 162 
 Hanlon GW. 2005. The emergence of multidrug resistant Acinetobacter 
species: a major concern in the hospital setting. Letters in applied 
microbiology 41:375-378. 
 
 Haseley, S., and S. G. Wilkinson. 1997. Structure of the O18 antigen from 
Acinetobacter genospecies 13 TU. Carbohydr Res 301:187-92. 
 
 Haseley, S. R., O. Holst, and H. Brade. 1998. Structural studies of the O-
antigen isolated from the phenol-soluble lipopolysaccharide of Acinetobacter 
genospecies 13 TU (DNA group 2) strain 9. Eur J Biochem 251:189-94. 
 
 Haseley, S. R., W. H. Traub, and S. G. Wilkinson. 1997. Structures of 
polymeric products isolated from the lipopolysaccharides of reference strains 
for Acinetobacter genospecies 13 TU O23 and O12. Eur J Biochem 244:147-
54. 
 
 Haseley, S. R., and S. G. Wilkinson. 1997. Structural studies of the putative 
O-specific polysaccharide of Acinetobacter genospecies 13 TU O24 
containing 5,7-diamino-3,5,7,9-tetradeoxy-L-glycero-D-galacto-nonulosonic 
acid. Eur J Biochem 250:617-23. 
 
 Helander, I. M., B. Lindner, H. Brade, K. Altmann, A. A. Lindberg, E. T. 
Rietschel, and U. Zahringer. 1988. Chemical structure of the 
lipopolysaccharide of Haemophilus influenzae strain I-69 Rd-/b+. Description 
of a novel deep-rough chemotype. Eur J Biochem 177:483-92. 
 
 Henry, M. 2005, posting date. Haemophilus influenzae type B (Hi ) Fact 
sheet. WHO. [Online.] 
 
 Henwood CJ, Gatward T, Warner M, James D, Stockdale MW, Spence 
RP, Towner KJ, Livermore DM, and W. N. 2002. Antibiotic resistance 
among clinical isolates of Acinetobacter in the UK, and in vitro evaluation of 
tigecycline (GAR-936). The journal of antimicrobial chemotherapy 49:479-
487. 
 
 Hermann, C., S. von Aulock, O. Dehus, M. Keller, H. Okigami, F. 
Gantner, A. Wendel, and T. Hartung. 2006. Endogenous cortisol 
determines the circadian rhythm of lipopolysaccharide-- but not lipoteichoic 
acid--inducible cytokine release. Eur J Immunol 36:371-9. 
 
 Heumann, D., and T. Roger. 2002. Initial responses to endotoxins and Gram-
negative bacteria. Clin Chim Acta 323:59-72. 
 
           Higgins, P. G., H. Wisplinghoff, O. Krut, and H. Seifert.  2007. A PCR-
based method to differentiate between Acinetobacter baumannii and 
Acinetobacter genomic species 13TU. Clin Microbiol Infect 13:1199-201. 
 
 Hirschfeld, M., C. J. Kirschning, R. Schwandner, H. Wesche, J. H. Weis, 
R. M. Wooten, and J. J. Weis. 1999. Cutting edge: inflammatory signaling 
 163 
by Borrelia burgdorferi lipoproteins is mediated by toll-like receptor 2. J 
Immunol 163:2382-6. 
 
 Hirschfeld, M., Y. Ma, J. H. Weis, S. N. Vogel, and J. J. Weis. 2000. 
Cutting edge: repurification of lipopolysaccharide eliminates signaling 
through both human and murine toll-like receptor 2. J Immunol 165:618-22. 
 
 Hirschfeld, M., J. J. Weis, V. Toshchakov, C. A. Salkowski, M. J. Cody, 
D. C. Ward, N. Qureshi, S. M. Michalek, and S. N. Vogel. 2001. Signaling 
by toll-like receptor 2 and 4 agonists results in differential gene expression in 
murine macrophages. Infect Immun 69:1477-82. 
 
 Horn, D. L., D. C. Morrison, S. M. Opal, R. Silverstein, K. Visvanathan, 
and J. B. Zabriskie. 2000. What are the microbial components implicated in 
the pathogenesis of sepsis? Report on a symposium. Clin Infect Dis 31:851-8. 
 
 Horn, D. L., S. M. Opal, and E. Lomastro. 1996. Antibiotics, cytokines, and 
endotoxin: a complex and evolving relationship in gram-negative sepsis. 
Scand J Infect Dis Suppl 101:9-13. 
 
 Horner, A. A. 2006. Toll-like receptor ligands and atopy: a coin w th at least 
two sides. J Allergy Clin Immunol 117:1133-40. 
 
 Hoshino, K., O. Takeuchi, T. Kawai, H. Sanjo, T. Ogawa, Y. Takeda, K. 
Takeda, and S. Akira. 1999. Cutting edge: Toll-like receptor 4 (TLR4)-
deficient mice are hyporesponsive to lipopolysaccharide: evidence for TLR4 
as the Lps gene product. J Immunol 162:3749-52. 
 
 Hujer, K., N. Hamza, A. Hujer, F. Perez, M. Helfand, C. Bethel, J. 
Thomson, V. Anderson, M. Barlow, L. Rice, F. Tenover, and R. Bonomo. 
2005. Identification of a new allelic variant of the Acinetobacter genospecies 
13 TU cephalosporinase, ADC-7 beta-lactamase: defining a unique family of 
class C enzymes. Antimicrobial agents and chemotherapy 49:2941-2948. 
 
 Janeway, C. A., Jr., and R. Medzhitov. 1998. Introduction: the role of innate 
immunity in the adaptive immune response. Semin Immunol 10:349-50. 
 
 Jansky, L., P. Reymanova, and J. Kopecky. 2003. Dynamics of cytokine 
production in human peripheral blood mononuclear cells stimulated by LPS or 
infected by Borrelia. Physiol Res 52:593-8. 
 
 Janssens, S., and R. Beyaert. 2003. Role of Toll-like receptors in pathogen 
recognition. Clin Microbiol Rev 16:637-46. 
 
 Jeon, B., S. Jeong, I. Bae, S. Kwon, K. Lee, Y. D, J. Lee, J. Song, and S. 
Lee. 2005. Investigation of a nosocomial outbreak of imipenem-resistant 
Acinetobacter genospecies 13 TU producing the OXA-23 beta-lactamase in 
korea. Journal of Clinical Microbiology 43:2241-2245. 
 
 164 
           Jones, R. J., E. A. Roe, and J. L. Gupta. 1980. Controlled trial of 
Pseudomonas immunoglobulin and vaccine in burn patients. Lancet 2:1263-5. 
 
 Jorgensen, J. H., G. V. Doern, L. A. Maher, A. W. Howell, and J. S. 
Redding. 1990. Antimicrobial resistance among respiratory isolates of 
Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus 
pneumoniae in the United States. Antimicrob Agents Chemother 34:2075-80. 
 Kaisho, T., and S. Akira. 2006. Toll-like receptor function and signaling. J 
Allergy Clin Immunol 117:979-87; quiz 988. 
 
 Kawahara, K., U. Seydel, M. Matsuura, H. Danbara, E. T. Rietschel, and 
U. Zahringer. 1991. Chemical structure of glycosphingolipids isolated from 
Sphingomonas paucimobilis. FEBS Lett 292:107-10. 
 
 Kintz, E., and J. B. Goldberg. 2008. Regulation of lipopolysaccharide O 
antigen expression in Pseudomonas aeruginosa. Future Mic obiol 3:191-203. 
 
 Kirkland, T. N., D. E. Colwell, S. M. Michalek, J. R. McGhee, and E. J. 
Ziegler. 1986. Analysis of the fine specificity and cross-reactivity of 
monoclonal anti-lipid A antibodies. J Immunol 137:3614-9. 
 
 Kollef, M. H., L. E. Morrow, R. P. Baughman, D. E. Craven, J. E. 
McGowan, Jr., S. T. Micek, M. S. Niederman, D. Ost, D. L. Paterson, and 
J. Segreti. 2008. Health care-associated pneumonia (HCAP): a critical 
appraisal to improve identification, management, and outcomes--proceedings 
of the HCAP Summit. Clin Infect Dis 46 Suppl 4:S296-334; quiz 335-8. 
 
 Kollef, M. H., A. Shorr, Y. P. Tabak, V. Gupta, L. Z. Liu, and R. S. 
Johannes. 2005. Epidemiology and outcomes of health-care-associated 
pneumonia: results from a large US database of culture-positive pneumonia. 
Chest 128:3854-62. 
 
 Kropinski, A. M., D. Berry, and E. Greenberg. 1986. The Basis of Silver 
Staining of Bacterial Lipopolysaccharides 
            in Polyacrylamide Gels. Current Microbilogy 13:29-31. 
 
           Kropinski, A. M., B. Jewell, J. Kuzio, F. Milazzo, and D. Berry. 1985. 
Structure and functions of Pseudomonas aeruginosa lipopolysaccharide. 
Antibiot Chemother 36:58-73. 
 
             Kumar, P., and M. Clark. 2002. Clinical Medicine. WB Saunders,          
             Edinburgh. 
 Kurt-Jones, E. A., L. Popova, L. Kwinn, L. M. Haynes, L. P. Jones, R. A. 
Tripp, E. E. Walsh, M. W. Freeman, D. T. Golenbock, L. J. Anderson, 
and R. W. Finberg. 2000. Pattern recognition receptors TLR4 and CD14 
mediate response to respiratory syncytial virus. Nat Immunol 1:398-401. 
 Landmann, R., B. Muller, and W. Zimmerli. 2000. CD14, new aspects of 
ligand and signal diversity. Microbes Infect 2:295-304. 
 165 
 Langley, J. M., and J. S. Bradley. 2005. Defining pneumonia in critically ill 
infants and children. Pediatr Crit Care Med 6:S9-S13. 
 Lee, J. D., K. Kato, P. S. Tobias, T. N. Kirkland, and R. J. Ulevitch. 1992. 
Transfection of CD14 into 70Z/3 cells dramatically enhances the sensitivity to 
complexes of lipopolysaccharide (LPS) and LPS binding protein. J Exp Med 
175:1697-705. 
 Lee, K., G. Ha, B. Shin, J. Kim, J. Kang, S. Jang, D. Yong, Y. Chong, and 
K. N. S. o. A. R. K. group. 2004. Metallo-beta-lactamase-producing Gram-
negative bacilli in Korean Nationwide Surveillance of Antimicrobial 
Resistance group hospitals in 2003: continued prevalence of VIM-producing 
Pseudomonas spp. and increase of IMP-producing Acinetobacter spp. 
Diagnostic Microbiology and Infectious Disease 50:51-58. 
 Leive, L., V. K. Shovlin, and S. E. Mergenhagen. 1968. Physical, chemical, 
and immunological properties of lipopolysaccharide rel ased from Escherichia 
coli by ethylenediaminetetraacetate. J Biol Chem 243:6384-91. 
 Lerouge, I., and J. Vanderleyden. 2002. O-antigen structural variation: 
mechanisms and possible roles in animal/plant-microbe interactions. FEMS 
Microbiol Rev 26:17-47. 
 Leung, W. S., C. M. Chu, K. Y. Tsang, F. H. Lo, K. F. Lo, and P. L. Ho. 
2006. Fulminant community-acquired Acinetobacter genospecies 13 TU 
pneumonia as a distinct clinical syndrome. Chest 129:102-9. 
 Levin, J., and F. B. Bang. 1964. The Role of Endotoxin in the Extracellular 
Coagulation of Limulus Blood. Bull Johns Hopkins Hosp 115:265-74. 
 Lien, E., T. K. Means, H. Heine, A. Yoshimura, S. Kusumoto, K. Fukase, 
M. J. Fenton, M. Oikawa, N. Qureshi, B. Monks, R. W. Finberg, R. R. 
Ingalls, and D. T. Golenbock. 2000. Toll-like receptor 4 imparts ligand-
specific recognition of bacterial lipopolysaccharide. J Clin Invest 105:497-
504. 
 Limansky, A. S., M. A. Mussi, and A. M. Viale. 2002. Loss of a 29-
kilodalton outer membrane protein in Acinetobacter g nospecies 13 TU is 
associated with imipenem resistance. J Clin Microbiol 40:4776-8. 
 Lindsay, G. K., P. F. Roslansky, and T. J. Novitsky. 1989. Single-step, 
chromogenic Limulus amebocyte lysate assay for endotoxin. J Clin Microbiol 
27:947-51. 
 Lolans, K., T. W. Rice, L. S. Munoz-Price, and J. P. Quinn. 2006. 
Multicity outbreak of carbapenem-resistant Acinetobacter genospecies 13 TU 
isolates producing the carbapenemase OXA-40. Antimicrob Agents 
Chemother 50:2941-5. 
 Machida, K., K. T. Cheng, V. M. Sung, A. M. Levine, S. Foung, and M. 
M. Lai.  2006. Hepatitis C virus induces toll-like receptor 4 expression, 
 166 
leading to enhanced production of beta interferon and interleukin-6. J Virol 
80:866-74. 
 MacLean, L. L., M. B. Perry, W. Chen, and E. Vinogradov. 2009. The 
structure of the polysaccharide O-chain of the LPS from Acinetobacter 
genospecies 13 TU strain ATCC 17961. Carbohydr Res 344:474-8. 
 Mannel, D. N., R. N. Moore, and S. E. Mergenhagen. 1980. Macrophages 
as a source of tumoricidal activity (tumor-necrotizing factor). Infect Immun 
30:523-30. 
 Marque, S., L. Poirel, C. Heritier, S. Brisse, M. D. Blasco, R. Filip, G. 
Coman, T. Naas, and P. Nordmann. 2005. Regional occurrence of plasmid-
mediated carbapenem-hydrolyzing oxacillinase OXA-58 in Acinetobacter spp. 
in Europe. J Clin Microbiol 43:4885-8. 
 Martine P. Bos, V. R., Jan Tommassen. 2007. Biogenesis of the Gram-
Negative Bacterial Outer Membrane. Annual Review of Microbiology 61:191-
214. 
 McGowan, J. E., Jr. 2006. Resistance in nonfermenting gram-negative 
bacteria: multidrug resistance to the maximum. Am J Med 119:S29-36; 
discussion S62-70. 
 Medzhitov, R., and C. Janeway, Jr. 2000. Innate immune recognition: 
mechanisms and pathways. Immunol Rev 173:89-97. 
 Medzhitov, R., and C. Janeway, Jr. 2000. Innate immunity. N Engl J Med 
343:338-44. 
 Mehta, R. M., and M. S. Niederman. 2003. Nosocomial pneumonia in the 
intensive care unit: controversies and dilemmas. J Intensive Care Med 18:175-
88. 
 Michalek, S. M., R. N. Moore, J. R. McGhee, D. L. Rosenstreich, and S. E. 
Mergenhagen. 1980. The primary role of lymphoreticular cells in the 
mediation of host responses to bacterial endotoxim. J Infect Dis 141:55-63. 
 Michalopoulos A, and Falagas ME. 2008. Colistin and polymyxin B in 
critical care. Critical care clinics 24:377-391. 
 Morrison, D. C., and L. Leive. 1975. Fractions of lipopolysaccharide from 
Escherichia coli O111:B4 prepared by two extraction procedures. J Biol Chem 
250:2911-19. 
 Nagai, Y., R. Shimazu, H. Ogata, S. Akashi, K. Sudo, H. Yamasaki, S. 
Hayashi, Y. Iwakura, M. Kimoto, and K. Miyake. 2002. Requirement for 
MD-1 in cell surface expression of RP105/CD180 and B-cell responsiveness 
to lipopolysaccharide. Blood 99:1699-705. 
 Nagano, N., Y. Nagano, C. Cordevant, N. Shibata, and Y. Arakawa. 2004. 
Nosocomial transmission of CTX-M-2 beta-lactamase-producing 
 167 
Acinetobacter genospecies 13 TU in a neurosurgery wa d. J Clin Microbiol 
42:3978-84. 
 Nesper, J., C. M. Lauriano, K. E. Klose, D. Kapfhammer, A. Kraiss, and 
J. Reidl. 2001. Characterization of Vibrio cholerae O1 El tor galU and galE 
mutants: influence on lipopolysaccharide structure, colonization, and biofilm 
formation. Infect Immun 69:435-45. 
 Netea MG, van Deuren M, Kullberg BJ, Cavaillon JM, and V. d. M. JW. 
2002. Does the shape of lipid A determine the interaction of LPS with Toll-
like receptors? Trends in Immunology 23:512-521. 
 Opal, S. M., P. J. Scannon, J. L. Vincent, M. White, S. F. Carroll, J. E. 
Palardy, N. A. Parejo, J. P. Pribble, and J. H. Lemke. 1999. Relationship 
between plasma levels of lipopolysaccharide (LPS) and LPS-binding protein 
in patients with severe sepsis and septic shock. J Infect Dis 180:1584-9. 
 Pandey, S., and D. K. Agrawal. 2006. Immunobiology of Toll-like receptors: 
emerging trends. Immunol Cell Biol 84:333-41. 
 Pantophlet, R., A. Nemec, L. Brade, H. Brade, and L. Dijkshoorn. 2001. 
O-antigen diversity among Acinetobacter genospecies 13 TU strains from the 
Czech Republic and Northwestern Europe, as determind by 
lipopolysaccharide-specific monoclonal antibodies. J Clin Microbiol 39:2576-
80. 
 Paterson, D. 2006. The epidemiological profile of infections with multidrug-
resistant Pseudomonas aeruginosa and Acinetobacter species. Clinical 
infectious diseases 43:S43-S48. 
 Peleg, A. Y., H. Seifert, and D. L. Paterson. 2008. Acinetobacter 
genospecies 13 TU: emergence of a successful pathogen. Clin Microbiol Rev 
21:538-82. 
 Perez, F., A. Endimiani, K. M. Hujer, and R. A. Bonomo. 2007. The 
continuing challenge of ESBLs. Curr Opin Pharmacol 7:459-69. 
 Perez, F., A. M. Hujer, K. M. Hujer, B. K. Decker, P. N. Rather, and R. 
A. Bonomo. 2007. Global challenge of multidrug-resistant Acinetobacter 
genospecies 13 TU. Antimicrob Agents Chemother 51:3471-84. 
            Peterson, A. A., S. W. Fesik, and E. J. McGroarty. 1987. Decreased 
binding of antibiotics to lipopolysaccharides from polymyxin-resistant strains 
of Escherichia coli and Salmonella typhimurium. Antimicrob Agents 
Chemother 31:230-7. 
 Peterson, L. R. 2005. Squeezing the antibiotic balloon: the impact of 
antimicrobial classes on emerging resistance. Clin Microbiol Infect 11 Suppl 
5:4-16. 
 168 
 Petrosillo N, Ioannidou E, and F. ME. 2008. Colistin monotherapy vs. 
combination therapy: evidence from microbiological, animal and clinical 
studies. Clinical microbiology and infection 14:816-827. 
 Poirel, L., A. Karim, A. L. Mercat, I. Thomas, H. Vahaboglu, C. Richard, 
and P. Nordmann. 1999. Extended-spectrum beta-lactamase-producing strain 
of Acinetobacter genospecies 13 TU isolated from a patient in France. Journal 
of Antimicrobial chemotherapy 43:157-158. 
            Poirel, L., S. Marque, C. Heritier, C. Segonds, G. Chabanon, and P. 
Nordmann. 2005. OXA-58, a novel class D {beta}-lactamase involved in 
resistance to carbapenems in Acinetobacter baumannii. A timicrob Agents 
Chemother 49:202-8. 
 Poltorak, A., X. He, I. Smirnova, M. Y. Liu, C. Van Huffel, X. Du, D. 
Birdwell, E. Alejos, M. Silva, C. Galanos, M. Freudenberg, P. Ricciardi-
Castagnoli, B. Layton, and B. Beutler. 1998. Defective LPS signaling in 
C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science 
282:2085-8. 
 Poltorak, A., P. Ricciardi-Castagnoli, S. Citterio, and B. Beutler. 2000. 
Physical contact between lipopolysaccharide and toll-like receptor 4 revealed 
by genetic complementation. Proc Natl Acad Sci U S A 97:2163-7. 
 Poole, K. 2005. Efflux-mediated antimicrobial resistance. J Antimicrob 
Chemother 56:20-51. 
 Poxton, I. R. 1995. Antibodies to lipopolysaccharide. J Immunol Methods 
186:1-15. 
 Prucha, M., I. Herold, R. Zazula, L. Dubska, M. Dostal, T. Hildebrand, 
and J. Hyanek. 2003. Significance of lipopolysaccharide-binding protein (an 
acute phase protein) in monitoring critically ill patients. Crit Care 7:R154-9. 
 Pugin, J., R. J. Ulevitch, and P. S. Tobias. 1995. Activation of endothelial 
cells by endotoxin: direct versus indirect pathways nd the role of CD14. Prog 
Clin Biol Res 392:369-73. 
 Quale, J., S. Bratu, D. Landman, and R. Heddurshetti. 2003. Molecular 
epidemiology and mechanisms of carbapenem resistance in Acinetobacter 
genospecies 13 TU endemic in New York City. Clin Infect Dis 37:214-20. 
 Raetz, C. R., and C. Whitfield. 2002. Lipopolysaccharide endotoxins. Annu 
Rev Biochem 71:635-700. 
 Reeves, P. 1995. Role of O-antigen variation in the immune response. Trends 
Microbiol 3:381-6. 
 Rello J, and D. E. 2003. Acinetobacter genospecies 13 TU: a threat for the 
ICU? Intensive care medicine 29:350-351. 
 169 
 Ribera, A., J. Ruiz, and J. Vila. 2003. Presence of the Tet M determinant in 
a clinical isolate of Acinetobacter genospecies 13 TU. Antimicrob Agents 
Chemother 47:2310-2. 
 Rietschel, E. T., L. Brade, U. Schade, U. Seydel, U. Zahringer, K. 
Brandenburg, I. Helander, O. Holst, S. Kondo, H. M. Kuhn, and et al. 
1990. Bacterial lipopolysaccharides: relationship of structure and 
conformation to endotoxic activity, serological specificity and biological 
function. Adv Exp Med Biol 256:81-99. 
 Rietschel, E. T., T. Kirikae, F. U. Schade, U. Mamat, G. Schmidt, H. 
Loppnow, A. J. Ulmer, U. Zahringer, U. Seydel, F. Di Padova, and et al. 
1994. Bacterial endotoxin: molecular relationships of tructure to activity and 
function. Faseb J 8:217-25. 
 Rosenthal, V. D., D. G. Maki, A. Mehta, C. Alvarez-Moreno, H. 
Leblebicioglu, F. Higuera, L. E. Cuellar, N. Madani, Z. Mitrev, L. 
Duenas, J. A. Navoa-Ng, H. G. Garcell, L. Raka, R. F. Hidalgo, E. A. 
Medeiros, S. S. Kanj, S. Abubakar, P. Nercelles, and R. D. Pratesi. 2008. 
International Nosocomial Infection Control Consortium report, data summary 
for 2002-2007, issued January 2008. Am J Infect Control 36:627-37. 
 Rosner MR, Khorana HG, and S. AC. 1979. The structure of 
lipopolysaccharide from a heptose-less mutant of Escherichia coli K-12. II. 
The application of 31P NMR spectroscopy. The Journal of Biological 
Chemistry 254:5818-25. 
 Sader, H. S., R. N. Jones, J. B. Silva, and T. S. P. G. L. America. 2002. 
Skin and soft tissue infections in Latin American medical centers: four-year 
assessment of the pathogen frequency and antimicrobial susceptibility 
patterns. Diagnostic Microbiology and Infectious Disease 44:281-288. 
 Schaub, B., R. Lauener, and E. von Mutius. 2006. The many faces of the 
hygiene hypothesis. J Allergy Clin Immunol 117:969-77; quiz 978. 
  
 
            Schletter, J., H. Brade, L. Brade, C. Kruger, H. Loppnow, S. Kusumoto, 
E. T. Rietschel, H. D. Flad, and A. J. Ulmer. 1995. Binding of 
lipopolysaccharide (LPS) to an 80-kilodalton membrane protein of human 
cells is mediated by soluble CD14 and LPS-binding protein. Infect Immun 
63:2576-80. 
 Schromm, A. B., K. Brandenburg, R. Blunck, K. Fukase, S. Kusumoto, E. 
T. Rietschel, and U. Seydel. 1999. A biophysical approach towards an 
understanding of endotoxin-induced signal transduction. Journal of Endotoxin 
Research 5:41-45. 
 Schromm, A. B., K. Brandenburg, H. Loppnow, A. P. Moran, M. H. 
Koch, E. T. Rietschel, and U. Seydel. 2000. Biological activities of 
 170 
lipopolysaccharides are determined by the shape of their lipid A portion. Eur J 
Biochem 267:2008-13. 
 Schromm, A. B., J. Howe, A. J. Ulmer, K. H. Wiesmuller, T. Seyberth, G. 
Jung, M. Rossle, M. H. Koch, T. Gutsmann, and K. Brandenburg. 2007. 
Physicochemical and biological analysis of synthetic bacterial lipopeptides: 
validity of the concept of endotoxic conformation. J Biol Chem 282:11030-7. 
 Schromm, A. B., E. Lien, P. Henneke, J. C. Chow, A. Yoshimura, H. 
Heine, E. Latz, B. G. Monks, D. A. Schwartz, K. Miyake, and D. T. 
Golenbock. 2001. Molecular genetic analysis of an endotoxin no responder 
mutant cell line: a point mutation in a conserved rgion of MD-2 abolishes 
endotoxin-induced signaling. J Exp Med 194:79-88. 
 Schumann, R. R., S. R. Leong, G. W. Flaggs, P. W. Gray, S. D. Wright, J. 
C. Mathison, P. S. Tobias, and R. J. Ulevitch. 1990. Structure and function 
of lipopolysaccharide binding protein. Science 249:1429-31. 
 Scott, P., G. Deye, A. Srinivasan, C. Murray, K. Moran, E. Hulten, J. 
Fishbain, D. Craft, S. Riddell, L. Lindler, J. Mancuso, E. Milstrey, C. T. 
Bautista, J. Patel, A. Ewell, T. Hamilton, C. Gaddy, M. Tenney, G. 
Christopher, K. Petersen, T. Endy, and B. Petruccelli.  2007. An outbreak 
of multidrug-resistant Acinetobacter genospecies 13 TU-calcoaceticus 
complex infection in the US military health care system associated with 
military operations in Iraq. Clin Infect Dis 44:1577-84. 
 Sebeny, P. J., M. S. Riddle, and K. Petersen. 2008. Acinetobacter 
genospecies 13 TU skin and soft-tissue infection associated with war trauma. 
Clin Infect Dis 47:444-9. 
 Seifert, H., L. Dijkshoorn, P. Gerner-Smidt, Pelzer N, I. Tjernberg, and 
M. Vaneechoutte. 1997. Distribution of Acinetobacter species on human skin: 
comparison of phenotypic and genotypic identification methods. Journal of 
Clinical Microbiology 35:2819-2825. 
 Seward, R. J., and K. J. Towner. 1998. Molecular epidemiology of 
quinolone resistance in Acinetobacter spp. Clin Microbiol Infect 4:248-254. 
 Seydel, U., A. B. Schromm, R. Blunck, and K. Brandenburg. 2000. 
Chemical structure, molecular conformation, and bioactivity of endotoxins. 
Chem Immunol 74:5-24. 
 Shimazu, R., S. Akashi, H. Ogata, Y. Nagai, K. Fukudome, K. Miyake, 
and M. Kimoto. 1999. MD-2, a molecule that confers lipopolysaccharide 
responsiveness on Toll-like receptor 4. J Exp Med 189:1777-82. 
 Smith, M. F., Jr., A. Mitchell, G. Li, S. Ding, A. M. Fitzmaurice, K. Ryan, 
S. Crowe, and J. B. Goldberg. 2003. Toll-like receptor (TLR) 2 and TLR5, 
but not TLR4, are required for Helicobacter pylori-induced NF-kappa B 
activation and chemokine expression by epithelial cells. J Biol Chem 
278:32552-60. 
 171 
            Song JY, Cheong HJ, Lee J, Sung AK, and K. WJ. 2008. Efficacy of 
monotherapy and combined antibiotic therapy for carbapenem-resistant 
Acinetobacter genospecies 13 TU pneumonia in an immunosuppressed mouse 
model. Internation journal of antimicrobial agents. 
  
            Su, G. L., P. D. Freeswick, D. A. Geller, Q. Wang, R. A. Shapiro, Y. H. 
Wan, T. R. Billiar, D. J. Tweardy, R. L. Simmons, and S. C. Wang. 1994. 
Molecular cloning, characterization, and tissue distribution of rat 
lipopolysaccharide binding protein. Evidence for extrahepatic expression. J 
Immunol 153:743-52. 
 Tanamoto, K., U. Zahringer, G. R. McKenzie, C. Galanos, E. T. Rietschel, 
O. Luderitz, S. Kusumoto, and T. Shiba. 1984. Biological activities of 
synthetic lipid A analogs: pyrogenicity, lethal toxicity, anticomplement 
activity, and induction of gelation of Limulus amoebocyte lysate. Infect 
Immun 44:421-6. 
 Teng, N. N., H. S. Kaplan, J. M. Hebert, C. Moore, H. Douglas, A. 
Wunderlich, and A. I. Braude. 1985. Protection against gram-negative 
bacteremia and endotoxemia with human monoclonal IgM antibodies. Proc 
Natl Acad Sci U S A 82:1790-4. 
            Texereau, J., J. D. Chiche, W. Taylor, G. Choukroun, B. Comba, and J. P. 
Mira.  2005. The importance of Toll-like receptor 2 polymorphisms in severe 
infections. Clin Infect Dis 41 Suppl 7:S408-15. 
 Thomas, C. J., M. Kapoor, S. Sharma, H. Bausinger, U. Zyilan, D. 
Lipsker, D. Hanau, and A. Surolia. 2002. Evidence of a trimolecular 
complex involving LPS, LPS binding protein and soluble CD14 as an effector 
of LPS response. FEBS Lett 531:184-8. 
           Tjernberg, I., and J. Ursing. 1989. Clinical strains of Acinetobacter 
classified by DNA-DNA hybridization. Apmis 97:595-605. 
 Tobias, P. S., K. Soldau, J. A. Gegner, D. Mintz, and R. J. Ulevitch. 1995. 
Lipopolysaccharide binding protein-mediated complexation of 
lipopolysaccharide with soluble CD14. J Biol Chem 270:10482-8. 
 Tobias, P. S., R. I. Tapping, and J. A. Gegner. 1999. Endotoxin interactions 
with lipopolysaccharide-responsive cells. Clin Infect Dis 28:476-81. 
 Triantafilou, M., and K. Triantafilou.  2005. The dynamics of LPS 
recognition: complex orchestration of multiple receptors. J Endotoxin Res 
11:5-11.         
            Trouillet, J. L., J. Chastre, A. Vuagnat, M. L. Joly-Guillou, D. Combaux, 
M. C. Dombret, and C. Gibert. 1998. Ventilator-associated pneumonia 
caused by potentially drug-resistant bacteria. Am J Respir Crit Care Med 
157:531-9. 
 172 
           Turton, J. F., N. Woodford, J. Glover, S. Yarde, M. E. Kaufmann, 
and T. L. Pitt. 2006. Identification of Acinetobacter baumannii by 
detection of the blaOXA-51-like carbapenemase gene intrinsic to this 
species. J Clin Microbiol 44:2974-6. 
 Underhill, D. M., and A. Ozinsky. 2002. Toll-like receptors: key mediators 
of microbe detection. Curr Opin Immunol 14:103-10. 
 Urban, C., N. Mariano, J. J. Rahal, E. Tay, C. Ponio, T. Koprivnjak, and 
J. Weiss. 2001. Polymyxin B-Resistant Acinetobacter genospecies 13 TU 
Clinical Isolate Susceptible to Recombinant BPI andCecropin P1. Antimicrob 
Agents Chemother 45:994-995. 
 Van Dessel, H., L. Dijkshoorn, T. van der Reijden, N. Bakker, A. Paauw, 
P. van den Broek, J. Verhoef, and S. Brisse. 2004. Identification of a new 
geographically widespread multiresistant Acinetobacter genospecies 13 TU 
clone from European hospitals. Research in Microbiol gy 155:105-112. 
 Van Looveren M, G. H;, and A. S. Group. 2004. Antimicrobial resistance of 
Acinetobacter spp. in Europe. Clinical microbiology and infection 10:684-
704. 
 Vasselon, T., and P. A. Detmers. 2002. Toll receptors: a central element in 
innate immune responses. Infect Immun 70:1033-41. 
 Vinion-Dubiel, A. D., and J. B. Goldberg. 2003. Lipopolysaccharide of 
Burkholderia cepacia complex. J Endotoxin Res 9:201-13. 
 Vinogradov, E. V., L. Brade, H. Brade, and O. Holst. 2003. Structural and 
serological characterisation of the O-antigenic polysaccharide of the 
lipopolysaccharide from Acinetobacter genospecies 13 TU strain 24. 
Carbohydr Res 338:2751-6. 
 Vinogradov, E. V., J. O. Duus, H. Brade, and O. Holst. 2002. The structure 
of the carbohydrate backbone of the lipopolysaccharide f om Acinetobacter 
genospecies 13 TU strain ATCC 19606. Eur J Biochem 269:422-30. 
 Vivier, E., and B. Malissen. 2005. Innate and adaptive immunity: 
specificities and signaling hierarchies revisited. Nat Immunol 6:17-21. 
 Vos, J. B., M. A. van Sterkenburg, K. F. Rabe, J. Schalkwijk, P. S. 
Hiemstra, and N. A. Datson. 2005. Transcriptional response of bronchial 
epithelial cells to Pseudomonas aeruginosa: identifica ion of early mediators 
of host defense. Physiol Genomics 21:324-36. 
 Walsh, T., M. Toleman, L. Poirel, and P. Nordmann. 2005. Metallo-beta-
lactamases: the quiet before the storm? Clinical Microbiology reviews 18:306-
325. 
 Weiss, J., M. Hutzler, and L. Kao. 1986. Environmental modulation of 
lipopolysaccharide chain length alters the sensitivity of Escherichia coli to the 
 173 
neutrophil bactericidal/permeability-increasing protein. Infect Immun 51:594-
9. 
 Werts, C., R. I. Tapping, J. C. Mathison, T. H. Chuang, V. Kravchenko, I. 
Saint Girons, D. A. Haake, P. J. Godowski, F. Hayashi, A. Ozinsky, D. M. 
Underhill, C. J. Kirschning, H. Wagner, A. Aderem, P. S. Tobias, and R. 
J. Ulevitch. 2001. Leptospiral lipopolysaccharide activates cells through a 
TLR2-dependent mechanism. Nat Immunol 2:346-52. 
 Westphal, O., and J. K. 1965. Bacterial lipopolysaccharide. Extraction with 
phenol-water and further applications of the procedur s. Methods in 
Carbohydrate Chemistry 5:83-91. 
 Wilkinson, S. G. 1996. Bacterial lipopolysaccharides--themes and variations. 
Prog Lipid Res 35:283-343. 
 Wolkewitz M, Vonberg RP, Grundmann H, Beyersmann J, Gastmeier P, 
Bärwolff S, Geffers C, Behnke M, Rüden H, and S. M. 2008. Risk factors 
for the development of nosocomial pneumonia and mortality on intensive care 
units: application of competing risks models. Critical care 12. 
 Wolkewitz, M., R. P. Vonberg, H. Grundmann, J. Beyersmann, P. 
Gastmeier, S. Barwolff, C. Geffers, M. Behnke, H. Ruden, and M. 
Schumacher. 2008. Risk factors for the development of nosocomial 
pneumonia and mortality on intensive care units: application of competing 
risks models. Crit Care 12:R44. 
 Wright, S. D. 1995. CD14 and innate recognition of bacteria. J Immunol 
155:6-8. 
 Yong, D., J. H. Shin, S. Kim, Y. Lim, J. H. Yum, K. Lee, Y. Chong, and A. 
Bauernfeind. 2003. High prevalence of PER-1 extended-spectrum beta-
lactamase-producing Acinetobacter spp. in Korea. Antimicrob Agents 
Chemother 47:1749-51.  
            Ziegler, E. J., J. A. McCutchan, J. Fier r, M. P. Glauser, J. C. Sadoff, H. 
Douglas, and A. I. Braude. 1982. Treatment of gram-negative bacteremia 
and shock with human antiserum to a mutant Escherichia coli. N Engl J Med 
307:1225-30. 
 Zilberberg MD, Exuzides A, Spalding J, Foreman A, Jones AG, Colby C, 
and S. AF. 2008. Hyponatremia and hospital outcomes among patients with 
pneumonia: a retrospective cohort study. BMC pulmonary medicine 8.        
            Zweigner, J., H. J. Gramm, O. C. Singer, K. Wegscheider, and R. R. 
Schumann. 2001. High concentrations of lipopolysaccharide-binding protein 
in serum of patients with severe sepsis or septic sho k inhibit the 
lipopolysaccharide response in human monocytes. Blood 98:3800-8. 
 Zweigner, J., R. R. Schumann, and J. R. Weber. 2006. The role of 
lipopolysaccharide-binding protein in modulating the innate immune response. 
Microbes Infect 8:946-52. 
 174 
 
